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Abstract
An injectable scaffold system for the delivery of cells and growth factors was
developed in this project to enhance healing of bone fractures. The project was
focused to meet the clinical need for an off-the-shelf synthetic biodegradable bone
graft material. The concept required the injection of a paste to fill defects then rapidly
solidify to a mechanically supportive macroporous structure. The injectable paste was
developed from a two-component biodegradable microparticle scaffold based on
poly(lactic-co-glycolic acid) (PLGA) and comprised of a versatile temperature
insensitive (type 1) carrier and an adhesive (type 2) component made temperature
sensitive with the addition of poly(ethylene glycol) (PEG) as a plasticizer. The
plasticized adhesive type 2 component achieved wet compressive strengths up to 18
MPa at 37 °C after 24 hours. The sintering strategy utilised the changes in
viscoelastic and mechanical properties that occur in the glass transition region of
amorphous polymers. The specific mechanism devised in this thesis exploited the
biocompatibility and diffusivity of PEG to increase polymer glass transition
temperature in the wet sintering process.
The solidification speed was demonstrated by rheological assessment of storage
modulus and wet compressive strengths up to 2 MPa after 15 minutes at 37 °C.
Restricting particle size distribution to narrow 100 µm bands controlled porosity
between 35-65%. The interconnectivity of the macroporous structures was
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demonstrated by the invasion of 3T3 cells seeded on the outer surface of the scaffold
and evaluated by microcomputed tomography. The innocuous nature of the
solidification process was demonstrated by the survival and proliferation of in situ
seeded primary human fibroblasts, osteoblasts and murine C2C12 cells. The
multifunctional type 1 component acted as a porous spacer, protein delivery vehicle
and cell carrier when modified with polyethylenimin. The potential use of the
scaffold as a controlled delivery system for recombinant human bone morphogenetic
protein-2 (rhBMP-2) was demonstrated by the sustained differentiation of murine
C2C12 myoblast to osteogenic alkaline phosphatase positive cells over 28 days.
In this thesis a novel sintering mechanism has been developed that facilitates control
of pore size and porosity of injectable scaffolds. The benign nature of the process
facilitates the potential use of this injectable system as a delivery vehicle for cell and
growth factor therapy.
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1.1 List of abbreviations
% per cent
± plus or minus
µg microgram
µL microlitre
µm micrometer
µM micromolar
ÛC degree Celcius
2D two-dimensional
3D three-dimensional
ANOVA one-way analysis of variance
bFGF basic fibroblast growth factor
BMP bone morphogenetic protein
BSA bovine serum albumin
CAS chemical abstracts service
cc centilitre
cm
2
square centimetre
cm
3
centimetre cubed
em emission
ex excitation
Da Dalton
DCM dichloromethane
DMEM Dulbecco’s modified eagle’s medium
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
D-PLA D-Poly(lactic acid)
DSC Differential Scanning Calorimetry
FCS foetal calf serum
FDA Food & Drug Administration
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FGF fibroblast growth factor
FITC-BSA fluorescein isothiocyanate bovine serum albumin
GAG glycosaminoglycan
G’ storage modulus
G’’ loss modulus
G* complex shear modulus
g gram
GPa Giga Pascal
HBSS Hank’s balanced salt solution
HPLC High pressure liquid chromatography
Hz Hertz
IUPAC international union of pure and applied chemists
J/g joules per gram
kDa kilo Dalton
kV kilo Volt
L litre
L-PLA L-Poly(lactic acid)
MDSC Modulated Differential Scanning Calorimetry
mg Miligram
mL millilitre
mm millimetre
mM milli molar
Micro CT micro-computed tomography
MPa Mega Pascal
N Newtons
NaCl sodium chloride
ng nanogram
oz ounce
p probability
Pa Pascal
PDLLA Poly(D,L-lactic acid)
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PBS Phosphate buffered saline
PDGF platelet derived growth factor
PEI Polyethyleneimine
pH measure of acidity/alkalinity
PLA poly(lactic acid)
PLLA poly(L-lactic acid)
PLGA poly(lactide-co-glycolide)
PTFE polytetrafluoroethylene
PVA Poly(vinyl alcohol)
rhBMP-2 recombinant bone morphogenetic protein-2
s-1 reciprocal second
SEM scanning electron microscopy
TCP Tricalcium phosphate
Tg glass transition temperature
UV ultra violet
VEGF vascular endothelial growth factor),
v
/v volume per unit volume
W/g heat flow Watts per gram
W/O Water in oil
W/O/W Water in oil in water
w/w weight per weight
x3 three times
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1 Introduction
Tissue engineering and regenerative medicine share a common goal for the
restoration or replacement of function lost through trauma and disease [1]. The aim of
tissue engineering is to generate new tissues from cells seeded onto scaffolds [3, 4].
Examples of early engineered tissues using naturally derived scaffolds include
keratinocyte sheets to treat skin burns and cloned endothelial cells reforming a
capillary network in vitro [5, 6]. Both examples demonstrated the strategy for tissue
growth from a combination of cells, inducing factors and scaffolds. Scaffolds are at
the core of the tissue engineering approach and interaction with cells, matrix and
growth factors determine the effectiveness of repair[7, 8].
The elderly have an increasing share of fracture complications and in recognition of
the growing socioeconomic cost, the World Health Organization declared the years
2000-2010 the bone and joint decade. The number of reconstructive bone and joint
surgical procedures in the period 2002-2003 in England alone was 636, 000 [9].
When bone damage is larger than self-reconstruction can repair (critical size defect)
alternative fillers or grafts are required. Graft materials are classified by source as
autograft, allograft, xenograft and synthetic materials. There is a need for synthetic
off the shelf solutions that are widely compatible between patients [10]. Due to cost,
the complexity of scale up and cell death, few new materials have translated into
clinical practise [1, 11].
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Tissue engineered solutions needs to be effective, safe, clinically expeditious,
generic, inexpensive and compatible with existing procedures [12]. The classical
tissue engineered approach is the in vitro expansion of cells and seeding of scaffolds
outside the body; however, for connective tissues with microstructure that reflects
their native mechanical environment, endogenous repair is advantageous to
regenerate the tissue [13]. In this thesis an injectable scaffold is developed for
endogenous repair of bone tissue. The injectable scaffold is innocuous but effective in
the delivery of cells and growth factor to improve tissue regeneration and repair.
1.1 Bone
Bone is composed of extracellular matrix, which is mineralized to varying extents
conferring rigidity and strength whilst maintaining elasticity [14]. Bone is remodelled
throughout life in response to loading, retaining form and function. Reduced bone
loading results in decreased mineral density and muscle atrophy in fracture patients
and astronauts subjected to prolonged low gravity conditions [15]. Bone structure
and composition therefore vary with age, site, health and level of activity (Figure 1-
1). Collagen type I is the dominant protein component of organic bone matrix and
the template for mineralisation [16, 17]. In bone cells, tropocollagen is produced as
three polypeptide chains linked by cysteine disulfide links. Outside cells, the cysteine
links are cleaved leaving the tri-polypeptide held together by hydrogen bonding.
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Figure 1-1 A schematic of long bone showing the periosteum, osteon, compact and
trabecular bone organization (biology.bangor.ac.uk/.../module/BSX1016/muscskel)
Bangor University.
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Tri-polypeptides self-assemble in a staggered alignment; head to tail, forming micro
fibrils stabilised by intermolecular cross-links between tri-valent pyrodinolines and
pyrroles with gap regions. During mineralization, hydroxyapatite crystals are
deposited into the gap regions of collagen fibres adding mechanical rigidity and load
bearing capacity [18]. The hydroxyapatite crystals contain impurities, such as
carbonate, citrate, magnesium and fluoride making it more soluble than geologic
apatite for bone to be remodelled [19]
The organisation of collagen matrix gives rise to two patterns of mineral deposition
known as woven (random) and lamellar (ordered) bone. Woven bone is a temporary
matrix deposited rapidly by osteoblasts during embryonic skeletal development, early
fracture healing, longitudinal bone growth and osteosarcoma formation [19]. After
fracture, a bony callus is rapidly formed providing a temporary functional scaffold
structure to partially restore mechanical stiffness properties. This allows functional
loading to stimulate remodelling and replacement of woven with lamellar bone.
Osteoblasts deposit collagen fibres in parallel aligned lamellae sheets, layer by layer,
3-20 µm thick with highly ordered and extensive mineralisation for bone strength
[20]. The 20-30 concentric lamellar sheets known as osteons are observed in the
Haversian system of cortical bone and are mechanically strong to withstand torsion
loading [21].
Cortical and cancellous bones are structurally and functionally distinct. In humans
cortical bone is 3-12% porous due to the Haversian and Volkmann’s canals that
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contain blood vessels and nervous tissue [19]. The Haversian canals, 200-300 µm in
diameter are bordered by the cement line that links one osteon to another. Osteons are
permeated with embedded osteocytes in lacunae chambers linked by canaliculi
(Figure 1-1). Cortical bone is oriented to the surface surrounding cancellous bone in a
tubular arrangement that varies in thickness. Adult cancellous bones are formed by
lamellar sheets in a porous (50-90%) network of trabeculae rods and plates
interconnected by pores up to 1 mm in size [22]. Trabeculae are preferentially aligned
giving anisotropy to the structure and elastic support to resist compression [17].
Property Cortical bone Cancellous bone
Compressive strength (MPa) 100-230 2-12
Flexural, tensile strength (MPa) 50-150 10-20
Strain to failure (%) 1-3 5-7
Young’s modulus (GPa) 7-30 0.05-0.5
Table 1 Compilation of the mechanical properties of cortical and cancellous bone
[23].
Bone strength is the maximum stress resisted before failure and is determined by
mineralisation and organisation of structure [24]. Stress is defined as the force applied
divided by the area of the load. Strain is a change in dimension as a result of the
applied stress. Young’s modulus is the stress divided by strain in the linear region
where stress is proportional to strain and indicates the stiffness of the material under
loading. The size and weight of animals do vary across species, but the average strain
and mechanical properties are similar with the femoral bone in rats and humans
having the same Young’s modulus [17, 25].
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1.1.1 Bone Repair and Remodelling
The major bone modifying cells are osteoblasts, osteocytes and bone lining cells
derived from mesenchymal stem cells and osteoclasts [26]. Multinucleated
osteoclasts 20-100 µm in diameter are derived from fused monocytes and
macrophages and have a half-life of 6-10 day [27]. Osteoclasts create ruffled cavities
200µm in diameter and 300 µm long [19]. At the end of osteoclast activity, a cement
line is formed by osteoblasts in the cavity as the outer sheath of the Haversian system.
The cavity is lined with new bone deposited in concentric lamellae layers, forming
the Haversian system with central blood vessels and nerves over 2-4 months. [17].
The cement sheath is permeated by canaliculi connecting new to old bone and is a site
of osteopontin concentration [16].
In development and repair, intramembranous bone formation occurs in an
environment where no pre-existing bone matrix is present. Invading undifferentiated
mesenchymal stem cells proliferate then differentiate via pre-osteoblasts to
osteoblasts which synthesise, then secrete collagen fibrils in a random array. During
collagen assembly some osteoblasts lag behind, becoming embedded in matrix that is,
mineralised by deposition to woven bone. Matrix embedded osteoblasts, differentiate
to smaller osteocytes and shrink from 7-1 µm in height at the end of bone formation
and connect to adjacent osteocytes via fluid filled canaliculi [28].
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Osteocytes are embedded in a lacunae chamber and have a reduced size and few
synthetic organelles. They are connected to other osteocytes and bone lining cells by
the canaliculi. Bone-lining cells are derived from surface osteoblasts after bone
formation and have an elongated appearance up to 12 µm diameter with a 1 µm thick
nucleus [29]. They communicate with other lining cells and osteocytes through gap
junctions and may be reactivated to active osteoblasts 20-40 µm in diameter [28].
Bone lining cells are believed to act as mechanical sensors, being connected to the
surface and the osteocytic extracellular fluid filled lacuo-canalicular network.
Distortions and deformations of the bone matrix are detected as fluid flow that
stimulates remodelling [30].
1.1.2 Fracture Environment
Fracture disrupts marrow architecture and periosteum blood vessels inducing an
inflammatory cascade producing pain, swelling, cytokine release, heat and blood clot
(haematoma) formation [31]. Inflammation is initially localised to a tissue by
arteriole dilation and the temperature generated can reach 41 °C [32]. Haematoma
produces an internal soft callus enclosing the fracture areas [33]. Haematoma removal
attenuates repair and its transplantation stimulates new bone formation [34]. If the
nutrient supply becomes impaired, osteocytes nearest the fracture site die, creating a
necrotic zone and osteoprogenitor cells differentiate to chondrocytes and produce
cartilage to stabilise the fracture. The cartilage is mineralised during endochondrial
ossification by invading osteoblasts concurrent with angiogenesis.
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1.1.3 Self-Repair Mechanisms
The mechanisms of bone repair are dependent on the biophysical environment [35].
In normal bone, the blood supply is split between the medullary, osseous and
periosteal supply (Figure 1-2) and the mechanism of repair can be specific to each
region [34]. New blood vessels formed during repair persist until the medullary
supply is regenerated. The fibrous periosteum membrane that surrounds compact
bone is rich in undifferentiated cells and blood vessels (Figure 1-1). When fractured,
recruitment of macrophage and periosteal fibroblasts simultaneously remove
damaged tissue by resorption and fibroblast growth factor (FGF) stimulates
osteoclastic action initiating bone remodelling [36, 37].
Repair by endochondral callus bone formation is mediated by the inner periosteal
layer and marrow tissue forming an internal callus, which is mineralized first to
woven, then replaced by lamellar bone. Intramembranous ossification of the
periosteum forms a hard callus around the injury, providing mechanical stability [34].
In the central necrotic zone, osteoclasts initiate bone resorption. In areas of rigid
stability primary contact bone repair occurs exclusively by Haversian system
osteoblasts that synthesise lamellar bone [35]. Gap repair in the interfragmentory
spaces >100 µm wide is by direct bone synthesis from mesenchymal and marrow
derived tissue [38].
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Figure 1-2 Schematic representation of bone fracture showing the composite layers of
bone that correlate with blood supply (adapted from [2])
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1.2 Intervention Strategies of Fracture Repair
Impaired healing occurs in 5-10% of fractures [39]. Critical size defects require
intervention to stabilise the fracture fragments and promote healing. Historically
external splints have been used for up to 2 months with inherently stable fractures and
for correcting bending deformities [9]. Such immobilisation avoids twisting and
shortening, but mechanical disuse results in trophic damage with pain, swelling,
patchy bone loss, and depletion of bone forming cells [40].
Materials used in repair can be divided into metals, polymers, ceramics and natural
substrates [41]. Independent of the type of material used to fill non-union gaps is the
concern of provoking inflammation at the biomaterial-host-tissue interface [31]. A
variety of factors influence tissue response from implant design, to its localisation,
physiochemical properties, mechanical loading, surface texture and the general health
of the patient [15]. Surgery utilises compression between fracture surfaces to
immobilise, align and stimulate repair. The trade off for optimal healing is the loss of
strength as implants can remain in place for up to two years [42]. Deformable splints
with variable degrees of immobilisation enable fracture detection and healing through
mechano-biological stimulation and transmission of strain. Osteoblasts in vitro
respond to dynamic oscillatory fluid flow by up regulating osteopontin and increasing
proliferation in culture [43, 44]. The natural movement of tissues induce shear stress
and strain at the tissue-biomaterial interface promoting mechanical interaction.
Submicron wear particles generated by friction from artificial prostheses can
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stimulate an immune cascade leading to high macrophage activity, bone resorption
and loosening of the implant. The time to reaction is modulated by the surrounding
tissue and in bone this may occur after a delay of up to 3 months leading to increased
osteocyte resorption [45]. Implants having a higher Young’s modulus than the tissue,
concentrate stress at the tissue-implant interface when movement occurs, resulting in
inflammation, fibrotic encapsulation and a conclusion of poor biocompatibility [15].
1.2.1 Autografts
Large segmental bone injuries caused by trauma and disease do not heal
spontaneously [46]. The implantation of cancellous bone grafts into wounds was
demonstrated to induce bone formation [47, 48]. Vascularised autografts are now a
standard treatment, having live cells with inherent osteogenecity, osteoinductivity and
osteoconductivity [49]. Autografts utilising expanded bone marrow aspirate cells, is
an option for elective surgery where time is not an issue, unlike trauma cases. The
survival and maintenance of bone marrow stem cells (BMSC) is dependent on
microenvironment [50]. BMSC can populate injured tissue through implantation in
scaffolds for articular cartilage and bone defects escaping alloantigen recognition [47,
51]. The major procedural drawbacks for autografts are: limited availability of tissue
in young and old patients, coupled with potential donor site morbidity, infection,
variable fusion rates and the creation of secondary defects with, long-term pain [52].
In paediatric and geriatric patients, autografts are ineffective when the defect size
exceeds the volume of healthy graft available to bridge it [53]. Calcium phosphate
cements have been utilised to reduce donor site morbidity, alleviating some issues
[54].
Chapter 1
14
1.2.2 Allografts
Allograft transplants are clinically common because of on-shelf availability following
harvesting from cadaver donors [55]. Protein removal reduces the risk of disease
transmission and avoids immunogenic reaction but has reduced osteoinductive and
osteoconductive performance [9]. Allogenic transplants suffer high (25-35 %) levels
of complications and re-fracture rates within 3 years [53]. The levels reach 60 %
within 10 years and were associated with osteoclastic resorption, increased micro
fracture and decreased bone mineral density within cortical and cancellous bone [56].
Allografts are subject to infection and immune responses after implantation as large
defects have limited osteoinductivity, suffer poor vascularisation and mass transport
[57, 58]. Sterilisation of allograft with ethylene oxide and gamma irradiation reduces
strength and the osteoinductive properties of the material [59]. Both autografts and
allografts suffer limited availability [60]. Hence, the need for alternative synthetic
bone grafts to be developed.
1.3 Regulators of Bone Activity
In principle, autologous bone grafts contain the essential elements of matrix, cells and
growth factors required for repair and vascularisation [57]. More than 40 proteins
have been identified that can induce endochondral bone formation in a variety of
animals [61]. Transforming growth factor-ȕ (TGF-ȕ) and insulin growth factor (IGF)
regulate differentiated bone cell proliferation, metabolism, motility and extracellular
matrix tissue formation [34]. IGF is believed to extend the effect of TGF-ȕ and bone
morphogenetic proteins (BMPs) [62]. Bone growth factors have a localised action on
angiogenesis through basal fibroblast growth factor and vascular endothelial growth
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factor (VEGF) [63]. Platelet derived growth factor (PDGF) was shown to stimulate
fracture healing, up regulate VEGF and mesenchymal cell proliferation in an
osteoporotic geriatric rat model [64]. The rate of new bone formation is believed to
be proportional to the number of active osteoblasts and osteoclast [39].
The other principal regulators of bone mineralisation and remodelling are osteocalcin,
bone sialoprotein, osteopontin, osteonectin, sulphated and acid mucopolysaccharides.
Osteocalcin has a high specific affinity for hydroxyapatite (HA) suppressing bone
formation [65]. Bone sialoprotein is multifunctional, promoting osteoblasts adhesion,
differentiation, osteoclast resorption, remodelling, and facilitating carbonate
hydroxyapatite nucleation [17, 21]. Osteopontin, involved in early cell attachment to
extracellular matrix slows giant cell formation and inhibits hydroxyapatite crystal
growth in solution but initiates it when attached to a solid surface through its negative
charged density [50, 66, 67].
1.3.1 Bone Morphogenetic Proteins
Bone morphogenetic proteins are effective across species from Drosophila
melanogaster flies to humans, controlling embryogenesis, homeostasis, postnatal
morphogenesis and repair [68-70]. To date at least 20 BMP isoforms have been
identified that can stimulate chemotaxis, proliferation of mesenchymal stem cells and
promote differentiation to either chondrocytes or osteoblasts [39]. The fate of
differentiated mesenchymal stem cells depends on the degree of vascularisation
present, with bone development requiring high oxygenation and short diffusion
distances. Low oxygen tension promotes cartilage formation [71].
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Both rhBMP-2 and rhBMP-7 on collagen type I sponge are FDA approved for limited
clinical use in open fractures to increase the likelihood of union in spinal fusion and
tibial fracture procedures [72]. BMP-2 and -7 are synchronous but spatially and
functionally distinct; they are used singly, in pharmacological rather than
physiological doses. BMP-7 was the first to be cloned; but work by [73] suggests
BMP-2, -6 and -9 to have the most potent osteogenic activity. Mice deficient in BMP-
2 are nonviable at the embryonic pre-limb patterning stage, whereas mice deficient in
BMP-7 die after birth because of poor kidney development [74]. The response to
BMPs was demonstrated to depend on cell type and differentiation status [73]. BMP-
2 stimulates mouse mesenchymal progenitor (C3H16T1/2) cells, preosteoblastic
C2C12 myoblasts and committed osteoblastic TE85 cells to produce osteoblast
differentiation markers alkaline phosphatase, osteocalcin and matrix mineralization
(Figure 1-3). The activity of BMP-7 was poor in mesenchymal progenitor cells and a
third of that for BMP-2 in preosteoblastic C2C12 myoblast cells. Both BMP-2 and -7
stimulated alkaline phosphatase activity in committed osteoblasts (TE85). Several
growth factors inhibit myogenic differentiation of C2C12 but do not induce
osteoblastic differentiation. Osteoblastic differentiation of C2C12 in culture was
maintained by continuous daily refreshment of low concentrations of rhBMP-2 [75].
C2C12 cells induced by BMP have up regulated core binding factor-1(Cbfa1) and can
mimic part of the process of ectopic bone formation [76]. Mice not expressing the
Cbfa1 gene fail to develop a mineralized skeleton [77].
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Figure 1-3 Hierarchical description of BMP activity on cells from mesenchymal
progenitor to terminal differentiation state (adopted from [73]).
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1.3.2 BMP Signal Transduction
Integrins mediate cell adhesion to extracellular matrix and biomaterial surfaces
regulating, motility, shape and differentiation [78]. Integrins form non-covalent Įȕ-
heterodimers and 24 combinations were identified [79]. The integrins and growth
factor receptors expressed, vary by cell type with stage of differentiation [77]. BMP-
signal transduction occurs via interaction with a heterodimeric complex of (type I and
II) transmembrane serine/ threonine kinase receptors (Figure1-4). Type II receptors
are activated by BMP binding and activate type I receptors by transphosphorylation.
The activated kinase receptor phosphorylates Smad proteins 1, 5 and 8. Two of these
receptor-regulated Smads form a heterotrimeric complex with Smad 4, which is
translocated into the nucleus to modulate target genes [73]. Smads are the main
signal transducers of serine-threonine receptors and regulators of TGF-ȕ family gene
transcription. These receptor regulated Smads stimulate gene expression by binding
to the regulatory sequence in the target promoter resulting in chromatin unfolding
[80]. BMPs also stimulate the production of inhibitory molecules to regulate the
signalling cascade. In the nucleus Smad 6 and 7, negatively regulate the cascade
through gene repression. Noggin, a BMP-2,-4 and-7 antagonist, is induced as part of
the negative feedback loop to block BMP binding to receptors in the extracellular
space [39, 74, 76].
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Figure 1-4 Schematic representation of a BMP signaling transduction pathway with
representative regulators. BMP signals are mediated by type I and II receptor
complexes and downstream Smad molecules that are translocated into the nucleus to
regulate gene transcription (adapted from [74]. Noggin is an antagonist that binds
with BMP-2, 4, and 7 to block signaling.
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1.3.3 Clinical use of BMPs
In primates and humans, BMP-2 induced greater mineralized tissue and matrix than
equivalent BMP-7 [61]. Induction of endochondral bone formation has been
demonstrated with rhBMP-2 implants preventing collapse of poly(propylene)
fumarate/tricalcium phosphate scaffolds in load bearing rat femur [9]. In Europe, the
maximum dose of rhBMP-7 is 2 units [81]. Each unit containing 3.5mg rhBMP-7 and
1g collagen type I administered in 3-5ml sterile saline [39]. BMPs promote osteoclast
activation and expansion before osteoblast formation; therefore, large doses can
stimulate resorption before significant bone formation. The upper limit for rhBMP-2
is 12 mg on absorbable collagen sponge, which is more than is present in 1000
humans and 18% of patients treated developed antibodies to bovine collagen [57, 82].
Regardless of this, BMP induction shows effectiveness similar to autografts [83].
BMPs on collagen sponges may suffer a combination of inactivation, physical
displacement and high rates of diffusion from the implant site causing local ectopic
bone formation and inflammation [61]. Humans require a BMP dose forty times
higher than rodents [84]. Large rhBMP-2 doses can induce monocyte adhesion and
contribute to atherosclerosis, swelling and heterotopic ossification [53, 85, 86]. As
soluble factors, BMPs have a short half-life of minutes up to 4 hours and are
systemically cleared by the kidneys [81, 87]. The in vitro effects of recombinant and
human BMP can be detected at femto- and nanomolar concentrations and may
indicate a flaw in the single morphogen approach. Improved efficacy of low dose
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human BMP-7 with recombinant TGF-ȕ was demonstrated in primates [68]. Multiple
growth factor combinations may be more effective than single factor release but
variation in site by site requirement and interactions occurring between specific
signaling pathways triggered by each growth factor adds complexity in vivo [88].
In orthopedic procedures risk factors retarding healing include age, poor nutrition,
diabetes, rheumatoid arthritis, and osteoporosis [89]. Smoking was a predictor of poor
surgical outcome accounting for 75% of post-operative infections [71, 90]. In
circumstances of non-union the number of cells responding to BMP may be limited,
predominantly in the elderly [39]. Efficacy varies with patients, but in aged and more
clinically complex cases rhBMP-2 is less effective than rhBMP-7 [57]. In impaired
patients, rhBMP-7 was superior to autologous bone grafts but more expensive even
with shortened surgery time, reduced pain, morbidity and faster recovery [91]. Due to
high cost rhBMP-2 and -7 are used when all other treatment options are exhausted.
1.3.4 BMP Carriers
Transplanted bovine bone pastes into rats were demonstrated to induce new bone and
marrow cavity formation only in the implantation area and never beyond it [48, 92].
BMPs were found combined with extracellular matrix and transformed attached
responding mesenchymal cells [93]. Purified BMP protein was shown to have
reduced potency when isolated from the matrix; hence, the need for a carrier and
correct local placement to prevent ectopic bone formation in adjacent muscle, nerve
and blood vessels [16]. To trigger the cascade of tissue induction and morphogenesis
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in large animals, sustained delivery of osteogenic BMP is required [93]. Associating
BMP with a carrier restricts degradation, distribution and solubility, to sustain and
enhance gene expression [81]. Heparin adsorption was demonstrated to extend 20-
fold, the half-life of rhBMP-2 and more recently a specific binding peptide sustained
delivery [76, 87].
Established BMP carriers include collagen, guanidine-extracted demineralized bone
matrix, hydroxyapatite and degradable poly(Į-hydroxyacid) polymers [39]. Collagen
sponge compared with a buffer delivery system in a rabbit ulna model retained ten
times more of the initial rhBMP-2 dose after surgery for twice as long [53]. Collagen
I depending on processing has an isoelectric point at neutral to slightly acidic pH and
electrostatically binds rhBMP-2 in the pH range 4.5-6.5, due to a positive net charge
below pH 9 [53].
The ideal qualities of a morphogen delivery vehicle include adequate porosity for
blood vessel invasion; spatial and temporal control of diffusion; mould to defect
shape, provide immediate structural support; minimal immunological response and
undergo resorption coupled to an advancing osteogenic front [94]. To date current
systems based on collagen, biomaterials and hydroxyapatite have advantages but fail
to provide all the requirements of an ideal delivery system.
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Recombinant BMP-2 has been effective in reducing secondary surgical intervention
in comparison to treatment without growth factors. However, the activity of
recombinant BMP-2 from bacteria is 10% of purified human BMP-2 [46] [9].
Competing scaffold growth factor release profile, i.e. burst versus slow release,
remains an issue for maintaining a localized effect, but a poly(lactide-co- glycolide)
scaffold delivering VEGF with plasmid DNA, coding for BMP-2, regenerated bone
in mice over 15 weeks [88].
1.4 Scaffolds
The scaffold is a temporary framework used for access and support in the erection
and repair of large structures. Bioabsorbable engineered scaffolds are temporary
replacement structures that preserve tissue dimension, provide anchorage and
guidance to cells in regeneration and repair [45, 95]. Scaffolds are produced from
inorganic, synthetic and naturally derived materials for use as alternatives to
autografts and allografts [96]. In orthopaedics, bone regeneration is compromised by
foreign body reactions and physical blocking due to incomplete degradation of the
scaffold [81]. Successful scaffold architecture and design should stimulate diffusion,
dictate spatial distribution and tissue ingrowth; hence, pore size and porosity are
crucial parameters.
Ideal bone graft materials incorporate features of a morphogen delivery vehicle with
responding cells [97, 98]. Cell diameter dictates scaffold pore size with 5 µm for
neovascularisation, 5-15 µm for fibroblast ingrowth, 40-100 µm for osteoid ingrowth,
100-350 µm for bone regeneration and > 500 µm recommended for rapid
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vascularisation and survival of transplanted cells [99, 100]. Surgeons want reliable
off-the-shelf graft materials for use in all patients [57]. Inorganic, synthetic and
composite graft materials to date have improved functionality and reduced
antigenicity; but the challenge remains to raise performance to be equal to or better
than autologous grafts [101].
Engineered solutions use metal splints, screws, plates and cages, restoring
functionality with little biological regeneration and interferes with normal growth
patterns, requiring follow up procedures to adjust and remove [45]. Titanium is the
most widely used material for orthopaedic reconstruction and its osteoconductivity
and integration are gained through calcium phosphate coating and surface
architecture [102]. Warnke repaired a mandibular discontinuity in a patient by
seeding a custom made ceramic scaffold with allograft bone marrow cells and
rhBMP-7 into a bovine derived bone mineral scaffold contained within a titanium
mesh [103]. The scaffold initially worked well restoring function, but developed a
fracture in the titanium mesh. Large tissue engineered bone constructs can fail and be
limited by insufficient vasculature and nutrient supply [37].Treating bone fractures
with synthetic tissue engineered bioactive constructs and the patients’ own cells can
potentially improve healing, reduce cost and the need for retrieval [104].
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1.4.1 Scaffold Integration in Bone Healing
Bone-bonding is defined as a “physiochemical process of continuity between an
implant and bone matrix” [105]. At fracture sites, bone formation requires
recruitment and migration of potentially osteogenic cells through the clot to reach the
damaged interface to initiate healing. Osteogenic cells that differentiate before
reaching the target surface stop migrating and produce bone matrix that appear as
bony spicules advancing towards the fracture site [105]. Mechanical stimuli vary the
remodelling rates that control the adaptive response of bone. Scaffold that transmit
strain, stimulate guided bone repair by creeping osteoid formation at 2-10µm/day in
the direction of dominant stress and at 0.3-1 µm/day for general bone remodelling
[20]. Strain stimulates both osteoblastic and osteoclastic activities in bone modelling
and remodelling [106]. Mechanotransduction of cyclic mechanical compression has
been demonstrated to positively influence repair; up regulating proteoglycan and
collagen I production in a chondrogenic model [107]. Strain in young bone can
cause diffuse cracks, but linear microcracks are formed in older bone [108].
Microcrack formation stimulates bone development but can cause implants to loosen.
The cement line is the first extracellular interfacial matrix formed by osteogenic cells
during new bone synthesis. It is a calcified interfacial bone matrix formed at stable
interfaces to tie surfaces together and anchor new to existing bone [105]. Cement
lines are formed during normal bone remodelling (section 1.1.1) and are highly
conserved features across species marking the boundary between one Haversian
system and the surrounding interstitial bone. Osteoclast resorption is an acidic two
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phase process of inorganic matrix dissolution and enzyme degradation to create a
recipient ruffled concave surface approximately 1µm deep, of demineralised collagen
[16].
The carbonated hydroxyapatite matrix of the cement line is deposited within these
invaginated surface contusions forming an interlocked, interdigitated anchorage [17].
Osteoblast attachment is followed by secretion and adsorption of bone sialoprotein
and osteopontin onto the prepared surface, initiating mineralization followed by
calcified crystal growth forming the cement line (Figure 1-5). Collagen is deposited
on the cement line becoming encrusted in it to form anchorage points for new
mineralised bone. The cement line is formed by direct contact osteogenesis on
surfaces with micron scale topography and submicron indentations as discrete
nanocrystalline deposits of calcium phosphate [109].
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Figure 1-5 Illustration of surface deposition of calcified bone matrix on new and
remodelled surfaces. The first step (a) involves adsorption of protein responsible for
(b) mineral nucleation and (c) crystal growth that is followed by (d) extracellular
matrix deposition and mineralization to bone (adapted from [27]).
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Intramembranous bone formation has been observed on inorganic calcified implant
surfaces and synthetic poly(Į-hydroxy acid) based polymers [10, 105, 110, 111].
Implant surfaces that are unstable or lack topological features and pores, including
hydroxyapatite have no cement line formation and poor osteoblast adhesion [112].
The cement line has adhesive bone-bonding and biomechanical function to absorb
energy and provide resistance to fatigue damage and crack growth. At the interface of
materials, direct scaffold contact with bone cement line results in structural continuity
and stability [109]. Hence as scaffolds degrade, the support function can be adopted
by the developing bone structure [113].
Acid etched titanium implants produce surface features on which a coating of
nanometre sized calcium phosphate crystals provide the interdigitation for cement
line formation, bone-bonding (Figure 1-6) and bone growth by apposition [109].
There is no evidence to suggest that the mechanism of bone-bonding with artificial
materials is any different to that which occurs normally [105, 114].
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Figure 1-6 Illustration of appositional bone growth and colonization of an osteogenic
surface by osteoconduction (adapted from [105]).
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1.4.2 Angiogenesis and Scaffolds
The formation of new blood vessels is a key process in tissue generation and is
stimulated by sustained supply of VEGF, PDGF and FGF [34]. VEGF stimulates
osteoblasts and osteoclasts survival, proliferation and migration of endothelial cells
that assemble, forming tubular structures [115]. Increased differentiation in vitro was
observed by co-transplanting endothelial cells in direct contact with bone
mesenchymal stem cells (BMSC), compared to BMSC alone [116]. Both endothelial
and smooth muscle cells produce BMP-2 when in direct contact with osteoblastic
cells, stimulating production of differentiation markers such as alkaline phosphatase
and osteocalcin [117, 118]. The intimate contact of endothelial with osteogenic cells
promotes direct exchange of BMP-2 that was less effectively reproduced by
supplementing media with 100ng/ml rhBMP-2 [115]. Endothelial cell transplantation
on polymeric scaffolds had improved angiogenesis, forming vessels that fused with
host vasculature. Production of BMP-2 by endothelial cells was increased under
hypoxic conditions that could occur after transplantation [117].
1.4.3 Scaffold Formats
Scaffolds can be classified as preformed structures, gels and particulates
(microspheres, fibres) [119]. Preformed fabrication techniques include supercritical
foaming; Rapid Prototyping, electrospinning and sintering [114]. A variety of natural
materials have been used as hydrogels including agar, fibrin, gelatine, and collagen
that form stable networks. Hydrogels can fill defects and deliver mesenchymal stem
cells facilitating their migration across gaps. However, they do not have the
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mechanical properties required for bone function [120]. As tissue engineered
scaffolds hydrogels are problematic suffering poor diffusion properties for nutrient
and oxygen supply which potentially restricts scaffold size [121, 122]. Combinations
of high and low molecular weight alginate gels achieved mechanical rigidity with
rapid bone tissue invasion by the selective diffusion of polymer fragments after chain
scission [123].
Wound closure is a priority action by contractile fibroblast to initiate repair through
scar tissue formation [124]. Porous particulate scaffolds can fill critical-sized defects
(Figure 1-7) providing a 3D template of the void that is, readily accessed by cells
regenerating extracellular matrix [2, 125]. Poly(lactide-co- glycolide) (PLGA)
microspheres cultured with adipose tissue-derived stem cells were demonstrated to-
self aggregate in vivo after injection and provide appropriate rigidity to function as
porous scaffolds for muscle development in nude mice [126]. Particulate scaffolds
with crenulated morphology at the interface may, improve interlocking between the
implant and surrounding fractured tissue walls to participate in bone bonding with
direct deposition of new bone by osteoconductive invasion from adjacent tissue into
the interconnected spaces (Figure 1-7) [55] [105].
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Figure 1-7 Representation of a bone fracture filled with particulate scaffold that define the
space and bridge the gap to connect wound surfaces (adapted from [2]).
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1.5 Particulates in Tissue Engineering
Bone has high tensile and flexural strength with energy dissipation through the ability
to distort [22]. Bone has a hierarchical structure and previous work has established
that it is not feasible to implant an exact replica of trabecular architecture as it
represents an end state unsupported by vascularisation [20]. The preservation and
regeneration of form and function are aims of tissue engineering that are achievable
with particulate materials when controlling parameters such as particle size,
interconnectivity, surface area, architecture and mechanical properties close to native
bone [127]. Commercially available injectable calcium phosphate cements are
biocompatible bone graft substitutes that can custom fit irregular bone defects then
harden in situ [71]. The cement adheres to soft tissue in the absence of blood and is
used for filling cancellous bone [128]. However, cement mixtures extruded beyond
the defect damage surrounding tissue and subtle differences in processing can alter
performance unduly [129]. Cements at 50-60% porosity are brittle with slow
degradation profiles in excess of 5 years [130].
Materials designed to fill bone voids must meet changing mechanical and biological
requirements by providing initial stabilisation, facilitating integration and new bone-
ingrowth with full degradation on completion of defect remodelling [131, 132].
Polyester implants possess mechanical strength that can be tailored to meet initial
requirements then progressively transfer load to surrounding tissues if the speed of
degradation is synchronous with integration and new tissue growth [119, 133].
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Scaffolds that utilise an open-cell repeated architecture have properties similar to
bone and cells may penetrate deeper into them to facilitate endogenous repair [12].
1.5.1 Particulate Design Requirements
Lickorish et al surmised that for bone, no one material possesses all the
physicochemical properties needed for success in situ; hence, there is a need for
adaptation and harnessing the advantages of multiple materials as composites [55].
Particulates may be regarded as modular components of a system that can be
administered by injection. Particulate scaffolds have reduced density in comparison
to monolith materials with increased surface area for physicochemical interaction
[127]. Particle shape is a key determinant of packing density that controls porosity
and rough, porous surfaces aid cell spreading and bone integration [134].[135,
136].High porosity increases the surface area available for protein adsorption, ion
exchange and bone ingrowth in comparison to solid walled materials [137].
1.5.2 Particulate Scaffolds with Gels
Fracture disrupts blood supply and results in fibrin clot formation, which adheres to
most surfaces and facilitates rapid osteogenic cell migration [21]. Combinations of
particulates in fibrin glue lacked porosity and had restricted cell penetration in
common with other gelled systems [122]. Fibrin and poly(ethylene glycol) based
hydrogels with FGF-1 in poly(D,L-lactic acid) and TGF-ȕ1 loaded PLGA
microspheres had retarded release rates that varied with viscosity [138, 139]. This
property of retarded diffusion has been used to protect cartilage cells in an FDA
approved injectable alginate wound dressing. Angiogenesis was stimulated from a
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slow release delivery system of VEGF linked to a fibrin-conjugated network [118,
140, 141]. Bone was produced in nude mice after an injection of goat mesenchymal
progenitor cells and ceramic particles were bound together by extracellular matrix
after in vitro culture [142].
1.5.3 Polymer Ceramic Composites
Preformed ceramic HA and ȕ-Tricalcium phosphate based scaffolds difficult to
shape in theatre to fit defect shapes and may encounter micro-motion that can cause
implant loosening [143]. This loosening can result in considerable tissue disruption;
bleeding, inflammation, coagulation and foreign body response with formation of a
fibrous capsule. Composite calcium phosphate and polymer microparticle based
systems rely on initial cell-polymer attachment and subsequent non-toxic polymer
degradation to form macropores and improve cell ingrowth [144, 145]. Polymer
ceramic composites have shown varying abilities to stimulate tissue growth and give
adequate degradation profile due to a buffering effect [114, 146]. Systems
incorporating enzymes to hasten degradation have been proposed, but such matrices
do not possess structural stability [147]. In addition, the compressive strength of a dry
poly(L-lactide-co-D,L-lactide)-tricalcium phosphate scaffold was reduced from 3.1 to
1.5 MPa in water [119].
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1.5.4 Polymer Scaffolds
Biodegradable polymers are reliably reproduced in high volumes and used in a
variety of fabricated formats in clinical procedures, having features of good
biocompatibility and reliable degradation characteristics [148]. Synthetic polymers
mimic biological matrix in facilitating cell attachment [149]. Scaffold surfaces
favouring strong adhesion and spreading promote osteoblast proliferation and
mineralisation [78, 150]. Demineralised bone matrix, a recognised osteoregenerative
material, produced faster healing when combined with PLGA [151, 152]. Controlled
growth factor release has been demonstrated by surface immobilization and
encapsulation into polymer devices that stabilised the protein and prevented
proteolysis [153], [154]. Protein loss, during fabrication, encapsulation and elevated
heat sintering, remain as issues [155, 156].
1.5.5 Particulate Sintering
The process of sintering enables a single unit to be manufactured from composites
and pure particulate materials [157]. The strength of particulate scaffolds is a result of
material composition, intergranular friction and geometric locking due to topological
surface irregularities [158]. Particulates used in drug delivery systems are now seen
as a means of achieving higher control of parameters such as pore size, surface area
and interconnectivity [127]. The method of manufacture influences the parameters of
shape, compressibility and apparent density. Only the high points of irregular
particles touch forming struts that define the edges of interconnecting (open) pores
[119]. A network of struts produce a low-density solid with voids connected to each
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other through open faces to accommodate mass transfer. Aggregation involves
particle adhesion resulting in higher resistance to compression and tensile stress
[159]. Adhesion between particles is a result of intermolecular forces affected by
material hardness, elastic modulus and temperature of glass transition (Tg), [160].
Adhesion is augmented by increasing the duration of contact or raising the
temperature of the particles.
Compacted, aggregates can be shaped to generate large porous supportive structures
that mimic cancellous bone. For sintering to proceed surface molecules must have
sufficient mobility to move to new positions which is temperature and solvent
dependent. Molecular motion is a consequence of thermal softening that is, time and
temperature dependent [161]. Packed powders will bond when heated in excess of
approximately half their absolute melting temperature in response to atomic motion
[162]. This temperature can be reduced by the addition of plasticizers and heat can be
localised by laser to produce complex shapes with interconnected pores [163].
Sintering involves the mobilization of surface molecules by mechanisms that may
including viscous flow, surface diffusion or evaporation and condensation as
illustrated by the partial dissolution of microsphere in solvent/non-solvent sintering
using ethanol and acetone [162, 164-166]. Surface area is reduced and strength
increased (Figure 1-8) [167]. Surface diffusion produces neck growth between
particles without shrinkage [168]. Recent work shows glassy state materials to have
orders of magnitude more mobility at the surface than in the bulk below Tg [169].
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Therefore, at low temperatures, viscoelastic sintering with reduced densification can
occur [170].
Glass transition varies interchangeably with time and temperature and is accompanied
by changes in thermal conductivity and ductility [160, 171]. Those particles in
cohesive contact with each other form a skeleton capable of mechanotransduction,
compression and resisting shear. After sintering, voids become pores, adding
structure, ductility and transmission [20].
In liquid sintering, a fluid phase coexists with a particulate solid at the sintering
temperature and enhances particle bonding with faster atomic diffusion and
densification during curing [162]. Sintering is quicker in liquid rather than solid
phase and the cohesive internal force generated through liquid capillary action on the
particulate solid gives rapid compact densification without the need for a large
external pressure [162]. An interconnected pore network is formed by the liquid
phase.
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Figure 1-8 Illustration of the particulate heat sintering process to show (A) mass flow
and coalescence through neck formation between particles and (B) diffusion bonding
through heat induced molecular mobility, entanglement, collapse and densification at
the interface of particles (adapted from [160, 162]).
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1.6 Review of Lactide Based Polymers in Scaffold Design
Poly(lactide) is a thermoplastic, biodegradable, aliphatic polyester derived from lactic
acid which is chiral in nature and exists as D and L optical isomers [172]. L- lactic
acid is naturally occurring as a metabolite in the body. Poly(D,L-lactide) is an
amorphous synthetic blend of the isomers made from the cyclic dimers. Condensation
reaction of cyclic lactide with glycolide dimers produces poly(lactide-co- glycolide)
(PLGA) copolymers that can be varied by composition with respect to component
ratio, molecular weight, crystallinity; feed rate during polymerization and post
formed processing to alter properties of strength, degradation rate and solubility [173,
174].
Crystalline polymers undergo a melt phase transition that is absent in amorphous
polymers [175]. The International Union of Pure and Applied Chemists defined Tg
as a second order phase transition, as there is no latent heat involved. Glass transition
is a time dependent change fixed by heating rate and marks the onset of segmental
mobility [168]. Amorphous non-cross linked thermoplastic polymers passing through
the glass transition region with increasing temperature change from brittle solids to
viscoelastic liquids. The properties that make PLGA copolymers suitable for use
include thermoplasticity, biocompatibility, controlled degradation and proven non
toxicity [176]. Lactide polymers and copolymers are thermoplastic and can be
fabricated by a myriad of techniques into structures from nano to centimetre scale
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with custom mechanical properties to fit roles as diverse as drug delivery and
orthopaedic fixation devices [177, 178]. Material use in vivo shows an absence of
infections and transient inflammation, dependent on copolymer blend and site
drainage [59, 179].
1.6.1 PLGA Interaction with Cells
PLGA 75:25 was demonstrated to have a higher rate of osteoblast adhesion in
comparison to tissue culture polystyrene despite being more hydrophobic [113].
Comparison with polystyrene showed the polymer to stimulate higher levels
mineralisation, support deposition of a mineralised cement line, extracellular matrix
production and extended the cell growth period [78, 113]. The initial rate of
adherence was significantly higher for PLGA in comparison to PLA for the first 12
hours with greater osteocalcin production indicating osteoblastic maturation [148].
Initial osteoblast attachment was higher for PLGA 50:50 than PLGA 85:15 but was
reversed by day 15 [180]. In conjunction with this, PLGA 50:50 was demonstrated to
be osteoconductive to osteoblast and fibroblast cells that migrated through the
structure using cytoplasmic extensions [113] [181]. Acellular scaffolds regenerated
bone slower than in vitro seeded constructs in the absence of growth factors [111].
Comparison of primary human osteoblastic cell growth on a variety of poly(Į-
hydroxy esters) used in skeletal engineering, found full expression of key osteogenic
markers, mineralization and maturation of cells [180, 182]. Foamed, porogen leached
and sintered PLGA copolymers have been shown to stimulate bone and cartilage
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repair [183-186]. Bone sialoprotein expression was limited and associated with the
mineralisation process. In combination with BMP-7, PLGA scaffold closed a 15 mm
segmental defect in a rabbit bone model [153].
1.6.2 PLGA Degradation
The popularity of polyesters is attributable to FDA approval status for selective
application, history of use, known degradation profile via ester linkages (Figure 1-9),
and relatively low toxicity potential of metabolites [153, 187]. Degradation in
vivo/vitro begins with random bulk (acid/ alkali ) hydrolysis of the backbone ester
linkages with pH reduction, erosion of mechanical strength without direct enzymatic
cleavage and progressive fragment mobility [179, 188]. Particles up to 10 µm can be
phagocytosed, stimulating an immune response [110, 189]. Enzymes can enhance the
initial in vivo attack producing lactic acid that is metabolised. PLGA copolymer
degradation rates are dependent on composition ratio as higher hydrophilic glycolide
content results in faster degradation [190].
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Figure 1-9 Schematic showing the degradation of poly(DL-lactide-co-glycolide) by
hydrolysis to its constituent materials lactic and glycolic acids that can be further
degraded within the body.
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PLGA 50:50 has the fastest degradation rate and copolymer lifetime is progressively
longer with diminished glycolide content; in addition, thick films degraded faster than
corresponding thin films of the same composition [191]. Fast degradation due to acid
stimulated autocatalysis is associated with low porosity and long diffusion path
lengths [113] [192]. Tissue necrosis occurs when clearance of breakdown products
and nutrient exchange becomes inadequate [34, 144, 193]. Calcium phosphate
addition to PLGA polymers reduced degradation rate and enhanced mechanical
strength [194]. Poly(glycolic acid) degrades quickly with the potential for toxic acid
accumulation as glycolic acid can dimerize to glycolide and activate the complement
inflammatory pathway [195] [190].
The polymer mass initially lost in degradation changes slowly until hydrolysed chains
are small enough to diffuse out of the polymer matrix. Degradation of PLGA
microspheres in mice to glycolic acid, lactic acid and lactoyllactic acid stimulated
increased production of glycosaminoglycans and type II collagen [196, 197].
Localised pH shifts from 7.4-6.8 inhibit alkaline phosphatase activity by > 90% and
stimulated osteoclastic bone reabsorption [198]. Studies with macroporous scaffolds
show bone formation was not demineralised by the acidic degradation products in
porous PLGA systems [10, 111].
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1.6.3 Polyester Plasticization
Polymer blending is a method used for developing new properties from existing
materials. To broaden polyester applications the physical properties of flexibility and
impact resistance are improved by the addition of plasticizers [199]. Plasticizers are at
least partially miscible with the polymer and reduce the temperature at which glass
transition occurs by disrupting the packing of amorphous polymers [200]. PLGA
monomers and oligomers, themselves, are effective plasticizers but accelerate
degradation; hence, choice is limited by the requirements of the application [192, 201,
202]. In the Tg region strength, volume, Young’s modulus and viscoelasticity change
significantly [203]. The mechanical properties of amorphous thermoplastic materials
can therefore be tuned by adjustment of the Tg to a desired temperature [204].
1.6.4 PEG
PEG acts as a hydrogen bond acceptor and its properties are temperature and
molecular weight dependent [205, 206]. High molecular weight PEG is FDA
approved for internal use and polymers 3,350-10000 Da are utilized as mild laxatives
[37, 207]. Ingested PEG 400 is used as an intestinal permeability marker in humans
and excreted unchanged [208]. Intravenous injections of 60% solutions of PEG 400
into primates were nontoxic and PEG 200 at 10% has been used in the
microencapsulation of L929 mouse fibroblast cells [209, 210]. Short chained PEG
has a low capacity to crystallize and high mobility [211]. PEG polymers below 400
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Da can be sequentially oxidised by alcohol and aldehyde dehydrogenase to toxic
diacid and hydroxy acid products and excreted in urine [212]. Reaction rates decrease
with increasing PEG molecular weight [213].
In melt blends with polyesters PEG forms a physical solution without chemical
reaction [214]. Excess plasticizer can separate, crystallize and promote polymer crack
formation under stress [201, 202, 215, 216]. At constant PEG loading PLGA strength
is increased with lactide content [200]. PEG addition exceeding 10%
w
/w to PLGA
significantly reduced tensile strength, and increased ductility [133]. Plasticizer
separation and migration to the surface results in spinodal decomposition (Figure 1-
10) and is accelerated by humidity and storage at temperatures close to and exceeding
the blend Tg [216].
Low molecular weight PEG has improved miscibility and increased plasticization
efficiency [214]. Polymer blends below glass transition undergo molecular relaxation
towards thermodynamic equilibrium [217]. This ageing process lowers the free
volume for molecular motion as a function of time. The further restrictions of
molecular motion in aged polymers prevent the absorption of impact energy and the
material becomes more brittle [218].
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Figure 1-10 Illustration of (A) thermodynamically unstable annealed polymer blend
that undergoes spontaneous separation, starting with small fluctuations in
composition (B) to produce a dispersed droplet structure and spinodal demixing
through to (C) coalescence of the segregated phases.
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PEG leached from PLGA left the polymer surface pitted [133]. PLGA wet strength is
inversely related to glycolide content [204]. Wet PLGA-PEG copolymers at pH 7.4
swell by a factor greater than 3.5 times and are progressively softened; losing
significant strength after a week; whereas wet PLGA polymers show increased
modulus [219, 220]. PEG via physical and covalent coating can modify polymer
biocompatibility [221, 222].
1.7 Structuring Mechanisms of Injectable Scaffolds
Injectable scaffolds administered by arthroscopic and open surgical procedures can be
moulded to fit defects then undergo in situ polymerization or cross linking to develop
mechanical integrity and interconnected porosity within clinically relevant timescales
for cell survival [223, 224] . All components of the injectable system introduced
individually and collectively must be non-toxic and the solidification mechanisms
have minimal impact on the homeostatic balance within the wound and surrounding
tissue.
Curing via chemical initiators activated by UV and visible light wavelengths include
camphorquinone and benzoyl peroxide [189]. Chemical cross-linking is a versatile
strategy as shown by poly(propylene fumarate) that cross links via thermal and
photochemical reactions with compressive strengths comparable to cortical bone
[225]. These cross linkable polymers must avoid dilution of the initiator and cross
linker ratios in order to control the density of the final polymer network structure
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[143, 226]. The toxicity of reactive agents in addition to collateral reactions require
temporary cell encapsulation in e.g. gelatine to improve viability [227].
Thermal gelation has been used for a number of synthetic and naturally derived
polymers such as poly N-isopropylacrylamide, gelatin and agarose [228]. Polymers
undergo reversible solubility changes involving chain entanglement and collapse in
response to temperature changes [229]. The sol-gel transition temperature can be
tuned by altering copolymer composition and polymer molecular weight [230, 231].
Poly-D,L-lactic acid-polyethylene glycol copolymer had to be heated to become
injectable and was used to deliver rhBMP-2 in mice with bone formation [232, 233].
Work at Nottingham University demonstrated the injectable delivery of solid
biotinylated PLA-PEG microspheres mixed with cells [234]. The system relied on the
specific interaction of avidin with biotin transforming an injectable dispersion into an
elastic solid with high storage modulus. The crosslinked structure, formed in situ with
cells, had controllable pore size up to 100µm in diameter and was capable of
delivering growth factors. The system achieved full structural integrity within
seconds to perform the tertiary function of retaining the existing tissue shape to
promote cell ingrowth.
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1.8 Porosity and Pore Size of Scaffolds
Scaffolds are a balance of competing parameters with mechanical strength inversely
related to the scaffold pore size [235] [236]. As the size of particulate scaffold
components are scaled up, porosity and flux are increased, but fewer struts hold the
construct together for a given volume. Pore size distribution, architecture, and
interconnectivity influences nutrient permeability, cell migration and polymer
degradation characteristics [58, 237]. The need for porosity to support bone
regeneration was demonstrated by comparing solid with porous HA implants
delivering BMP-2 in a rat ectopic model. Bone was formed only on the porous
implant [112, 238]. Low porosity and reduced pore size (< 40 µm) induced hypoxia,
cell aggregation and differentiation to chondrocytes [20, 236].
Increasing scaffold porosity alone is insufficient; the balance between mechanical
strength and sufficient initial void volume for cells must be met [132, 239]. High
porosity (>80 %) in vivo and large pore size produce improved bone ingrowth but
compromised scaffold strength [240]. PLGA scaffold collapse due to extracellular
matrix contractile forces from fibroblasts and osteoblasts was observed [240] [49,
143, 241].
The clinical requirement for porosity vary by fracture site with spinal fusion 80%
porosity and hip revision 60% porosity[7]. The 100 µm minimum pore size was
proposed following in vivo work in dog femoral bone with calcium aluminate
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cylindrical pellets of 46% porosity [242]. In contrast titanium plates with 50-125 µm
pore sizes, implanted in non load-bearing rabbit femoral had bone ingrowth in all
voids [236]. Scaffolds with pore diameters of 10-100 µm have been used as
haemostatic devices [111]. Optimal pore size for tissue regeneration was believed to
be in the 100-500µm range with bone ingrowth biased towards larger pores [243]
[244]. Rose et al showed a minimal diameter of 80µm was required for cell
migration in ceramic scaffolds, but Jones and Hench suggested pore diameters
>100µm to be secondary to interconnectivity affecting the type of tissue and rate of
formation as early fibrous tissue invasion can choke pores[132, 245]. Work with HA
based scaffolds with BMP-2 showed pore diameters of 95-120 µm to initially favour
chondrogenesis and pores > 350 µm osteogenesis [246]. Recently, 350-800 µm
diameter pores were shown to have a limited impact on bone regeneration in vivo
with poor growth factor retention [247]. Pore dimensions and diffusion path lengths
play a crucial role in solute transport and the occurrence of autocatalysis in PLGA
microparticle based scaffolds [192]. Material and biological requirements play a key
role in determining minimum pore size and interconnectivity.
In vitro culture and cell colonization of constructs can indicate porosity requirements
quite different to that required in vivo and was most notable in load bearing
conditions where HA with pore diameter < 200 µm was not regarded as suitable for
in vitro cell seeding due to limited cell penetration and growth of cell sheaths that
choked pores, further restricting diffusion [111, 248].
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1.8.1 The Compromise of Structure and Morphology
Dense ceramics and polymers have high strength and stiffness to match cortical and
cancellous bone; but porosity causes a reduction in strength [249]. The designed
mechanical properties of a scaffold are dependent on geometry, material composition,
compilation and must be based on measurable bone mechanical properties such as
stiffness (Young’s Modulus) and strain encountered [101]. Young’s modulus is a
structure-insensitive property barely influenced by small in-homogeneities in micro-
and macro- construction [250]. The mechanical properties of cancellous bone vary
with orientation and the morphology of bone present with the upper limits of porosity
and pore size dependent on mechanical and structural constraints specific to the tissue
sites [22] [251]. Scaffolds must satisfy local mechanical properties specific to the
implant site, in order to optimise integration with surrounding tissue [15, 251].
1.8.2 Living Constructs
Cell survival in large (4-8 cm diameter) scaffolds for segmental bone defects remain
an issue as initial surface growth at the implant boundary can limit nutrient and
oxygen transport to the interior in osteogenic scaffolds [49]. Asymmetric cell loading
to the periphery of scaffolds produced greater ingrowth in comparison to evenly
seeded structures [252]. To increase the potential for vascularisation and cell
penetration a polarised hierarchical distribution design with large pores oriented to
the exterior in a heat sintered PLGA scaffolds has been proposed [49]. In mice,
defects showed faster cell differentiation and bone deposition to occur with PLGA
implants than without and seeded scaffolds in critical-sized defects produced faster
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bone regeneration than acellular constructs [111, 253]. However, this method
potentially requires two invasive procedures; the first to recover bone fragments for
expansion and seeding of the scaffold and the second to implant the construct. Ex-
vivo cultivation is expensive with potential to introduce infections [243].
There is a clinical need to ensure even cell growth throughout tissue engineered
scaffolds, avoiding dead void volumes. Strategies devised to facilitate this include in
vitro use of rotational bio cultures to perfuse media throughout preformed scaffolds,
plasma polymerised surface chemical gradients, entrapment of chemotropic growth
factors acting to stimulate inward cell migration and pre-vascularised implants
generated in the body [254-258].
1.9 Injectable Scaffolds
The emergence of arthroscopic techniques in tissue repair, provide alternative
procedures to open surgery and implant removal. Minimally invasive techniques
preserve the integrity of blood supply in soft tissues, decrease complications and
reduce recovery time [90]. Injectable bulking agents have been delivered
endoscopically to treat clinical conditions of reflux and incontinence [118]. The
reduced invasiveness of procedures and low associated morbidity minimise scar
tissue formation, patient discomfort and make this an outpatient procedure. Injectable
poly(lactide) nanoparticles have been widely used in parenteral drug delivery and
molecular self-assembly systems that reside at the injection site until biodegraded
[259, 260]. Injection of polymeric micro and nanoparticles form porous networks of
fluid permeated diffusion channels and improved localised targeted drug efficacy
over conventional applications with reductions in side effects, drug costs and
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frequency of administration [84, 261]. Injectable solid rhBMP-2 formats would have
low systemic exposure and provide an alternative to open surgical procedure [70, 81,
262]. Simultaneously delivery of cells with growth factor may therefore be
advantageous in stimulating healing.
1.10 Aim:
If Tg controls amorphous material transition from soft to hard matter then reduction
of polymer Tg may improve particulate sintering at physiological temperature. This
research aims to develop an injectable scaffold system for use in bone regeneration
and repair. In this system, micron sized particulate PLGA based polymer will be
applied as an injectable cell delivery vehicle that can custom fit defects then harden to
a macroporous structure to support and regenerate bone with the option for localised
controlled growth factor release.
In detail, the material is injectable as a two component system with a component I
that is temperature insensitive. Component II is the cohesive temperature sensitive
constituent with a Tg within the normal physiological range of the body. Component
Ι depending on its morphology and composition may functions as a porous spacer, 
cell carrier and drug delivery vehicle. Component Ι can be a randomly shaped 
microparticle or microsphere that can be further modified to be of low or high
porosity with surface modifications for enhanced cell attachment and or drug delivery
potential. Mixing Component Ι and ΙΙ in an appropriate ratio with exposure to body
heat results in a crosslinked fully-interconnected porous structure (Figure 1-11).
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Figure 1-11 Illustration of scaffold components that are sintered to form a porous
structure composed of microspheres in combination with adhesive component II.
When the temperature is raised above the glass transition temperature of the adhesive
component II, it softens and deforms by mass flow resulting in particle coalescence.
Component I microspheres have a glass transition temperature higher than the
adhesive component and are not deformed at the sintering temperature; this results in
limited shrinkage and retained interconnected porosity.
Chapter 1
56
The objectives will be to:
x Optimise temperature sensitivity to be clinically relevant and non-toxic to
cells.
x Design in mechanical properties compatible with the structural properties of
bone.
x Be injectable and mouldable
x Define and measure what is happening macroscopically to the scaffold around
the softening and sintering points.
x Control porosity to improve nutrient diffusion and cell ingrowth into the
scaffold.
x Demonstrate cell and therapeutic growth factor delivery
1.11 Conclusion
Improved understanding of fracture complications has enabled the use of degradable
synthetic materials to be considered advantageous in tissue engineered solutions. The
current challenges and complications in bone repair are infections, low strength of
union, incomplete degradation of implants and poor vascularisation leading to re-
fracture with slow and painful healing rates in some patients [42]. Tissue engineering
as a concept can address these challenges. In this work, cells, growth factor and
scaffold are deliverable by a minimally invasive technique to develop an environment
suitable for bone growth.
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2 Materials and Methods
This chapter describes the materials and methods used for work carried out in
this thesis. All general chemicals and reagents were purchased from Sigma-
Aldrich (Dorset, UK) unless otherwise stated.
2.1.1.1 Microspheres Preparation by Emulsion and Solvent
Evaporation
Poly(vinyl alcohol) (PVA) molecular weight 23,000 and 87-89% hydrolyzed
was purchased from Sigma-Aldrich (UK) and poly(DL-lactide-co-glycolide)
from Lakeshore Biomaterials, USA (PLGA 50:50, Low I.V. inherent viscosity
of 0.57 dL/g and 2kD polydispersity). A 1litre solution of PVA 0.3%
w
/v in
distilled water was made the day before use and stirred overnight in a glass
container. The solution was filtered twice: first through a Whatman 540
ashless filter followed by a 0.2 Pm pore size filter before use. In a scintillation
vial, 6 mL of dichloromethane (HPLC grade) was added to PLGA (1.2 g) and
blended. PEG 400 (Fluka, Germany), 0.9 mM, (360 mg) was added to the
scintillation vial and vortex mixed at 2750 rpm for 2 minutes. PVA 0.3%
solution, 6 mL, was added to the scintillation vial and vortexed for 20-30
seconds at 1500 rpm. The resulting mixture was pipette transferred to a
hardening bath containing 800 mL of PVA 0.3% solution and stirred overnight
in the fume hood to allow evaporation of DCM. The microspheres were
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recovered on a Whatman 540 filter, washed three times with distilled water,
vacuum-dried for a minimum of 48 hours and vacuum-sealed prior to storage
in a fridge until used.
2.1.1.2 Microsphere Preparation with Polyethylenimine
In a scintillation vial, 4 mL of dichloromethane was added to PLGA (1.2 g)
and blended. Dichloromethane 1.5 mL was added to a blend of 1.33 µM
polyethylenimine (0.033 g) (Sigma-Aldrich (UK)) with PEG 400, 0.9 mM,
(0.36 g) and dispersed by vortex before being added to the scintillation vial
with PLGA and mixed at 2750 rpm for 2 minutes. PVA solution, 6 mL, was
added to the scintillation vial and vortexed for 20-30 seconds at 1500 rpm. The
resulting mixture was pipette transferred to a hardening bath (800mL of PVA
0.3% solution) and stirred overnight in the fume hood to allow evaporation of
DCM and microspheres recovered as previously described in section 2.1.1.1.
2.1.2 Salt Leached Porous Particles
PLGA (0.9 g), was placed into a 50 mL centrifuge tube with 2 mL DCM and
blended until homogenous. Sieved 212-300 µm sodium chloride (Sigma-
Aldrich, UK), (12 g), was added in stages to the centrifuge tube interspersed
with vortex mixing to form a sticky ball. Additional sodium chloride (6 g), was
placed onto a ceramic tile and the polymer ball blended with it and flattened to
a thin flake layer using a rolling pin. The solvent was removed from the flakes
by evaporation in a fume hood over 24 hours [133]. After evaporation, the
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brittle flakes were broken into pieces approximately 1x1 cm in dimension and
placed in 2 L of distilled water with 4 changes in 48 hours to leach the sodium
chloride out of the polymer. The leached particles were recovered on a
Whatman 540 ashless 125 mm filter and dried overnight at 40 °C. The dried
flakes were vitrified in liquid nitrogen; ground and sieved fractions were
vacuum sealed and stored in the fridge.
2.1.3 Type II Temperature Sensitive Particles
PEG 200 was supplied by Fluka (UK) and PEG 1000, 2000 and 5000 by
Sigma-Aldrich (UK). PLGA and PEG were combined in a range of weight
fraction melt-blends as small (2 g) batches.
PLGA 100 99 98 95 85 80 0
PEG 1000 0 1 2 5 15 20 100
Blends were ground into a powder using a standard coffee bean grinder. Melt
blend PLGA with PEG powder (approximately 110 mg) was placed in each
well x12 of a Teflon mould (5 mm diameter and 10 mm height), used to
standardise scaffold dimensions for testing.
Chapter 2
60
2.1.4 Compression Testing
Scaffolds, 9 mm long and 5 mm diameter were cast in a mould and sintered at
different combinations of time and temperature, dry and wet. Constrained and
unconstrained uniaxial compression tests were conducted with a TA XT plus
Texture Analyser from Stable Micro Systems (Surrey, England) fitted with a
Peltier controlled environmental chamber. The ramp speed of 0.01 mm/sec
was used for all test conditions, dry and wet [17]. Uniaxial compression test
measurements were displayed as stress versus strain graphs. For each
specimen tested, the maximum force resisted (strength) and Young’s modulus
were recorded and displayed as mean ± standard deviation. Statistical tests
used were analysis of variance and Tukey-Kramer multiple comparison test to
determine significance between variables.
2.1.5 Rheology
Rheological measurements were conducted on a Physica RC 301 (Anton Paar,
Austria) with parallel plate geometry and environmental hood. Non-destructive
oscillatory measurements were conducted under nitrogen gas flow to
determine structural change with temperature. Figure 2-1 shows the
temperature response profile of an amorphous PLGA material and the Tg
detected by the three principal parameters of elastic modulus (G’), loss
modulus (G’’) and phase angle (į). The phase angle (į) plot (Figures 2-2)
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provides more information on the structural changes occurring in response to
temperature and was used in this thesis. The rubber plateau occurs in the
region after the Tg where the material has a deformable structure due to
increased molecular mobility but does not flow as polymer network
entanglement and interactions form a highly viscoelastic state.
Oscillation measurements were conducted at constant gap and controlled strain
(0.1%) with a 25 mm parallel plate. The temperature was ramped from 4-90 °C
at a rate of 1 °C / minute. Samples (0.2-0.4 g) were loaded onto the plate at 18
°C and the environmental hood lowered into place. The temperature was
lowered to 4 °C under a dry nitrogen stream, prior to starting the experiment.
This procedure was necessary to prevent condensation of water on the sample.
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Figure 2-1 Oscillation temperature ramp profile from 4-90 °C of amorphous
PLGA 85:15 with 5% PEG content at 0.1% strain. It shows the phase angle
(ratio of loss modulus to storage modulus) plot (į) to provide the most
information on structural changes in response to temperature.
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Figure 2-2 Oscillation phase angle profile illustrating changes in the material
in response to temperature ramp from 4-90 °C and 0.1% strain. Physical
properties such as elastic and viscous moduli change significantly across the
glass transition region.
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2.2 Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry measures heat flows associated with
temperature-induced transitions (Figure 2-3). Standard DSC experiments were
conducted to find the temperature and width of transitions. Differential
scanning calorimetry measurements were conducted on a 2920 DSC from TA
Instruments (UK). Powder polymer samples, 5-10 mg, were placed into
aluminium pans and hermitically sealed. The samples were heated at 10 qC per
minute under a flow of nitrogen in temperature ramps from –40 qC to 120 qC
followed by a 10 qC per minute cooling ramp and subjected to five
temperature ramp cycles.
2.2.1 Modulated DSC
It is not possible to achieve optimum sensitivity and resolution in a single
standard DSC experiment. Modulated DSC measurements were conducted on
samples at a heating rate of 1 qC per minute, from -20 qC to 120 qC, r0.159 qC
amplitude, 60 seconds modulation period and cooled at 10 qC/minute to -20 qC
for two repeated cycles.
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Figure 2-3 A differential scanning calorimetry (DSC) profile of an amorphous
polymer with a glass transition phase detected as a sigmoidal shift in heat
flow. Typically, a single temperature taken at the inflection point (the midpoint
between extrapolated onset and end temperatures) represents the temperature
range over which the glass transition takes place.
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2.3 Wenger Transition Phase Analyser
The Wenger Transition Phase Analyser is a closed-chamber capillary
rheometer designed to detect softening and flow of multi-component solid
materials in response to temperature at a constant pressure. The closed system
does not allow moisture to escape; hence, its effect can be measured linking
thermal transitions to physical compaction strength [263]. Particulate scaffold
materials were made up fresh and stored at 5 qC under vacuum before 1.83 g
was loaded into the compression chamber. Samples were compacted at 10 qC
and 150 Bar pressure for 5 seconds to form solid pellets. The pressure was
reduced to 100 Bar and the temperature ramped linearly at 5 qC per minute.
The experiment was ended when the material was mobile enough to flow out
of the chamber through a rubber seal under pressure. The equipment measures
displacement induced by temperature and enables the controlling glass and
melt transitions to be detected (Figure 2-4). The controlling Tg onset, is the
temperature at which displacement begins when a sufficient amount of the
sample has softened. The transition melt is the point at which the material
begins to flow. The Transition Phase Analyser enables the correlation between
temperature and physical change. The amount of plasticizer and increasing
pressure can shift the measured Tg [264].
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Figure 2-4 Displacement plot showing features of a Transition Phase Analyser
curve, relating thermal transitions to physical compaction.
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2.4 Cell Culture Methodology
Cells were seeded in Dulbecco’s Modified Eagle’s Medium (42430-025) from
Gibco (Paisley, Scotland), supplemented with 10% (
v
/v) foetal bovine serum
(FCS), antibiotic consisted of 100 units/mL penicillin, 25 µg/mL amphotericin
B and 0.1 mg/mL streptomycin. Recombinant BMP-2 was purchased from
Peprotech Incorporated (New Jersey, USA), BSA Fraction V (A7906) and
FITC-BSA (A9771) from Sigma.
2.4.1 Metabolic Assay
The Alamar Blue (Serotec) oxidation-reduction assay was used to determine
cell activity. Nonfluorescent resazurin indicator was reduced in cells to
resorufin within minutes and correlate with the number viable cells [265].
Dead and dying cells reduce resazurin slowly over two to four days and heat
inactivation stops reduction showing enzyme dependence [266, 267]. Alamar
blue was diluted to 10% (
v
/v) in phenol free Hank’s balanced salt solution
(HBSS) buffer, sterile filtered and equilibrated to 37 °C. Scaffolds (x3) were
washed in PBS (x3) and transferred into new tissue culture wells. Cells grown
on tissue culture plastic were rinsed ( x3) in PBS and incubated in a
standardized volume (1 mL) of Alamar Blue solution for a maximum of 90
minutes and measured on a MFX Microtiter plate fluorimeter at 530 nm
extinction and 590 nm emission with Dynex Revelation 4.21 software.
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2.4.2 Hoechst 33258 Quantification of DNA/ Cell Number
Scaffolds and controls without cells were washed (x3) in phosphate buffered
saline then freeze dried overnight. Dried scaffolds were incubated with 1 mL
papain solution (1.06 mg/mL) overnight at 60°C in pH 6.5 papain buffer.
Papain buffer (200 mL) was prepared by dissolving 0.1 M dibasic sodium
phosphate (1.42 g) , 0.005 M cysteine hydrochloride (0.079 g) and 0.005 M
EDTA (0.186 g) in distilled water. Papain digest aliquots (38 µL) were placed
in triplicates in a 24-well plate and 0.75 mL Hoechst 33258 (1.8x 10
-6
M) in
distilled water added to each well. Fluorescence induced by the DNA and dye
complex was measured using a MFX Microtiter plate fluorimeter at 355 nm
excitation and 450 nm emission.
2.4.3 In situ Cell Seeding
The introduction of a cell suspension to compressed particulates in the barrel
of a 1ml syringe (with the nozzle cut off) to trigger wet sintering of a scaffold,
was termed in situ seeding (Figure 2-5). Blended type 1 and 2 particles, 200
mg, in a 1:3 ratio was loaded and compressed using a plunger from another
1ml syringe (secondary plunger). A suspension of 5x105 cells in 100 µL buffer
was introduced into the syringe barrel with a pipette and mixed through the
compacted particulate by the pull/push (x4) action of the primary plunger. The
syringe was placed upright in a humidified incubator (37 °C, 5% carbon
dioxide in air) for 15 minutes to sinter and the moulded scaffold ejected into
warmed media and cultured on an orbital rocker plate (88 rpm).
Chapter 2
70
Figure 2-5 The staged process of in situ scaffold production with (a) 1 mL
syringe from which the nozzle was removed (b): a secondary plunger was
provided and used in (c) to compress particulates before introducing (d) the
cell suspension dose. After sintering in the upright position the cell seeded
scaffold (e) was ejected.
a
b c
d e
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2.4.4 Scanning Electron Microscopy (SEM)
Scaffolds with cells were washed with PBS (x3) to remove media then
immersed in glutaraldehyde solution 3% in PBS overnight at 4
o
C. These
scaffolds were rinsed (x3) in PBS and covered in 1% osmium tetroxide
solution (TAAB Laboratories, UK) for two hours at room temperature.
Osmium tetroxide oxidises unsaturated bonds to carboxylic acid and is itself
reduced adding density /contrast to cells. Scaffolds were washed in distilled
water (3 x 15 minutes) and air dried in a fume hood overnight. At this stage
samples could be viewed by micro CT prior to gold coating for SEM.
Scaffolds without cells were air dried, mounted on adhesive aluminium stubs
and gold coated for 3 minutes in a Blazer SCD 030 sputter at 30 mA (Blazers
Union Ltd. Liechtenstein). The samples were viewed with a Jeol 6060LV
variable pressure scanning electron microscope (Jeol Ltd. UK) at an
accelerating voltage of 15 kV.
2.4.5 Alizarin Red Staining
Cell seeded scaffolds were fixed in cold buffered formalin 10% solution
overnight and washed (x3) in distilled water. A 2% (
w
/v) solution of Alizarin
red (Sigma, UK) in water was prepared fresh, prior to use and adjusted to pH
4.2 with sodium hydroxide. Samples were stained for 5 minutes then rinsed
three times in distilled water.
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2.4.6 Alkaline Phosphatase Detection on Tissue Culture Plastic
The Sigma Fast p-Nitorphenyl phosphate test kit (Sigma, UK) was used as
per the instructions. Briefly, the tablets were dissolved in 20 ml distilled water
forming a 1 mg/mL solution and 600 µL was added to the test material for a
specified period of time and measured on the KC4 (Bio-Tek Instruments USA)
plate reader at 410 nm. Alkaline phosphatase activity was expressed per well
or per cell.
2.4.6.1 Alkaline Phosphatase Detection on Scaffolds
Scaffolds were washed in PBS prior to staining for the localization of alkaline
phosphatase activity. Scaffolds were immersed in Napthol AS-MS buffer
solution (Sigma, UK) containing 1 mg/mL Fast violet B salt (Sigma, UK) up
to 25 minutes at room temperature for colour development by precipitation
onto the cells due to the action of alkaline phosphatase enzyme. Scaffolds were
washed three times in distilled water then viewed.
2.4.7 Micro-computed Tomography of Scaffolds
Micro-computed tomography (micro-ct) is a non-invasive technique
combining x-ray with tomographical reconstruction to create 2D consecutive
images (slices) of the internal structure of porous materials. From the 2D slices
3D images of scaffolds can be reconstructed to show internal structure.
Scaffolds, with and without cells were examined with a Micro-CT 40
instrument from Scanco Medical, Bassersdorf, Switzerland; to determine
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porosity and pore size distribution. The visualisation of cells required
densification or use of a contrast agent such as osmium tetroxide [268, 269]
detailed in section 2.4.4. Scaffolds were scanned at the same power setting of
55 kV and 145 mA current. Scaffold 2D images were threshold to distinguish
polymeric structures from pores. Parameters such as volume, porosity and pore
size were determined from the threshold images.
2.4.8 Statistical Analysis
All the results were expressed as the mean ± standard deviation. The statistical
package used was GraphPad InStat® 3.05 (GraphPad Software Inc., San
Diego). Statistical analysis was performed on a minimum number of samples
(n = 3) and comparison between groups was performed using a one-way
analysis of variance (ANOVA) with Tukey-Kramer multiple comparisons
post-test. Statistical significance was set at p < 0.05 (*), very significant p <
0.01 (**) and highly significant p < 0.001 (***).
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3 Plasticization of PLGA Particles
3.1 Introduction
Minimally invasive surgical techniques with injectable matrices can readily fill a
defect void to mimic its shape [270]. To prevent collapse of the filled volume the
injectable material must harden to become self supporting against the local
mechanical environment. In order to develop mechanical integrity, injectable
materials must polymerise or crosslink in situ requiring the components and
process to be non-toxic to the surrounding tissue [271]. If solidification can be
achieved at body temperature with minimal cell disruption, then the low
invasiveness of the procedure retains tissue integrity and function whilst filling the
architecture of the defect [272]. The structural rigidity developed by the scaffold
facilitates healing by bridging the void to provide continuity with migratory access
to cells if porous and a boundary for the regenerating tissue [2, 225].
The work in this chapter builds on the literature reports of PEG as a plasticizer for
PLGA. The Tg of blends with PLGA and PEG was tailored to undergo a phase
transition, post injection; as it is warmed to body temperature. The aim of the work
in this chapter was to produce a particulate PLGA formulation optimised to sinter
within the body. The amorphous state is unstable to thermal and mechanical stress
[203, 273]. Retaining the amorphous state is essential to control the
physiomechanical properties of the material. DSC and rheology are established
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independent material characterisation techniques that are complementary for
measuring thermal and structural changes.
3.2 Methods
3.2.1 Manufacturing Particles
PLGA with PEG melt-blends were prepared as described in chapter 2, section
2.1.4. Particles were reduced in size to pass through a 500 µm sieve then dried and
stored under vacuum until used.
3.2.2 Differential Scanning Calorimetry (DSC) Evaluation
Standard DSC heating rate of 10 qC/minute has a high level of sensitivity and low
rate of resolution. The polymers PLGA 50:50 Low IV and 85:15 High IV were
supplied by Alkermes Inc. Blends of PLGA with PEG were stored in vacuum
sealed glass vials in the fridge. The weighed samples (5-10 mg) were sealed into
hermitic aluminium pans and measurements were conducted on a TA2920 DSC
(TA Instruments, UK) at 10 °C/min ramp from -40 to 120 °C. Modulated DSC
was conducted on PLGA with PEG blends to improve resolution at heat only
amplitude of ± 0.159 °C over a modulation period of 60 seconds and 1 °C/minute
heating rate to determine Tg and the impact of composition on thermal transitions.
3.2.3 Rheological Evaluation
Oscillation temperature ramp measurements were conducted as described in
chapter 2, section 2.1.5.
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3.2.4 Wenger Transition Analyzer
The transition analyzer measures the ability of a material to resist physical
compaction as a function of increasing temperature. Blends of 50:50 PLGA with
PEG 1000 were compared to determine the impact of varying PEG content on
compression strength. The second series of experiments combined the temperature
sensitive 50:50 PLGA with PEG 1000 microparticle blend with microspheres or
porous salt leached particles at a ratio of 3:1 whilst maintaining the weight load of
1.83 g. Experiments were conducted using the procedure detailed in chapter 2,
section 2.3.
3.3 Results and Discussion
3.3.1 Rheological Evaluation of PLGA Blends with PEG of Varying
Molecular Weights
The oscillation temperature ramp profile detects thermally induced phase changes
occurring between 4-90 °C. PEG 200 and 400 were fluid with viscous behaviour
under the test conditions used. For clarity PEG 200 was not included in Figure 3-1
as it was overlaid by the PEG 400 profile. PEG 600 and 1000 were of a paste or
soft wax consistency at 4 °C.
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Figure 3-1 Comparison of oscillation temperature ramp profile of PEG using
controlled strain (0.1%) from 4-90 °C. The graph compares PEG 400, 600, 1000,
2000 and 5000 used to modify the Tg of PLGA.
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PEG 600 and 1000 lose structure over a narrow temperature range and Figure 3-1
shows the materials to have a staggered increase in Delta values. PEG 2000 and
5000 had a low delta plateau at temperatures below 40 °C followed by a rapid
increase in values. The oscillation profile clearly distinguishes between those
materials (PEG 400, 600 and 1000) that melt below 37 °C and higher molecular
weight material that do not. The staggered rise in Delta value may be due to the
polydisperse nature of the melting phases of PEG materials that are often blended
to achieve an average molecular weight [212, 274].
3.3.2 DSC Evaluation
The DSC trace of PLGA 50:50 in Figure 3-2 show the glass transition in the
heating curve and solidification from the cooling cycle. The first cycle in Figure
3-2 detected transitions in the material influenced by processing, and storage
conditions referred to as thermal history. This was observed as the separation of
the first from the 4 successive repeat cycles. The energy required to traverse the
phase transition on the first heating cycle was 2.67 J/g with 0.44 J/g for the
second and subsequent heating cycles. For amorphous materials ageing effects
occur in the glass transition region [217]. Thermal history of a sample can be
eliminated by heating 30 °C above the Tg and maintaining temperature for 5
minutes.
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Figure 3-2 DSC trace of 50:50 PLGA (36 kDa) ramped at 10 °C/ minute through
five cycles from -40 to 120 °C. The plot shows the Tg region to shift with the
elimination of the ageing effects after the first cycle. Tg values for the first and
fifth cycles are shown.
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The heating protocol used in these experiments eliminated the ageing effect and
the overlay of subsequent cycles shows the DSC characterization did not damage
or alter the polymer. The age induced shift in the Tg was to a lower temperature
value, but required greater energy input to pass through the transition.
The result for PEG 1000 run on the same protocol (Figure 3-3a) shows that there
was no glass transition present in this material, only a broad melting peak with the
midpoint at 40.48 ±15 °C. The large crystallization peak in the cooling cycle
began below 20 °C. The first heat ramp cycle was displaced to a higher
temperature in comparison to successive cycles that overlap to show repeatability.
The PEG 1000 cooling cycle profile detected solidification beginning at 19 °C and
showing less uniformity than the melting curve. These results may indicate the
disperse molecular weights of components or the presence of competing PEG
crystal forms in the cooling exotherm. Enthalpy relaxation involves molecular
rearrangement to a more stable configuration and a reduction in free volume with
time [218]. Ageing enhances crystallization of PEG with higher rigidity resulting
in a shift to higher temperature and energy being required for the melt transition
[201, 273].
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Figure 3-3 DSC trace showing melt and crystallization peaks of (a) PEG 1000 and
(b) PEG 400 ramped at 10 °C/ minute through five cycles from -40 to 120 °C.
Crystallization peak
Melting peak
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The DSC profile for PEG 400 (Figure 3-3b) has similar features of melt and
crystallization peaks to PEG 1000, but displaced to lower temperatures.
The crystallization peak for PEG 400 was displaced below -5 °C and the melting
peak began at -20 °C. The transitions for PEG 400 were overlaid for each cycle
and were below the proposed conditions for use in the body (37 °C). There was no
age induced effect present in the PEG 400 DSC profile as crystallization occurs
below storage conditions. Additional structures were therefore present in PEG
1000 and eliminated by the heating protocol. Comparison of Figures 3-2, PLGA
and 3-3a, b shows the dominance of the PEG transitions from the scaling of the
heat flow. PEG 1000 melt transitions occur at a lower temperature than the Tg of
PLGA and the re-crystallization transition was close to fridge (0-5 °C) storage
conditions indicating that sample ageing was likely to occur.
In Figure 3-4, the 99% PLGA with 1% PEG 1000 blend and Figure 3-5 98%
PLGA with 2% PEG 1000 showed a progressive displacement of the Tg to lower
temperatures with increased PEG content. In melt blends with polyesters PEG
forms a physical solution without chemical reaction [214]. The 95% PLGA blend
with 5% PEG (Figure 3-6) shows a separation of the first from successive cycles.
For the 95% blend the transition was displaced to below body temperature. The
age induced displacement of the first run was present in all blended materials.
Similar effects have been reported for PLA [275].
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Figure 3-4 DSC trace of 50:50 PLGA (36KDa) with 1% PEG 1000 ramped at 10
°C/ minute through five cycles from -40 to 120 °C . The graph shows the
separation of the first from subsequent cycles that overlay each other. The Tg
values for the first and fifth cycles are shown.
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Figure 3-5 DSC trace of 50:50 PLGA with 2% PEG 1000 ramped at 10 °C/ minute
through five cycles from -40 to 120 °C. The graph shows the separation of the first
Tg from subsequent repeat cycles that overlay each other. The Tg for cycle 1 and 5
are shown.
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Figure 3-6 DSC trace of 50:50 PLGA with 5% PEG 1000 blend ramped at 10 °C/
minute through five cycles from -40 to 120 °C. The graph shows the Tg for cycle
1 and 5.
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The DSC trace of 85% PLGA with 15% PEG blend (Figure 3-7) shows separation
of each of the successive temperature ramp cycles, resolved in the Tg region.
These phase transitions were not eliminated after the first or successive
temperature ramp cycles, but diminished. The gradual erosion of this phase
transition may indicate the increasing effect of PEG. The first cycle transition
peak also shows a shoulder at 32 °C that was not repeated in the successive cycles.
The DSC plot for the 80% blend showed a definite shoulder and separation of the
successive ramp cycles in Figure 3-8. The separation occurred not just in the peak
transition, but also throughout the heating ramp indicating that high PEG content
introduces variability in the thermal transitions and phase separation. Uneven
mixing of PEG at 20 % w/w with PLA has been recorded, with separation in PLGA
at 30 %
w
/w [133, 201].
At high PEG content  15% w/w , the inability of the heating protocol to overlay
successive temperature ramp cycles indicates possible de-mixing and separation
of the blend has occurred. The effect of PEG has been previously recorded to
become dominant at 10% addition with evidence of rapid demixing at higher
levels [200, 273]. Molecular mobility effects in glassy materials have been
detected by DSC up to 50 °C below Tg [203].
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Figure 3-7 DSC profile of 50:50 PLGA with 15% PEG 1000 ramped at 10 °C/
minute through five cycles from -40 to 120 °C. The graph shows a separation of
first and successive cycles with a large endothermic transition. The Tg for run 1
and 5 are shown.
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Figure 3-8 DSC five cycle run of 50:50 PLGA 80% with 20% PEG 1000 ramped
at 10 °C/ minute from -40 to 120 °C. The graph shows a separation and change in
heat flow for each successive heating ramp. The Tg values for run1 and 5 are
shown.
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Comparison of the first cycle run MDSC data from 50:50 PLGA blends with PEG
1000 in Figure 3-9 show a positive correlation of increasing transition width with
increased PEG content of the blends. Thermal sensitivity of PLGA blends with
PEG 1000 up to 15 %
w
/w was enhanced and broadened; responding to lower
trigger temperatures. The increasing PEG 1000 content lowers the transition
temperature reaching an optimum at 5% content. The peaks for the 95 and 85%
PLGA 50:50 blends coincide on the temperature scale as can be seen in Figure 3-9
differing in the energy required to traverse the transition by 50%. This may have
implications in the body with a restricted maximum temperature and limited
heating rate; it would take longer to traverse the transition.
For the 50:50 PLGA dominated materials containing up to 5% PEG, the effect of
ageing was a decrease in the transition temperature whereas for the blends
containing greater than 15% PEG there were two glass transition regions above
and below the normal region in Figure 3-9. The 80% PLGA 50:50 blend has a first
cycle transition similar to a melting event and is attributable to the dominance of
PEG that requires 6 times more energy to go through the thermal melt transition
and may indicate separation of the blend. In contrast, the second MDSC heat cycle
in Figure 3-10 shows a single broad transition displaced to lower temperatures,
requiring less energy.
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Figure 3-9 MDSC comparison of the first heating cycle of 50:50 PLGA and blends
with increasing levels of PEG 1000. MDCS was conducted at 1 °C/minute from -
20 to 120 °C, modulated ± 0.16 °C for 60 seconds (n = 3). The width of the
transitions increased with PEG addition.
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Figure 3-10 Comparison of the second MDSC heating cycles of 50:50 PLGA with
increasing levels of PEG 1000 in blends. MDCS was conducted at 1 °C/minute
from -20 to 120 °C, modulated ± 0.16 °C for 60 seconds (n = 3). The plot shows a
reduction in the temperature at which transitions occur with increased PEG
content.
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PLGA 85:15 polymer with blends varying in PEG 400 content were evaluated by
MDSC and the first cycle results in Figure 3-11 shows that Tg was reduced with
increased levels of PEG 400. The width of the transitions was widened with
increasing levels of PEG 400 extending Tg onset to lower temperatures. For the
PLGA 80 curve with 20% PEG 400 added, there was a second transition present;
displaced to below 0 °C. A similar feature was present in the 80% PLGA 50:50
blend with PEG 1000 in Figure 3-9. Comparison of the second heating cycles for
85:15 PLGA 80 Figure 3-12 and 50:50 PLGA Figure 3-11, shows only one
transition that began below 0 °C. Comparison of the heat flow energy between the
first and second cycles of Figures 3-11 and 3-12 show them to be much reduced.
Hence the impact of ageing was to increase the energy required to effect a
transition.
Summary of the second cycle Tg values in Figure 3-13 compare PLGA 50:50 and
85:15 blends and shows PEG 400 to be more effective than PEG 1000 in reducing
glass transition temperatures despite differences in the molecular weight and
composition of the initial materials. The efficiency of Tg reduction by low
molecular weight PEG has been previously reported [276]. Miscibility of blends
was improved by lower PEG molecular weight and reduced polydispersity [277].
Both PLGA polymers show a similar profile with declining impact on Tg
reduction above 5% PEG addition.
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Figure 3-11 First cycle MDSC profiles comparing 85:15 PLGA blends with
increasing PEG 400 content. MDCS was conducted at 1 °C/minute from -20 to
120 °C, modulated ± 0.16 °C for 60 seconds (n = 3). The plot shows a reduction in
Tg and a widening of the transitions with the increased addition of PEG 400.
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Figure 3-12 Second heating cycle MDSC comparison of 85:15 PLGA with PEG
400 blends. MDCS was conducted at 1 °C/minute from -20 to 120 °C, modulated
± 0.16 °C for 60 seconds (n = 3). The plots show a progressive reduction of Tg
with increasing PEG content.
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Figure 3-13 Second cycle MDSC derived glass transition temperature summary
compares blends of 50:50 PLGA /PEG 1000 with 85:15 PLGA/ PEG 400 (n = 3).
The profiles show increasing PEG content to reduce Tg.
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3.3.3 Rheological evaluation
The oscillation rheology profiles of 50:50 PLGA blends with PEG 1000 in Figure
3-14 show the onset of phase angle increase to occur at progressively lower
temperatures with increased PEG content. The increased phase angle values at low
temperature indicate enhanced viscoelastic mobility with PEG addition.
Increasing the PEG content of blends to 15 % and above produced a shoulder in
the curve displaced to lower temperatures that may indicate thermal demixing and
spinodal decomposition within the composite.
The increased viscoelastic mobility of the blends at low temperatures was
reconciled with the MDSC observations of widening transitions with higher PEG
content. The phase angle increase at lower temperatures with elevated PEG 1000
content show that the material was more readily deformed. Similar changes in
phase angle have been observed for plasticized PLA [202]. The temperature range
of the rubbery phase after Tg was reduced and displaced to lower temperatures
with increased plasticizer content. This may indicate the disruption of polymer
molecular packing and chain interaction.
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Figure 3-14 Oscillation rheology temperature ramp comparison of 50:50 PLGA
and blends with PEG. The temperature ramp from 4-90 °C (n = 3) shows increased
low temperature sensitivity with elevated levels of PEG addition.
Chapter 3
98
The rheological profile for PLGA 85:15 blends with PEG (Figure 3-15) show
similar trends in Tg reduction and viscoelasticity to that of the 50:50 PLGA in
Figure 3-14. Increasing levels of PEG 400 enhanced viscoelastic mobility at low
temperatures. PLGA 85:15 blend with 10% PEG 400 had two peaks in the
temperature ramp profile that may indicate phase separation at this level of
addition. Similar changes in thermal transitions and mechanical properties in
response to increased PEG content have been reported [216].
The graphs (Figures 3-14, 15) differ in appearance with the 50:50 PLGA peaks
becoming broader with increased PEG content and the 85:15 PLGA profiles
remaining narrow, but shifted to a lower temperature. This may be due to a
molecular weight effect with 85:15 PLGA 118 kDa and 50:50 PLGA 36 kDa . The
impact of increased plasticizer levels on disrupting molecular packing results in a
loss of structure. A similar loss in phase angle was reported by [202]. The graph
in Figure 3-16 provides a summary of the Tg shift determined by oscillation
rheometry and shows PEG 400 to have a greater reducing effect on the glass
transition temperature. The Tg values of the blends compared show a plateau
effect on increasing PEG content above 5% in Figure 3-16. From the MDSC and
rheology results, the 5% blend was regarded as optimum for Tg reduction to
within body temperature whilst retaining miscibility and used on both PLGA
50:50 and PLGA 85:15 blends for further studies.
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Figure 3-15 Oscillation temperature ramp rheology profile of 85:15 PLGA blended
with PEG 400 from 4-90 °C showing increased viscoelastic behavior at lower
temperatures with increasing levels of PEG (n = 3).
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Figure 3-16 Comparison of glass transition temperature determined by oscillaton
rheology; comparing the polymers PLGA 50:50 blended with PEG 1000 and
PLGA 85:15 blended with PEG 400; showing Tg reduction with increased PEG
addition (n = 3). PEG 400 achieved a greater effect on lowering Tg temperature.
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3.3.4 Transition Phase Analyzer
Unmodified PLGA particulates under pressure had a stable plateau up to a Tg
onset temperature of 18.5 qC in Figure 3-17 and indicates the ability of the
material to withstand loading. The rate of deformation slowed to a second (rubber)
plateau between 39 and 50 qC, after which the rate of deformation increased with
further softening of the polymer in this region. The results for particulate blends of
PLGA 50:50 with PEG 1000 in Figure 3-17 showed Tg displacement to begin at
lower temperatures with increased PEG content.
As the PEG content of the blends increased the low temperature plateau became
shorter to not being detected in the 85% PLGA sample under the run conditions
used. Increased PEG content has also reduced the extent of the upper rubber
plateau and the temperature at which it occurs. Increased levels of PEG reduced
the network structure of the polymer, its ability to bear load and therefore maintain
porosity. The glass plateau region for 85% PLGA 50:50 was therefore below the
measurable operating temperature of the equipment indicating that the thermal
sensitivity for such blends could occur close to fridge storage temperatures of 4
°C. These results were in agreement with the parallel plate oscillation experiments.
Similar observations of reduced strength and increased ductility have been
reported [133, 200].
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Figure 3-17 Transition phase analyzer 5 qC/min temperature ramp profiles of
PLGA 50:50 blends with PEG 1000 under 100 Bar constant load. It shows
decreasing structural resistance to deformation under pressure with increased PEG
1000 content.
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The relationship between storage temperature and Tg is crucial to preventing
premature particle aggregation and ageing. There was good agreement between
results obtained with the phase analyzer and MDSC glass transition onset
temperature. The glass transition region covers a temperature range conventionally
quoted as a midpoint value; however, a more relevant measure for use might be to
quote an onset value given our intention to place the material in bone cavities
under pressure from the surrounding tissues.
The Transition Phase Analyzer measures the controlling Tg of blended materials
under constant load and increasing temperature as structural loss and displacement
attributable to increased polymer chain mobility [264, 278]. The magnitude of
thermal change as detected by DSC was small in comparison to the physical
impact of the change in solid structure under compression. Thermomechanical
methods are more sensitive in resolving the strength of transitions than DSC
measurements [279].
Figure 3-18 compared 95% PLGA 50:50 particulate blends in combination with
PLGA 50:50 microspheres or PLA salt leached particles. The data shows that the
inclusion of spheres and particles increased resistance to compression. Plasticized
95% PLGA 50:50 particulates had lower compression resistance than unmodified
PLGA with higher displacement at lower temperatures.
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Figure 3-18 Comparison of a 3:1 weight ratio of 50:50 PLGA 95% PEG blend
with microsphere and microporous PLA salt leached particles in resisting
compression forces in a Transition phase analyzer. The 5 qC/min temperature
ramp profiles were conducted with 100 Bar constant load.
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Both microspheres and salt leached spacer particles increased the length of the
rubber plateau compared to the starting 95% PLGA 50:50 blend. Microspheres
showed higher compression resistance that extended above 40 qC. Figure 3-18
shows the rapid compression of salt leached particulates. The lower density of the
salt leached material was apparent from the initial loading equilibration point
showing a larger volume to be occupied by the same loading weight of particles.
The displacement for the 95% PLGA with microsphere combination was 2 mm in
comparison to 6.2 mm for the salt leached particulate. This salt leached material
had faster compaction under loading in comparison to the other materials under
test at lower temperature, indicating high porosity and low strength [204, 280,
281]. To increase the strength of salt leached PLGA particulate scaffolds,
compression moulding in the rubber region but below flow was conducted to
retain porosity [282].
The 95% PLGA 50:50 blend and microsphere particulate combination had higher
strength and resistance to compression than salt leached particles. Compression
resistance is a critical feature in supporting the integrity of scaffold filled defects.
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3.4 Conclusion
Hot blended PLGA with PEG mixtures produced polymers with reduced Tg and
mechanical properties that could be tuned to desired temperatures. The
combination of PLGA with PEG blends was shown by DSC to reduce Tg and
induce an enthalpic ageing shift that required more energy to pass through the
phase transition. The dominant effect of phase separation was detected at 10% and
higher PEG addition levels with DSC and oscillation methods. The impact of PEG
extends beyond initial glass transition temperature reduction to influence
compressive strength, manufacturing consistency and storage stability of the
blend. The selection of the 95% PLGA blend for further work represents a
compromise between required body temperature sensitivity, reproducibility,
strength as measured rheologically and the properties desirable for application of
the blended material.
DSC measures the amount of energy needed to effect phase changes in materials.
PEG 400 achieved a greater reduction in Tg at moderate addition levels of 5% in
comparison to PEG 1000, but the magnitude of enthalpy change in the blends were
similar. DSC does not indicate the point at which temperature stimulates flow.
Rheology was complementary in linking physiochemical properties with thermal
transitions. The oscillation method used, produced results similar to the DSC
showing PEG 400 to have a greater reduction of the glass transition temperature.
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Within a multi-component system, a major component may become sufficiently
melted to flow without other components approaching their melt temperature. The
results from the Transition Phase Analyzer showed that minimizing PEG content
increased the resistive compressive strength of PLGA blends. The addition of the
porous component increased compression resistance with microspheres having a
greater impact than salt leached microporous material. Microspheres as spacers
formed pores as could be discerned from the starting displacement position.
Microspheres in combination with blended temperature responsive 95% PLGA
improved scaffold compression resistance strength and may help retain porosity
post sintering. The two-component scaffold system has been formulated, based, on
a single polymer using different processing routes.
The aim of the work in this chapter was to produce a blend of PLGA and PEG
with a glass transition phase response below 37 °C. The Tg of the PEG/PLGA
blend was tailored close to body temperature, in order to undergo a phase
transition post injection; during the rise to body temperature. The techniques used
to detect changes in the physiochemical and mechanical properties of the blended
polymers passing through the glass transition indicated a requirement to minimize
plasticizer levels to reduce the impact of ageing and phase separation.
Optimization of scaffold features including strength, porosity and degradation are
determined by application and influence the choice between PLGA 50:50 and
85:15.
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4 Evaluation of Sintering Characteristics and Scaffold
Strength
4.1 Introduction
Injectable scaffolds for connective tissue repair must undergo a mechanism of
structuring to develop mechanical integrity. Scaffold mechanical integrity is
necessary to maintain the bone-implant interface and enable load transfer [97].
Mechanical stress and strain provides essential stimulus as part of the normal
signal transduction pathway for maintenance, growth and the repair of injury [15,
283]. Mechanical stimuli vary with the remodelling rate of bone [20, 284, 285].
Bone cells respond to static, cyclic and compressive strain with increased
remodelling and BMP-2 release [117, 286, 287]. Implants that elastically oscillate
reproducing normal mechanical stresses have a reduced foreign body response at
the tissue- implant interface [251].
Thermoresponding systems undergo physico-chemical changes at transition
temperatures that may depend on molecular weight and adsorption. The
determination of setting time to gain mechanical integrity for injectable calcium
phosphate cements was evaluated by compressive strength testing of cylinders
after various incubation times and by rheological measurement methods [288,
289].
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4.1.1 Aims
The aim of the work in this chapter was to evaluate particulate sintering of PLGA
85:15 blends with PEG. To investigate the setting time and compressive strength,
measurements were conducted on cylinders sintered under various conditions of
temperature, time and environment. The fluids tested included potential carriers
for cell transplantation. To determine solidification times and analyze the nature of
the sintering mechanisms, oscillation rheology and DSC techniques were used to
inform discussion of the sintering mechanism. The objective was to develop a
particulate formulation that can be triggered to assemble in situ at normal body
temperature, forming a self-supporting, porous, biodegradable scaffold with
strength comparable to cancellous bone.
4.2 Methods
4.2.1 Viscoelastic Measurements and Tg
Oscillatory temperature ramp measurements were conducted as described in
chapter 2, section 2.1.5. The effect of varying PEG molecular weights on PLGA
phase transitions were monitored with phase angle.
4.2.2 Scaffold Compressive Strength Evaluation
Scaffolds were sintered in a Teflon mould from compacted melt blended
particulates to determine the strength and the impact on mechanical properties.
Temperature and sintering duration were varied. Cylindrical scaffolds (5 x 9 mm
high) were ejected from the moulds prior to unconstrained compression testing.
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Uniaxial compressive strength of the scaffolds formed, was determined at a
constant strain rate of 0.01 mm/sec. A Peltier hood attached to the equipment
allowed samples to be tested under constant environment of temperature, wet and
dry.
4.2.3 Wet Sintering
The fluids tested for wet sintering were distilled water, phosphate buffered saline
(PBS), supplemented Dulbecco media (42430) containing 10% serum, 0.9%
sodium chloride solution (NaCl) and Hanks balanced salt solution (HBSS). A
range of PLGA 85:15 compositions with PEG 400 were evaluated for temperature
sensitivity and the strength of association formed.
4.2.4 Constrained and Unconstrained Compression
To determine the impact of confining environments on scaffold strength,
constrained compression tests were conducted on 97 and 95% PLGA 85:15 blends
with PEG 400. Scaffolds were sintered for one hour in a variety of wet and dry
environments; equilibrated for a period of 30 minutes at 37°C and tested immersed
in the sintering fluid.
4.2.5 Evaluation of Liquid-scaffold Interaction
To evaluate compositional changes in the particulate components, sintering was
conducted for fixed 24 hour time periods and the materials vacuum dried for 5
days. Samples pre and 24 hour post sintering were subjected to oscillation
rheology and MDSC evaluation.
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4.3 Results and Discussion
4.3.1 Rheological Evaluation of PLGA Blends with PEG
PLGA 50:50 was blended with 5% wt/wt PEG of varying molecular weight to form
95% PLGA 50:50 and the effect on Tg profile compared to the unmodified
material. All PEG materials reduced the Tg of PLGA 50:50 to varying extents as
shown in Figure 4-1 and increased the viscoelastic mobility of the blended
material at lower temperatures. The glass transition temperature values for the
series PEG 200 - 5000 varies from -63 to -23 °C [290].
The thermal responsiveness of the blends did not correlate with PEG molecular
weight as can be seen in the onset temperature rise in delta value of the PLGA
50:50 blends. The pattern of delta values below 40 °C differed to those above 60
°C. Blends formed with PEG 5000, 2000 and 200 had lower mobility above 60 °C
and the results were not correlated with PEG molecular weight. Below 40 °C the
highest mobility was achieved with PEG 600 followed by PEG 1000 and 400. The
PLGA 50:50 blend with PEG 1000 shows a double peak in the oscillation
temperature ramp profile. The peaks coincide with PEG 1000 melting point and
Tg end point peak for the PLGA blend at 49 °C (Figure 4-1).
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Figure 4-1 Oscillation temperature ramp comparison of PLGA 50:50 and 5%
weight fraction blends of PEG, varying in molecular weight, to determine the shift
in viscoelastic properties (phase angle). Oscillation temperature ramp profiles were
conducted from 4-90 °C at 0.1 % strain (n = 3).
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The Tg onset profile in Figure 4-2 was viewed with consideration to the 37 °C
sintering temperature target. The profile was more clearly resolved with the mid-
range molecular weight PEG blends performing better than PEG 200, 2000 and
5000. Similar results of blends with PEG 400 having a lower glass transition than
those with PEG 200 have been previously described [291]. This may indicate that
there is an optimum packing distribution based on the molecular weight
distribution of the PEG or the presence of water.
The phase angle (delta (į)) values show the viscoelastic properties in the Tg
region, which indicates the adhesive properties of toughness and flexibility. The
flexibility was due to the addition of PEG that increased the delta value, showing
greater viscoelastic behaviour in comparison with the unmodified PLGA. To act as
an adhesive, the PLGA/PEG blended material needs a degree of mobility to
deform and spread. Viscoelastic behaviour in the Tg region dictates adhesive
properties and the lower the delta value the higher the elastic modulus and
adhesive strength as bonding involves low deformation rates.
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Figure 4-2 Oscillation temperature ramp profile comparing PLGA 50:50 and 5%
weight blends with PEG of varying molecular weight from 4-60 °C at 0.1% strain
(n = 3). This plot shows the activation region for Tg onset and viscoelastic
mobility.
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4.3.2 Effect of Sintering Temperature and Composition on
Compressive Strength
The summary graph of cylindrical scaffold compressive strength in Figure 4-3 was
compiled from materials dry sintered for 24 hours, then compression tested at 25
°C. There was an inverse relationship between PEG molecular weight and
sintering temperature below 60 °C. The highest scaffold strength below 60 °C was
achieved with low molecular weight blends. The sintered compressive strength of
each PEG blend series decreased with temperature. The graph shows a very
significant (p < 0.001) decrease in the PEG 200 blend compressive strength with
sintering at 37 °C and 35 °C.
As the sintering temperature was raised incrementally for each condition there was
an increase in the lateral mobility of particle surfaces then an increase in bulk
diffusion [292]. Sintering at 60 °C exceeded the Tg of all materials and scaffolds
were reduced in size to solid pellets. Sintering above the TG temperature results in
Newtonian viscous flow [167]. The plasticising influence of PEG was not apparent
at 60 °C and the statistical variation in the p-value was not significantly greater
than would be expected by chance. The plasticizing influence of PEG was seen at
sintering temperatures below the Tg for the unmodified PLGA such as 45 °C.
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Figure 4-3 Comparison of unconstrained uniaxial compression strength of 95%
PLGA cylindrical scaffolds sintered at a range of temperatures for 24 hours with
PEGs of different molecular weight. Scaffolds (n = 4) were subjected to uniaxial
compression at 0.01 mm/sec strain at 25 °C. Statistical significance denoted as *
(p < 0.05), ** (p < 0.01) and *** (p < 0.001).
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The unmodified PLGA particle formed a scaffold of lower strength than the PEG
5000 blend at 45 °C, but was not significantly different. Scaffolds formed by the
PEG 5000 blend were significantly (p< 0.05) weaker in compressive strength than
PEG 2000. The blend rheology profile in Figure 4-1 showed PEG 5000 to have the
least influence on TG and was confirmed by low sintering strength below 45 °C.
Figure 4-3 shows that low temperature sintering was best with low molecular
weight PEG blends. Weak scaffolds were produced by PEG 2000 and 5000 blends,
sintered at 37 °C. The strongest scaffolds were produced by low molecular weight
PEG blends. Scaffold blends made from 5% PEG 2000 and 5000 in Figure 4-3
were very significantly lower in strength (p< 0.001) than the other PEG blends.
From these results, blends with PEG 200-600 appear to be the most appropriate
choices for low temperature sintering at and below 37 °C. For sintering at
temperatures higher than 45 °C the choice of PEG 2000 and 5000 blends offer the
added advantage of stable non-sintering products at room temperature in contrast
to the low molecular weight PEGs that require cold storage for stability.
Figure 4-4 shows representative raw stress-strain compression profiles obtained
for 95% PLGA blends with PEG scaffold series sintered at 37 °C. Compressive
resistance to stress was inversely related to PEG molecular weight. The results in
Figure 4-4 also show the ability of low molecular weight PEG to plasticize PLGA
at low sintering temperatures to improve ductility [214].
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Figure 4-4 Representative stress/strain compression profiles (n = 4) of 95% PLGA
blends with PEG of varying molecular weight sintered at 37 °C and compression
tested at 0.01 mm/sec and 25 °C.
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4.3.3 Sintered 98% PLGA 85:15 with PEG Varying in Molecular
Weight
For comparison with the 95% PLGA series, 98% PLGA 85:15 blends with the
same PEG profile as previous, were sintered and compression tested under the
same experimental conditions and shown in Figure 4-5. The graph shows that the
highest values of strength were obtained for the 60 °C sintering condition. At the
45 °C sintering condition, the unmodified PLGA and PEG 5000 blend failed to
form viable scaffolds. The strongest scaffolds formed at 45 °C were blended with
PEG 400. The ability of low molecular weight PEG to form scaffolds at 37 °C and
below was lost in 98% PLGA blend compositions, showing the level of PEG
inclusion to be vital to scaffold formation. Comparison of 95% and 98% PLGA
85:15 PEG blend series showed a very significant reduction in sintered strength for
equivalent scaffolds.
4.3.4 Impact of Varying PEG400 Content on Sintered 85:15 PLGA
PLGA 85:15 and blends with PEG 400 at 45 °C were dry sintered for two and a
half hours; equilibrated for an hour at room temperature and subjected to
unconstrained compression test at 25 °C. The results (Figure 4-6) show the
compressive strength to increase with PEG 400 addition reaching a maximum at
15% that was significantly (p< 0.05) higher in comparison to 5% PEG 400.
Unmodified PLGA 85:15 polymer did not sinter under these conditions.
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Figure 4-5 Comparison of compressive strength for 98% PLGA blended with
varying PEG molecular weight after sintering for 24 hours at 45 °C. Compression
profiles were obtained at 0.01 mm/sec and 25 °C (n = 4). Statistical significance
denoted as ** (p < 0.01) and *** (p < 0.001).
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Figure 4-6 Effect of PEG 400 blends with PLGA 85:15 on compressive strength
and Young’s modulus of scaffolds, dry sintered at 45 °C for 2.5 hours.
Compression profiles were obtained at 0.01 mm/sec strain and 25 °C (n = 4).
Statistical significance denoted as * (p < 0.05) and ** (p < 0.01).
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Unconstrained scaffold strength was increased by material flow at sintering
temperatures and neck formation between particles. Therefore scaffold strength
increased until material flow continued at the 25 °C test condition. The results in
chapter 3 showed 15% PEG addition to reduce Tg within test conditions. The
highest value for Young’s modulus was obtained for the PLGA 95% blend and
was within the range needed for cancellous bone. In the PLGA 95% blend
Young’s modulus shows neck formation to have occurred during sintering but the
rigidity of the weld and Tg remained high and were unaffected by the 25 °C test
condition. The effects of PEG were shown to become dominant at 10% addition in
chapter 3 with Tg below 30 °C (Figure 3-12). Similar results of increased structure
disruption at 10% plasticizer addition have been recorded [200, 202]. The
significant (p<0.01) increase in Young’s modulus with PEG 400 addition from 2
to 5% was due greater neck formation during sintering and Tg being unaffected by
the compression test temperature. Scaffolds require stiffness for transmission of
strain.
4.3.5 Comparison of 24 hour Dry and Wet Sintering
The image in Figure 4-7 shows wet sintering to alter the appearance of 85:15
PLGA with PEG 400 blends in comparison to unmodified PLGA. The appearance
of the PLGA 85:15 control particles was unchanged and all particles were similar
in appearance to the control before immersion.
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Figure 4-7 Teflon mould with scaffolds wet sintered in distilled water. The un modified
PLGA 85:15 control particles were unchanged in appearance and did not sinter after 24
hours at 45 °C to form cylindrical scaffolds. Particles containing PEG 400 turned white in
appearance from the colour of the PLGA 85:15 control.
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The change in appearance may have been due to the creation of submicron pores
that scatter light. Plasticizers have been postulated to occupy pores that disrupt
polymer packing and lower Tg. When plasticizers are leached from polymers they
leave subsurface voids of the order 0.2- 0.5 µm that scatter impinging light that
pass through media with different refractive indices [293]. Similar results have
been recorded by others with PEG migration [133, 294].
The particulate scaffold was intended for use as an injectable material, which
would sinter in situ in a physiologically wet environment. Blended PLGA with
PEG was evaluated under conditions that were clinically relevant. Blends were
sintered at temperatures up to 45 °C and compression strength tested at 37 °C wet
and dry for comparisons. In this study, wet sintering did not decrease scaffold
compressive strength. The graph (Figure 4-8), confirmed earlier observation that
sintering at 45 °C produces scaffolds with higher strength than at 37 °C for both
dry and wet conditions. Sintering at both 37 and 45 °C in distilled water (DW)
produced scaffolds significantly (p< 0.001) stronger than the dry condition. The
result for dry compressive strength at 37 °C was similar to that 3.2 MPa obtained
for foamed PLGA (Thomson et al 1995). Previous work with PLGA 75:25 films
immersed in buffer has recorded increased strength and modulus [220]. Wet
strength and modulus was demonstrated to increase with lactide content of PLGA
[204].
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Figure 4-8 Comparison of wet and dry compressive strength of cylindrical
scaffolds after 24 hours sintering at 37 and 45 °C. Particulate 95 and 97% PLGA
85:15 blends with PEG 400 were sintered dry, in DW (distilled water), PBS,
Serum (10% serum containing media), HBSS and NaCl (0.9% sodium chloride
solution). Compression test was conducted at 0.01 mm/sec strain and 37 °C (n = 3).
Statistical significance denoted as ns (not significant) and *** (p < 0.001).
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The data also show that PBS, serum, HBSS and sodium chloride at body
temperature retard the development of scaffold strength in comparison to distilled
water. With the exception of the dry sintered scaffolds at 45 °C, PLGA 97%
produced weaker scaffolds than the corresponding PLGA 95% blend but was not
significantly different. PBS sintering of the PLGA 95% PEG 400 blend at 45 °C
produced scaffolds significantly (p < 0.001) stronger than the dry condition. Serum
sintered scaffolds at 45 °C were of lower strength in comparison to 0.9% sodium
chloride, water and HBSS. Serum proteins have been recorded to reduce the
strength of calcium phosphate bone cement [128]. In contrast to these results
increasing the temperature from 25 °C to simulated physiological environment at
37 °C for PBS incubated PLA and PLGA scaffolds reduced compressive strength
and was attributed to water uptake [204, 241].
In Figure 4-9, the graph of Young’s modulus for the PLGA 95% blends show that
very significantly (p < 0.001) stiffer scaffolds were produced in distilled water
(wet) sintering at both 45 and 37 °C in all combinations except for the 97% PLGA
blends. At elevated temperatures of 45 °C significantly stiffer scaffolds (p <0.001)
were produced under wet sintering conditions compared to dry. Sintering at 45 °C
produced stronger scaffolds than at 37 °C and appears to offer a method to
circumvent issues of interference with phosphates (PBS) and serum proteins.
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Figure 4-9 Comparison of dry and wet 24 hour sintering at 37 and 45 ° C to show
Young's modulus developed under the experimental conditions with PEG 400
loading at 3% and 5%. The conditions were dry, DW (distilled water), PBS, Serum
(10% serum containing media), HBSS and NaCl (0.9% sodium chloride solution).
Compression profiles (n = 3) were obtained at 0.01 mm/sec and 37 °C conditions.
Statistical significance denoted as ns (not significant), ** (p < 0.01) and *** (p <
0.001).
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4.3.6 Sintering Strength Comparison at Short Timescales
This comparison was conducted at reduced time scales to determine the integrity
of structures formed at clinically relevant timescales of 15 minutes and 1 hour in
Figure 4-10. The scaffold structures formed were ~20% of the strength of 24 hour
sintered scaffolds. 97% PLGA with PEG 400 blended particles formed a scaffold
suitable for handling and test only in sodium chloride after one hour. After 15
minutes dry sintering 95% PLGA scaffolds were very significantly (p < 0.001)
stronger than 97% PLGA. The scaffold structures formed in HBSS buffer by the
95% PLGA blend were comparable to those formed in sodium chloride and PBS.
The 95%PLGA blend in serum containing media was significantly weaker (p <
0.05) than HBSS and other sintering conditions except for PBS where there was no
significant difference. The Young’s modulus developed in these wet sintered
scaffolds (Figure 4-11) was greater than those values developed by dry sintering
with the exception of serum containing media. The 95% PLGA scaffolds sintered
at 37 °C for 24 hours in both HBSS and sodium chloride solution were stiffer than
those produced in PBS but not significantly so. These results indicate that the
95% PLGA 85:15 PEG 400 blend formed stronger scaffolds, faster than 97%
PLGA. Both PBS and serum containing media appeared to retard the formation of
scaffolds at 37 °C after 24 hours. Dried scaffolds formed at the reduced timescale
were less stiff than wet sintered scaffolds.
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Figure 4-10 Comparison of scaffold compressive strengths after sintering at 15
minutes (Q) and one hour (H) with PEG 400 compositions at 5% (95%) and 3%
(97%). The sintering conditions were dry, wet DW (distilled water), PBS, 10%
serum containing media (Serum), HBSS and 0.9% sodium chloride solution
(NaCl). Compression profiles were obtained for n = 3 at 0.01 mm/sec strain and 37
°C. Statistical significance denoted as * (p < 0.05) and *** (p < 0.001).
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Figure 4-11 Graph comparing Young's modulus developed by scaffolds sintered at
the reduced timescales of 15 minutes (Q) and one hour (H) with PEG 400
compositions at 5% (95%) and 3% (97%) loadings. The conditions were dry, wet
DW (distilled water), PBS, 10% serum containing media (Serum), HBSS and
0.9% sodium chloride solution (NaCl). Compression profiles were obtained for n =
3 at 0.01 mm/sec strain and 37 °C. Statistical significance denoted as ** (p < 0.01)
and *** (p < 0.001).
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Dissolution of PEG is exothermic and its diffusion in water shows molecular
weight dependence dominated by hydrogen bonding [274]. Water forms a
hydration shell around surfaces to influence diffusion kinetics and
thermodynamics. Water alone does not stop PEG migration or miscibility, which
is influenced by the concentration and type of ion present in solution [295, 296].
The development of two or more immiscible phases in an aqueous system is
commonplace with water soluble polymer and low molecular weight solute above
a critical concentration. PEG is one of the most common components of these
systems and is hydrated strongly with several water molecules accounting for its
high solubility [297].
The electrostatic interaction of ions with surfaces affects the hydration layer and
interaction of absorbed molecules such as proteins [298]. Phosphate anions have a
greater electrostatic potential and interaction than chlorides in the Hofmeister
series [296]. Ion induced hydration crowding of the surface may impede PEG
desorption and interrupt surface sintering. PEG interaction with phosphate anion
results in decreased solubility and increased hydrophobicity [295, 299]. The
precise mechanism is uncertain and may involve direct ion-molecule interaction or
electrostatic screening that result in charge shielding [300].
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4.3.7 Comparison of Constrained and Unconstrained Strength Testing of
95%PLGA 85:15 with PEG 400
Comparison of unconstrained compression strength (Figure 4-12) shows the serum
containing media to have the lowest strength 0.8 ± 0.19 MPa. The Young’s
modulus values for unconstrained saline (NaCl) solution was higher (12.29 ± 4
MPa) than PBS (5.3 ± 1 MPa). HBSS scaffolds produced very significantly (p <
0.001) higher values for Young’s modulus than PBS. The constrained samples
had higher strength values that were extremely significant (p < 0.001) in
comparison to unconstrained scaffolds. The Young’s modulus was also increased
for the constrained sample. Injectable scaffolds were designed to be placed in a
constrained tissue environment. The unconstrained material was of lower strength
for all conditions and particularly affected by serum containing media.
Saline solution does not appear to hinder the formation of high strength scaffolds
under the sintering conditions. Differences with PBS and serum containing media
may be due to the presence of multivalent salts and the formation of a two phase
aqueous system at elevated temperature with low levels of leached PEG 400 [300].
Monovalent salts form two phase systems at high concentrations of PEG ensuring
that PEG 400 diffusion is unimpeded.
Chapter 4
133
Figure 4-12 Comparison of constrained and unconstrained compression strength
and Young’s modulus was conducted on 95% PLA 85:15 with PEG 400 samples
sintered wet and dry at 45 °C for an hour and tested at 37 °C. The unconstrained
samples were prefixed (u) and constrained (c). Samples were sintered dry, wet
(distilled water), PBS, serum (10% serum supplemented media), (NaCl) 0.9%
sodium chloride solution and HBSS. Compression profiles were obtained at 0.01
mm/sec strain (n = 3). Statistical significance denoted as ns (not significant), ** (p
< 0.01) and *** (p < 0.001).
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4.3.8 Comparison of Un-sintered and Sintered Sized Particles
The constrained compressive test on un-sintered restricted size particles in Figure
4-13 shows the particles <100 µm to be significantly (p < 0.01) lower in strength
than particles > 100 µm. Particles > 400 µm in size were significantly (p > 0.01)
stronger than particles > 200 µm. The lower strength shown by particles < 100 µm
may have been attributable to settling caused by compaction during compression.
The Young’s modulus was also reduced in comparison to compressive strength.
The relationship may be due to the fact that the particles are connected by physical
interlocking rather than a deformable bond.
Comparison of the un-sintered constrained strength in Figure 4-13 with dry and
wet sintered scaffolds in Figure 4-12 shows the unconstrained scaffolds to have
higher Young’s modulus than strength. The relationship between strength and
Young’s modulus for sintered constrained scaffolds was generally similar with
modulus not significantly greater than strength. The comparison of sintered
scaffold strength in comparison to loose dry powder shows liquid sintering not to
have softened the particles or made the scaffold susceptible to compaction under
reduced force. This result was similar to other plasticizer leached systems [301].
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Figure 4-13 Comparisons of un-sintered size restricted 95% PLGA 85:15 with
PEG 400 particulates, by constrained compression test (n = 3). The test was
conducted dry at 25 °C and 0.01 mm/sec compression rate. Statistical significance
denoted as ** (p < 0.01) and *** (p < 0.001).
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4.3.9 Investigation of Liquid Sintering
To investigate liquid sintering at 37 °C, particles were rheologically compared
before and after water immersion for 24 hours. Figure 4-14a of unmodified PLGA
showed a 3 °C shift in the post sintered curve to lower temperatures in the Tg
onset region with no other significant change noted in the oscillation profiles. The
97% PLGA blend, Figure 4-14b shows a slight shift to lower temperatures in the
Tg onset zone with little separation in the remaining profile. A greater shift of 6
°C in the end TG region to higher temperatures was noted for (Figure 4-14c) 95%
PLGA with PEG 400 blend. Figure 4-14d showed a 22 °C peak shift to higher
temperatures for the 85% PLGA with PEG 400 blend. This peak shift represents a
loss of 65% of the PEG 400 content. Plasticizer leaching has been previously
observed with increased modulus [301].
Onset Tg reduction for the PLGA 85:15 control, may be due to retained water that
also obscured the peak shift in the 97% PLGA sample; as the change in
appearance of Figure 4-7 was substantial. The 95% PLGA with PEG 400 curve
shift indicates a loss of > 20% of the initial PEG loading. This loss of PEG 400
and peak shift has simultaneously raised Tg and increased the stiffness modulus of
the sintered material seen in earlier wet compression test results. These
observations may explain differences in results for 95 and 97% PLGA material
after sintering. This liquid based process may provide a mechanism to limit
sintering at physiologically isostatic temperatures.
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Figure 4-14 Representative wet sintering results showing oscillation temperature
ramp comparisons with and without PEG 400. Particulates not sintered were
designated pre and those sintered for 24 hours in distilled water at 37 °C then dried
post. Graph (a) unmodified PLGA, (b) 97% PLGA (c) 95% PLGA and (d) 85%
PLGA. Oscillation temperature ramp profiles were conducted from 4-90 °C at
0.1% strain.
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4.3.10 MDSC Investigation of Liquid Sintering
MDSC investigation of thermal transitions was conducted on 85:15 PLGA with
PEG 400 blends pre and post sintering for 24 hours in distilled water. In Figure 4-
15(a), the unmodified 85:15 PLGA as the control material showed little variation
in the comparison of 2
nd
cycle Tg profiles for pre and post sintered materials. The
profiles overlay closely. In Figure 4-15(b), the comparison of pre and post sintered
97% PLGA with PEG 400 shows that there was a reduction in the heat flow
profile with the Tg for the pre sintered sample of 40 °C and 34 °C for the post
sintered material.
In Figure 4-16(a) comparison of the 95% PLGA blend pre and post sintering,
shows the post sintered material with a a higher Tg transitions. A similar result
was obtained for the comparison of pre and post sintered 85% PLGA with PEG
400 in Figure 4-16(b). The Tg profile for the 85% PLGA post sintered sample was
narrower and more distinct than for the pre sintered material. These observations
suggest a reduction in the PEG content for the 95% and 85% PLGA blend
compositions. Similar results by others suggest the plasticizer was not completely
leached out [282, 301]. Water bound to PLGA is not discernible by DSC and does
not freeze [302]. An exchange of PEG for water in the 97% PLGA post sintered
material, would depress Tg.
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Figure 4-15 Modulated DSC second cycle Tg profile comparison of particulates
not sintered was designated pre and those sintered for 24 hours in distilled water at
37 °C then dried post. Graphs (a) unmodified PLGA 85:15 and (b) 97% PLGA
with PEG 400 blend. Modulated DCS was conducted at 1 °C/minute from -20 to
120 °C, modulated ± 0.16 °C for 60 seconds (n = 3).
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Figure 4-16 Modulated DSC second cycle Tg profile comparison of particulates
not sintered designated pre and those sintered for 24 hours in distilled water at 37
°C then dried post. Graph (a) 95% PLGA 85:15 with PEG 400 blend and (b) 85%
PLGA with PEG 400 blend. Modulated DCS was conducted at 1 °C/minute from
-20 to 120 °C, modulated ± 0.16 °C for 60 seconds (n = 3).
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The result summary of the 2nd cycle run Tg values for blends in Figure 4-17,
compares the whole curve (onset, inflection and end) Tg values. Figure 4-17
shows the post sintered unmodified control and blends to 97% PLGA post
sintered, having a lower Tg than the pre sintered blends. The Tg for post sintered
materials at 5% PEG 400 addition and greater were higher than the pre sintered
materials. These values plateau at 95% PLGA post sinter, indicating the loss of
PEG 400 to a minimal value or a proportional uptake of bound water. This
possible conclusion was reached by examination of the unmodified PLGA and
97% PLGA post sintering result in Figure 4-15 a,b.
Comparison of Figure 4-17 with Figure 3-12 show the pre blended PLGA 85:15
series to have a similar profile to earlier batches of the same polymer and the post
sintered material to have a similar profile to PLGA 50:50. This comparison
indicates that the loss of PEG during wet sintering may be proportional to the
initial content as the lactide content of the polymers was different. If the Tg post
sintered remains lower than the starting blend it may also indicate mass or strength
loss [220].
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Figure 4-17 Modulated DSC summary plot of the second run Tg values for 85:15
PLGA with PEG 400 blends pre and post wet sintering (n = 3). Modulated DCS
was conducted at 1°C/minute from -20 to 120 °C, modulated ± 0.16 °C for 60
seconds.
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In Figure 4-18, the heat capacity values for Tg profiles of the blend pre and post
sintering were compared. Increasing the content of PEG 400 in blends with 85:15
PLGA decreased the heat capacity of the Tg transition. The heat capacity for the
post sintered control was reduced, when compared to the pre sintered control
material. The heat capacities for the post sintered 99% and 97% PLGA with PEG
400 blends were lower than the pre sintered blends. Absorption of small quantities
of bound water can reduce Tg as in the case of the untreated control and is similar
rot results obtained elsewhere [303]. Residual PEG would also be present with
residual water and depress further the Tg as previously observed for salt leached
polymers [133].
The heat capacity for the 95% PLGA with PEG 400 blends was higher than its pre
sintered blend. Post sintered blends above 5% PEG 400 addition had higher heat
capacity values than pre sintered equivalents. The plateau of the values for heat
capacity may indicate that a residual amount of PEG and bound water to be
present. Similar conclusions have been reached by others [204].
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Figure 4-18 Modulated DSC summary plot of the second cycle Tg heat capacity
values for 85:15 PLGA with PEG 400 blends pre and post wet sintering (n = 3).
Pre sintered blends showed a decrease in heat capacity with Tg decreasing with
PEG 400 content. The heat capacity for the post sintered unmodified 85:15 PLGA
was reduced in comparison to the pre sintered material but post sintered blends
above 5% PEG 400 had higher heat capacity values. Modulated DCS was
conducted at 1 °C/minute from -20 to 120 °C, modulated ± 0.16 °C for 60 seconds.
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Figure 4-19 compares the modulated DSC profiles of the first and second heat
flow transition profiles for the post sintered 85% PLGA with PEG 400. The graph
shows the first run cycle to have two glass transition regions. In the second cycle
run, only one thermal transition was present. The presence of two transition
regions may have been due to an uneven distribution of PEG remaining within
particles after being leached out. Enthalpic relaxation would have been
superimposed onto the glass transition region if it had occurred [304]. By heating
to 120 °C the sample history was eliminated along with regional differences in the
sample resulting in a single transition in the second run.
The SEM image in Figure 4-20(a) shows the results of wet sintering with adhesive
particles sintered to each other and to (b) porous microspheres. The welded contact
between the adhesive and porous particle shows that the microsphere has retained
its morphology and the adhesive component has flowed to achieve sintering. The
sintering between adhesive components appears virtually seamless and the
distinction between particles was unclear.
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Figure 4-19 Modulated DSC comparison of the first and second heat flow
transition profiles for post sintered 85% PLGA 85:15 blended with PEG 400. The
graph shows the first run to have two glass transition regions and the second run to
have one transition. Modulated DCS was conducted at 1 °C/minute from -20 to
120 °C, modulated ± 0.16 °C for 60 seconds.
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Figure 4-20 Representative SEM images of sintered PLGA 85:15 scaffold with
porous type 1 sphere blended with type 2 adhesive particles in a 1:3 ratio and (a)
dry pressed at 25 °C for two hours; (b) sintered in distilled water at 37 °C for 15
minutes, (c) one hour and (d) 24 hours. Scaffolds were gold coated and captured at
15 kV.
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4.3.11 Proposed Sintering Mechanism
For sintering to occur, molecules at the surface must have sufficient mobility and
plastic deformation to increase the contact area between particles [292]. Activation
energy is required for surface diffusion which leads to a temperature dependence
of an Arrhenius kind i.e. reaction rate depends on temperature; and has been
experimentally confirmed by the increase in scaffold strength with sintering
temperature.
Particles are packed to maximize exposed surface area whilst, encouraging flow to
occur through pores. Desorption, requires reduced external pressure or increased
temperature. In this sintering system a pre-warmed liquid is added to particles that
sinter, to form a porous structure. The rate of exchange with the solid surface
depends on the concentration of material in the solid, the surrounding bulk liquid
phase and the temperature [168]. PEG interrupts PLGA inter-chain packing,
promoting segmental mobility that increases thermal conductivity [168, 171].
Below Tg, thermal conductivity increases with temperature, reaching a maximum
at Tg then decreases above it. PEG dissolution in water is rapid, due to hydrogen
bonding interactions and high mobility [274]. As desorption proceeds, diffusing
PEG molecules leave behind a void as the polymer reorders itself by condensing
and decreasing chain mobility (Figure 4-21).
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Figure 4-21 Schematic representation of the liquid welding process believed to be
occurring during wet particulate sintering. It proposes that the particles encounter
layered laminar heating that result in a zone of condensed polymer that participates
in the sintering of touching particles.
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The void created by PEG migration may be responsible for light scattering and the
change in adhesive component appearance. As PEG is leached out thermal
conductivity drops and the localized Tg increase PLGA hardening by phase
separation. At the junction of point contact where polymer flow and chain
entanglement has occurred an inter-particle neck is formed (Figure 4-21). The
temperature gain from the bulk fluid to the particle is confined to a narrow
boundary-layer at the surface. There is likely to be a significant Tg difference
between the inner particle bulk and surface shell resulting in a PEG depleted
PLGA zone. The peripherally increased Tg will slow further PEG diffusion from
the inner bulk and the predominantly hydrophobic polymer surface loses its ability
to soften when wet [204, 273, 301]; hence, a solid structure is formed between
adjacent particles that are mechanically strong to withstand vibration and bulk
movement
Low molecular weight PEG (< 1500 Da) diffuses into the continuous liquid
volume and do not accumulate at the surface of PLGA [305]. However, PEG,
though stable to a range of pH, can interact with ions to separate into polymer-rich
and polymer-poor phases that are similar to temperature induced phase segregation
and can retard diffusion [306, 307]. Inorganic salts can have a strong electrostatic
effect on macromolecule to influence solubility and precipitation in water that
follows the trend of the Hofmeister series of anions [296, 299]. The Hofmeister
series ranks the effectiveness of salts in precipitating macromolecules and was
thought to be due to the making and breaking of bulk water structure.
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Water has a high dielectric constant and tends to shield ionic charge and reduce the
energy of interaction by forming a hydration shell. Water near an isolated
interface was conceptually divided into three single layers, each being one water
molecule thick [308]. The solute determines the behaviour of the first, inner
interfacial water layer and bulk water the third, with the intermediate second layer
influenced by both. Recent time and thermodynamic studies with salt solutions
have resolved that bulk water structure is not central to the Hofmeister series. Ions
don’t affect hydrogen-bonding networks beyond the first hydration shell [309] and
consequently bulk water does not show structural variation consistent with the
Hofmeister series [310].
Inorganic salts are divided into two groups based on the behavior of aqueous-
macromolecules in the presence of salts and work by different mechanisms. Direct
interactions of ions and macromolecules are key to understanding the Hofmeister
series and may involve dispersion forces that depend on ion size and polarizability,
ion binding to macromolecules and modulation of surface tension by the ions.
There is a partitioning of ions from bulk solution to the aqueous interface of
hydrophilic polymers [311] and water mobility at the surface is reduced by
electrostatic interactions. Large anions bind more easily to hydrophilic groups due
to binding site accessibility. Kosmotropes are responsible for salting out effects on
macromolecules and order water molecules around themselves to lower entropy of
the aqueous solution. Kosmotropic anions therefore polarize interfacial water
attracting the protons in the first hydration shell. This polarizing effect weakens
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the hydrogen-bonding to macromolecules. This effect may explain the reduction in
strength observed in the wet sintering comparisons between distilled water and
solutions with inorganic salts.
Chaotropic ions are water structure breakers with hydrophobic interactions
dominated by the entropy of salvation that show salting in behaviour due to
saturation binding of anions with macromolecules [312]. Chaotropes don’t
polarize polymer-associated water, instead they destabilise hydrophobic hydration.
At high salt concentration surface tension is increased at the salt-polymer
interface. Phosphate ions are more structure making than chloride ions. Chloride
ions are anomalous in the Hofmeister series and show intermediate behaviour that
may be a function of concentration. Chloride ions are weakly hydrated and
sufficiently small not to induce polarization but can bind to weakly hydrated
surfaces [313] and behave like chaotropes.
Charged amino acid groups present on protein surfaces at the protein-water
interface can react electrostatically with surfaces and may be strongly hydrated.
This hydration at the polymer surface may have retarded the diffusion and
interaction of PEG with water, resulting in the lower strength values recorded for
scaffolds wet sintered in media containing serum. There is increased screening and
reduced mobility with ion concentration and packing around a charged molecule.
In a vacuum the free energy of interaction between charged groups is entirely
enthalpic and independent of temperature [312]. In water it is dominated by
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entropy that reflects the ways ions can reconfigure. The dielectric constant
responsible for the polarization of water decreases steeply with increasing
temperature and results in greater water disorder [312]. The increase in disorder
allows polarized groups to approach each other more closely and result in
interaction. This may explain the increased strength of scaffolds wet sintered at
45°C where PEG hydration and release from the surface of the PLGA polymer
resulted in increased Young’s modulus.
4.4 Conclusion
Dry sintering of the scaffold could be reproducibly initiated from 25 ± 3 °C
maintaining mild conditions for the protection of functional proteins and cells.
Sintered scaffold strength was demonstrated to be inversely correlated with lower
PEG molecular weight. The increased viscoelastic behaviour also correlated
positively with scaffold strength at low sintering temperatures. Trapped moisture
and air are known to decrease compressive strength in bone cement. However, in
these particulate scaffolds, water was found to increase compressive strength and
stiffness. Optimization of the components was demonstrated to produce scaffold
strengths and modulus comparable with cancellous bone. Strong porous structures
can be produced and maintained under this new liquid weld sintering regime.
The speed of wet sintering was demonstrated to require less than 15 minutes, at 37
°C to begin producing scaffolds with strengths in the region of cancellous bone.
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The wet sintering process also provides a mechanism to control the degree of
sintering that would otherwise leave the scaffold soft and deformable at body
temperature with the potential of decreasing porosity. This environmentally
responsive polymer composition was tuned to solidify at physiological
temperature and pH within a clinically relevant time frame. A sintered porous
network was achieved by wet sintering compacted particulates without gelation of
the surrounding aqueous environment that can slow diffusion and stifle cell
viability.
Injecttable scaffolds designed to sinter at body temperature need a mechanism to
stop the sintering process after an appropriate time, with a reproducible structure
of a defined strength and modulus to achieve required porosity and structural
integrity. A sintering system with reverse temperature dependence has been
developed that is tuned to undergo transition within physiological conditions and
develop mechanical properties in situ.
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5 Injectability and Scaffold Structure
5.1 Introduction
Alternative approaches to minimise the side effects of open craniofacial surgery
have been demanded by surgeons [314]. Injectable porous biodegradable
microspheres and particulates have been developed as low density cell carriers
filling a gap with voids [315]. These materials have potential application in low
density bone that resembles open-cell foam [316]. The reduced invasiveness of
injectable procedures, allows the potential introduction of large volumes reducing
the healing effort required to cope with surgical damage to soft tissue [317].
Biomaterial success depends on the outcome of a complex process requiring cell
invasion and neovascularisation [115]. Bone induction does not occur on flat
ceramic surfaces, instead, between particles, on profiled concavities and rough
surfaces with microporosities for calcium nucleation [55, 102]. Porous synthetic
organic surfaces in body fluids can precipitate a bone like carbonated
hydroxyapatite surface layer in non-bone environments [10, 27, 109].
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5.1.1 Injectable Scaffold Requirements
The ideal injectable material for use in bone repair must be non-migratory, non
antigenic, encourage integration, be volume stabilizing and prevent adjacent tissue
encroachment [118, 318]. Loose plasma sterilized PLGA 50:50 microspheres,
injected from a 1ml syringe barrel into rabbit bone defect were demonstrated to
enhance healing without inflammation and fully degraded after 12 weeks [129].
However, bone-grafts must also provide mechanical stabilisation [9]. Several
injectable drug delivery systems form scaffolds comprising of composite nano-
and microparticles based on modified PLGA [319]. For these systems injectability
was dependent on particle–matrix ratio and the injector system used. Calcium
phosphate cements are used as injectable bone substitutes and wet setting involves
the exothermic reaction of acidic and basic components that can last for hours and
raise pH locally [320]. In a composite cement/ PLGA microparticle blend,
reduction in the ratio of the continuous calcium phosphate matrix and size of the
extrusion orifice increased the injection force and decreased the homogeneity of
the material flow [321].
Minimum porosity results in less dimensional change upon compression [316]. In
theory, powders containing particles with a wide range of sizes can approach 0%
porosity as the finest grains are distributed in the interstices of larger packed
particles. However, powder mixtures do not naturally pack to the closest
configuration even if free movement was induced by vibration or shaking [322].
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Differential gravitational settling of the mixture tends to segregate particles and
some degree of aggregation/jamming occurs immediately upon formation of the
powder compress generating internal friction that strongly impedes further
compaction by 15–20% porosity [323]. Initial particle packing influences
mechanical strength, density of the microstructure on sintering, shrinkage and pore
properties of the final product.
Hard mono-diameter spheres packed like cannonballs into body-centred arrays
theoretically have a porosity of 25%, significantly lower than the disordered
packing minimum of 35-45% for vibrated collections of mono diameter spheres
[323, 324]. Packing density is a function of the initial packing efficiency, particle
size ratio and volume fraction variation of the system [136]. Calculation of ideal
packing density assumes the size ratio of course to fine is infinitely large [322].
For particle size ratios greater than 10, the maximum ideal packing density of two
component systems is more closely predicted by the Furnas theoretical model
[325]. The model is not predictable for a particle size ratio lower than 10 [322].
Packing efficiency and density are lower when the ratio of coarse to fine particles
decreases [324]. Conventionally heat sintered PLGA scaffolds typically have an
interconnected porosity around 32% and newer solvent/non-solvent systems have
a maximum interconnected porosity of 37% [166].
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Patient specific fabrication of preformed polymers can be time consuming before
and during surgery; requiring open cavities and potentially damaging blood vessels
and surrounding soft tissue, stimulating further inflammation to achieve a tight fit
[319]. Cell seeding of preformed constructs can also be inefficient [326].
Injectability allows filling of defects with limited accessibility as exemplified by
the techniques of vertebroplasty and kyphoplasty that are now preferred options to
open surgery where large volumes can be introduced through small incisions [317,
327]. The composition, particle size distribution and shape are critical features of
particulate solids [134]. For injectable systems, the resistance to flow is dominated
by the size and shape of free space between particles that are in contact with each
other [322]. Fluid flow across stationary granules sees a pressure drop due to the
resistance of solid particles. A decrease in the average particle size, increases net
particle surface area; enhancing the contact aggregation effect and improve the
"green strength" of relatively uncompressed powder.
5.1.2 Injectability
Injectable calcium phosphate cements acting like grout set in situ forming an
implant conforming to the contours of the defect void surfaces [144]. Injectability
is not a clearly defined term [328]. However, bad injectability involving phase
separation of solid/liquid components, blocking and partial extrusion is clear.
Injectability is assisted by having a short travel distance and small particles
relative to the cannula diameter. The force applied (max ~200 N by hand)
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measures the ease of injection but in surgery cements are applied using injection
guns. Bohner defined injectability in a constant geometry as the capacity to stay
homogeneous during injection independent of the force required [328].
In-use reaction times need to be slow enough for surgeons to implant and fast
enough not to delay the operation. Cement injectability decreases with time and
must be completed in 6-8 minutes in the viscosity range 100-1000 Pa s before it
increases to become stringy, forming a damaging cement tail can be deposited in
soft tissue [328]. The viscosity of the hardening phase must increase quickly as
short setting times from 11-17 minutes assist geometrical integrity and fast
postoperative recovery of function [326, 329, 330]. Poly(ethylene glycol fumarate)
hydrogels can be formed in 10 minutes at 37 °C alone or with PLGA
microparticles/ microspheres [225].
Phase separation occurs when the pressure to filter liquid through the
agglomerated particles is lower than the pressure to inject the paste i.e. filter
pressing occurs and liquid is pushed out of the cannula [328]. The plastic limit is
the minimum amount of liquid required to form a paste. Below the plastic limit the
powder is dry and viscosity high. If the extrusion force is high and the flow rate
too fast shear thickening (dilatancy) occurs and a powder cake is formed. Having a
multimodal particle size decreases the amount of liquid required to form a paste,
but also reduced the final porosity. Decreasing the particle size in a fixed geometry
system reduces the extrusion force required [288].
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High water content in calcium phosphate cement lowers viscosity, the extrusion
force required and particle interaction. The ability of the final cement structure to
harden is reduced and it is more porous with lower mechanical strength [289]. An
upper plastic limit was not described by Bohner and Baroud; however, this might
define it [328]. In addition transplant of autogenous cancellous grafts were
determined to be most effective in low aspiration volumes [318].
5.2 Aims
The aim of the work in this chapter was to develop an injectable particulate
scaffold that remains homogenous post injection. The injection force was
measured to determine ease of injectability. In order to assess the morphology of
the injected scaffold post hardening at physiological conditions, micro-computed
tomography measurements were conducted to determine porosity and pore size.
Scaffolds need flexibly to fill a fracture gap without settling, retaining the moulded
defect shape then solidifying to a macroporous structure. The setting time was
rheologically monitored to measure the injectability period before hardening
began.
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5.3 METHODOLOGY
5.3.1 Evaluation of Liquid Mixing Ratio for Injection
This experiment was devised to determine the appropriate ratio of liquid required
to produce a self-levelling injectable paste. A 3:1 blend of 95% PLGA 85:15 with
PEG 400 temperature sensitive particles to 85:15 PLGA sphere was prepared with
HBSS buffer as the diluents added to the pre-weighed material in a Plastipak
TM
1
mL syringe. The syringe nozzle was removed to leave a 4 mm diameter barrel.
Particles 200-300 µm in diameter were ejected form the syringe. The ratio of solid
to liquid evaluated was varied from 4:1 to 1:2. Mixing was achieved using the
plunger to pull liquid through the loaded particulate. A second plunger was used to
achieve compaction (Section 2.4.3) before the material was extruded from the
syringe onto a six-well plate and incubated at 37 °C and 5% carbon dioxide for 30
minutes. Samples were also ejected into a 0.75 ml Eppendorf
TM
tube to evaluate
injectability.
5.3.2 Ease of Injectability
Injection force measurements were conducted at ambient conditions with a syringe
holder on the Texture Analyser TA HD Plus supplied from Stable Micro Systems.
Injection force was determined at an extrusion rate of 2 mm.s-1 through a 1 mL BD
Plastipak
TM
syringe. This extrusion rate was previously used by Bohner for
investigations on injectable calcium phosphate cements [328]. Scaffold
compression strength (wet and dry) was determined at 0.01 mm/sec following
sintering in a 4 mm diameter syringe barrel at 37 °C for 30 minutes.
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5.3.3 Evaluation of Structure with Micro CT
Micro CT assessment was conducted with a Scanco 40 instrument on dry two
component scaffolds with a 4:3 ratio of adhesive particle to porous cell carrier
after wet sintering in moulds for dimensional consistency. Scaffolds were
constructed from sieved components with a 100 µm size width range. Scaffolds
were scanned at 55 kV and a current of 55 mA.
5.3.4 Rheological Monitoring of Liquid Sintering
The injectable material being measured by oscillation rheology was transformed
from a suspension to a solid structure. During transition, particles conformed to the
smooth measuring surface of the parallel plate geometry resulting in slippage. A
serrated geometry and Peltier base was used to grip the sample allowing structural
detail to be resolved using an oscillation time sweep protocol at 0.01% strain, 37
°C and 1 Hz.
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5.4 Results and Discussion
5.4.1 Evaluation of Liquid Mixing Ratio for Injection
Scaffolds were formed in a 1 mL syringe barrel then extruded onto the surface of a
6 well plate. Cylindrical scaffolds conforming to the syringe barrel dimensions
were formed at solid: liquid ratio above 2:1 as can be seen in Figure 5-1. These
samples showed no tendency to self-level after incubation at 37 °C without
external application of force. The 1:1 scaffold showed some levelling under
gravitational force whilst retaining a high degree of cohesion. At higher fluid
content, beginning with the solid: liquid ratio of 1:1.5; there was extensive self-
levelling and spreading of the extrudate, with no retention of the original mould
shape. The unconstrained constructs were demonstrated to be cohesive at  1:1
solid to liquid blend under the influence of gravity and sintering at 37 °C. The 1:1
ratio blend showed time dependent levelling as the cylindrical shape was distorted.
Scaffolds formed from the 1:1 ratio and higher solids content were strong, easily
handled structures. The higher the levels of liquid present the less compact the
structure formed and the weaker the scaffold in line with observations of calcium
phosphate cement and its plastic limit [328, 331]. Capillary action exerts strong
forces on particulate solids, equivalent to external pressure in liquid phase
sintering. Problems associated with liquid sintering include shape distortion with
excess liquid [162].
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Figure 5-1 Comparison of wet scaffolds ejected from a 1ml syringe consisting of
95% PLGA 85:15 with PEG 400 adhesive particles and PLGA 85:15 spheres
blended by weight at a 3:1 ratio. The solid to liquid wt: wt ratios of 4:1, 3:1, and
2:1 retained the cylindrical shape of the syringe barrel. Solid: liquid blends at
higher liquid content leveled without retaining the shape of the syringe barrel.
Compositions (n = 3) were sintered in a 37 °C humidified incubator at 5% carbon
dioxide.
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The 2:1 ratio had compressive strength of 88 ± 10 MPa compared to 5 ± 1.4 MPa
for the 1:1.5 scaffolds (dry, ambient). Synerhesis was present in the 1:1 blend and
higher liquid content and would not be clinically acceptable. Synerhesis does not
provide the ideal situation for patients as wound sites need to be clean and free of
excess liquid that may cause secondary issues of infection, inflammation and
sepsis [40].
5.4.2 Injectability
Scaffold paste of various solid: liquid blends were injected into a 0.75 mL
Epppendorf tube to simulate closed cavity defect filling Figure 5- 2. The results
show that the 2:1 solid to liquid blend extruded into the closed cavity, conformed
to the shape of the tube (defect) and retained it. The 1:1 blend failed to reach the
end of the tube after three attempts. The 1:1 blend was observed to show a degree
of compressibility and resistance, encountered pushing the scaffold backwards into
the syringe after ejection. The 1:1.5 blends failed to fill the end of the tube,
becoming fractured and showed some filtering of fluid. Some particulate material
was lost from the high liquid content paste (1:1.5 blends) due to pooling of the
excess liquid volume caused by synerhesis during ejection. These blends show
that higher solids ratio may provide better controlled fill of a closed defect giving
more intimate contact and precise fill. It may also be necessary to avoid tail
formation encountered with cements in procedures such as vertebroplasty that
cause soft tissue damage [144].
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Figure 5-2 Comparison of scaffolds ejected from a 1 ml syringe barrel into a 0.75
mL Eppendorf tube to simulate filling of a small defect cavity (n = 3). This shows
the degree of control possible with blends of solid: liquid ratios of 2:1, 1:1 and
1:1.5 being injected by hand into a tube. Scaffolds consisted of 95% PLGA 85:15
with PEG 400 adhesive particles and PLGA 85:15 spheres blended by dry weight
at a 3:1 ratio.
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5.4.3 Ease of Injection
The Plastipak 1 mL syringe used was tested to failure and the maximum injection
force tolerated was 92.98 ± 2 N to distort the plunger piston. Figure 5-3 shows the
force profile recorded to inject the dry material. It shows an initial peak followed
by a plateau over the travel distance to extrude the syringe contents. The initial
peak in force was in part due to the force needed to overcome the friction of the
plunger in the barrel. The plot (Figure 5-3) shows the repeatability of the test
procedure at a constant loading of powder at 0.64 ± 0.015 g/cm
3
.
Figure 5-4 compares the initial and steady force needed to extrude varying
volumes of dry particulate loads at a constant density of 0.64 ± 0.015 g/cm3
loading from the 4 mm opening at 2 mm/sec. There was a very significant (p <
0.001) increase in the injection force on the initial volume loading of 0.1 cc
compacted particulate in comparison to the empty syringe barrel. Figure 5-4 shows
the initial injection force to be similar for loadings between 0.2-0.8 cc requiring
2.6 ± 0.11 N of force to initiate extrusion. Doubling the dry particulate load to 0.2
cc in the barrel very significantly (p < 0.001) increased the force to overcome
inertia and friction in the syringe barrel. There was no further significant increase
in force to initially extrude higher loadings from the syringe barrel from neither
0.2-0.4 cc nor 0.4 cc- 0.8 cc.
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Figure 5-3 Repeat extrusion profiles of injection force used to deliver 0.1 cc
loading volume of the dry scaffold from a 4 mm syringe opening (n = 3). The chart
shows a profile of the initial force required to move the plunger in comparison to
the force required to keep the bulk moving at a constant rate. Injection force was
determined at an extrusion rate of 2 mm.s-1 .
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Figure 5-4 Comparison of initial and steady injection force required to move the
plunger and deliver variable volumes of dry scaffold from a 4 mm syringe barrel
(n = 3) at 0.64 g/ cm
3
. Injection force was determined at an extrusion rate of 2
mm.s-1. Statistical significance denoted as *** (p < 0.001).
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When the packing density was raised to 0.74 g/cm3 and above the force needed to
eject the material from the barrel was increased 40 times across all loading
volumes and shown in Figure 5-5. This deviation from homogeneous flow
indicates that jamming and cake formation has occurred. This phenomenon was
consistent for all volumes loaded  0.74 g/cm3. In these circumstances extrusion is
through fracture of the cake.
The plot in Figure 5-6 shows the force extrusion profile for the 60% wet sintered
scaffold. The force required to overcome the initial inertia 4.6 ± 0.5 N was not
exceeded by the force required to extrude the material at 2.7 ± 0.6 N. The jagged
profile of the injection force required to extrude the wet formula was similar to the
dry formula, but required less force. The profile variability may have been due to
filtration and compaction of the material as force was transmitted through the bulk
by the plunger.
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Figure 5-5 Injection force required to eject a dry scaffold blend, shows the effect
of increased loading density at 0.65 and 0.74 g/cm
3
to result in a 40x increase in
the force required to eject the sample (n = 4). Injection force was determined at an
extrusion rate of 2 mm.s-1.
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Figure 5-6 Extrusion force profile for a 60% wet scaffold composite (n = 5).
Injection force was determined in a 1 mL syringe at an extrusion rate of 2 mm.s
-1
.
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5.4.4 Evaluation of Structure with Micro CT
Micro Ct imaging provides information on the internal structures formed by
particulate scaffolds. Figure 5-7 shows a cross-section of wet sintered scaffolds
and the internal structure created by use of restricted 100 µm particle size band to
produce scaffolds. Scaffolds were made with 4:3 ratios of adhesive particles to
microspheres in cylindrical moulds 9x5 mm (height x diameter). The decrease in
the number of particles involved with increased particle size was most apparent
when comparing >500 µm scaffold with other compositions. The apparent size of
pores was also increased with particle size.
Figure 5-8 compares the porosity distribution across the particle size bands and
shows that there was a plateau at 45% porosity for the > 100 to > 300 µm diameter
size bands. This was very significantly higher (p < 0.001) than the < 100 µm
particle size. Porosity was increased for the > 400 and > 500 µm particulate size
band scaffolds with a significant (p <0.01) difference between them. The
difference between the >200 and >400 µm was very significant (p < 0.01). The
difference between < 100 and > 100 µm particle sizes were extremely significant
(p < 0.001) and attributable to a higher ratio of particle sizes present in the <100
µm blend. Within this band, particles < 10 µm would exceed the size ratio of 10:1
and pack more efficiently [322]. The measured porosity for the < 100 µm scaffold
was < 35% indicating very efficient packing of the particles.
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Figure 5-7 Micro Ct 40 µm resolution X-ray reconstructed images of 9x5 mm
molded and wet sintered scaffolds with, 4:3 ratio of adhesive particles to spheres.
Scaffolds were scanned at 55 kV.
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Figure 5-8 Porosity profile for the 9x5 mm diameter scaffolds with 100 µm
restricted particle size distribution created from micro Ct evaluation of wet
sintered two component scaffold with 4:3 ratio of adhesive type II to type I
particles scanned at 55kV. Statistical significance denoted as ** (p < 0.01) and ***
(p < 0.001).
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The successive particle size rages have lower size ratios in the order 1:2 for the >
100 µm band, 1:1.5 for > 200 µm band, 1:1.3 for > 300 µm band, 1:1.25 for > 400
µm and 1:1.43 for the >500 µm band size as a 712 µm upper limit was used. The
mid-range porosity did not significantly change however the size of the pores did
as can be seen from the images in Figure 5-7. The graph in Figure 5-9 shows the
scaffold pore size distribution to widen with the size of the particles. The two
smallest particle size range at < 100 and >100 µm had very narrow pore size
distribution with the smaller (< 100 µm) having no pores greater than 100 µm in
diameter. For particles >100µm there were no pores greater than 150 µm in
diameter.
Figure 5-10 shows more clearly the impact of restricted particle size change on
the distribution of pore sizes present. As particle size was increased across the
range of scaffolds the number of small pores diminished, becoming larger in size
and more frequent distribution. The scaffold with > 400 µm particle size contained
less than 25% of pores below 100 µm. The altered distribution of pore size may
have significant impact on cell seeding and penetration into the scaffold. The
consensus minimum average pore size required for bone growth is 100 µm [132,
242]. The percentage of pores required to achieve and exceed this minimum pore
size has not been addressed. Figure 5-10 shows the percentage of pores greater
than the critical 100 µm diameter generally agreed for in vivo cell growth and
colonization of cells.
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Figure 5-9 Effect of increased particle size on changes in scaffold pore size
distribution with increased particle size. The graph was created from micro Ct
evaluation of wet sintered two component scaffold with 4:3 ratio of adhesive type
II to type I particles at 55 kV.
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Figure 5-10 Percentage of pores greater than 100 µm in diameter with an increase
in the average band width of particles used to form the scaffold. The graph was
created from micro Ct evaluation of wet sintered two component scaffold with 4:3
ratio of adhesive type II to type I particles.
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From Figure 5-10, scaffolds in the restricted particle size range > 300 µm have
45% of pores greater than 100 µm. What is not clear however is the amount of
porosity required to achieve the goal of full colonization [245]. There are
strategies to improve the supply of nutrients into the centre of the scaffold by
drilling wide channels to boost the survivability of the construct [332]. These
channels can lead to fibrous growth within the centre of constructs. In addition
multi channelled pores can compromise the mechanical integrity of the scaffold. It
may not be necessary to have all the pores within the scaffold to be greater than
100 µm diameter in order to achieve full colonisation and integration from initial
implantation [132]. Pore interconnectivity was considered to be more important
than pore diameter. The significance of this can only be determined by evaluation
of cell growth and distribution in scaffolds.
5.4.5 Rheological Evaluation of Liquid-scaffold Interaction
Rheologically the wet sintering process was monitored on the rheometer by
measuring the increase in structure build up as complex modulus (G*) at 37 °C.
The oscillation time sweep profile in Figure 5-11 shows that significant structural
build occurs sharply after 10-15 minutes exposure to fluid at body temperature.
The initial increase in structure as measured by the complex modulus G* was
followed by a gradual increase over time. Similar profiles of structure gain have
been reported [204].
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Figure 5-11 Representative oscillation time sweep profile of 95% PLGA with PEG
400 composite, conducted at 0.01% strain and 1.6 Hz. Samples were wet paste as
would be prepared for injection to deliver cells and held at 37 °C. Oscillatory
measurements were conducted in distilled water, Hanks balanced salts solution
(HBSS) and 0.9% sodium chloride (saline) solution. The profile shows the change
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5.5 Conclusion
The work here has demonstrated that the ratio of liquid to particulate component
of the scaffold can potentially influence defect filling and self-levelling behaviour.
The proposed injectable scaffold may be introduced as either a liquid suspension
or semisolid paste that can self-level within a defect or be pushed into place,
intimately interfacing with boundary walls without injury and restricting its
distribution whilst allowing reshaping to fit.
The compaction and packing of the structure formed affects scaffold strength,
retention and precision placement in void filling. Scaffold injectability ultimately
depends upon the design of the injecting device and the relationship between exit
orifice diameters with particle size. However, attention to solid packing density
may help to assist in the reduction of force needed to extrude the material. This
will be dependent on particle size ratio that crucially influences the porosity of the
final scaffold structure. The lower the ratio of component particle sizes, the higher
the likelihood that the void volume will approach 50%. Spherical particle shape
and narrow particle size distribution are desirable when the end product is to be
porous. The use of irregularly shaped particles increases the porosity of packed
powders.
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Porosity greater than 60% has been achieved by these scaffolds and more crucially
high distributions of pores greater than 100 µm in diameter are present within the
structures. It is not known what proportion of pores > 100 µm are crucial for full
scaffold colonization; however, the larger the particle size the greater the
distribution of pore diameters > 100 µm present in the scaffold that may positively
impact on nutrient permeability, cell survival and cell penetration. Particle size
may be used to match the required morphology of the defect site. The controlled
sintering process was essential to preventing porosity loss following compaction
and injection. These scaffolds may find use as cellular or acellular constructs.
Polymer based scaffolds have been manipulated to perform increasingly complex
and independent tasks such as cell and peptide delivery. The control of porosity
with mild sintering may facilitate the development of facile, one shot solutions to
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6 Cell Interaction with Injectable Scaffold
6.1 Introduction
The work in chapter 5 demonstrated the injectability of the scaffold material and
its ability to solidify with controlled porosity. The field of regenerative medicine
and cell therapy demands macroporous injectable systems that can deliver both
growth factors and cells with maximal viability directly at the injury site by
minimally invasive surgery. These systems should develop adequate mechanical
integrity comparable to host tissue and have potential use in both elective and
trauma surgery to promote engraftment [333].
In vitro cell proliferation for human transplantation is slow and expensive with risk
of contamination from bacteria and virus. Cell expansion also risks depletion of
proliferative capacity and selection of mutagenic cells [318]. Bone marrow
aspirate contains progenitor cells with high proliferative capacity that enhances
intramembranous bone formation [334, 335]. Aspiration is a relatively common,
inexpensive procedure, with low morbidity, providing a cell suspension that can be
processed intraoperatively, for immediate implantation [333]. An injectable
scaffold able to utilise aspirated cells and deliver them into a defect by minimally
invasive surgery could provide a cheap, quick procedure to prevent soft tissue
collapse whilst assisting repair.
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Most primary organ cells are anchorage dependent [99] and the injection of cells
alone into a tissue site results mainly in death, with minor incorporation (3%) into
the host without organ regeneration [336]. Cell carriers can dramatically improve
survival and localisation in vivo acting as temporary architectural templates, for
new tissue formation that provide a stable interface for host-cell integration [337].
Cell transplantation relies on attachment substrates having good performance and
reproducibility hence the interest in poly(Į-hydroxy ester). Cationic
polyelectrolyte modification of polymer surfaces has been demonstrated to
enhance cell adhesion, spreading and proliferation [338].
6.1.1 Biomimetic Activity
PLGA has been demonstrated to support and maintain the osteoblastic cell
phenotype [148]. Organic substrates in human and simulated body fluids can
precipitate an apatite-like surface layer through negatively charged carboxyl group
induced heterogeneous nucleation [339]. The apatite layer formed is tightly
attached to the polymer and correlated to the quantity of carboxyl groups. During
cell delivery, physiologically compatible fluids are in contact with the scaffold
components during and after surgery.
Carboxyl anions are responsible for strong electrostatic and repulsive forces
among polymer chains that contribute to swelling [340]. Polymer swelling occurs
gradually and is accelerated by low pH and reaction between carboxylic end
groups with sodium cations. When constrained by the bone defect surface,
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polymer swelling is restricted. The pressure generated creates a press fitting effect
providing intimate contact and adhesion to the host tissue and is regarded as
advantageous with respect to implant loosening and fracture stability by
compression [341, 342].
6.1.2 Cell Carrier Size Limitations
In cell transplantation, access to nutrients and metabolite clearance is vital and
dependent upon cell density and diffusivity distance [343]. Analyses of cell
viability in vitro poorly translate in vivo [15], and scaffold support improves
outcome if parameters have been optimised [185, 243, 336]. Few cells can tolerate
diffusion distances in excess of 200 µm; hence, cartilage cells have been the most
successful to date [318]. Typically on constructs, an outer 100-200 µm thick radius
of live cells is formed around a central necrotic zone of [344]. Work by Holy et al
[111] proposed the in vitro seeding level of 1x10
6
osteoblast cells per cm
3
of
scaffold as optimal, but Skuk et al [344] showed cell survival to diminish in
primates when more than 0.3x10
6
cells were transplanted. It is therefore crucial to
select cells that contribute to tissue repair as in a graft of 5 mm radius; oxygen
diffusion will support a limited number of transplanted cells [343]. In bone repair,
initial cell colonization of scaffolds has been restricted to the superficial pore
layers resulting in limited regenerated tissue depth [111, 345].
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6.1.3 Poly(ethylenimine) Modified Cell Support
To enable use as cell carrier devices, scaffolds must support cell adhesion [346].
Adhesion to scaffolds is vital to control spatial distribution; cell survival and
migration in the scaffold. Surface modification by plasma polymerized allyl amine
has been demonstrated to enhance cell adhesion [255, 347, 348]. Chitosan as a
cationic polyelectrolyte biopolymer supports cell adhesion and proliferation [349,
350]. The cationic polyelectrolyte poly(ethylenimine) (PEI) shows dose
dependent cytotoxicity in freeform that was reduced by adsorption to solid (silica)
nanoparticles and in complexes used to enhance transfection [351, 352]. PEI has
been used to coat rigid porous supports for the ionic adsorption protein [353].
Fibronectin and vitronectin mediate osteoblast adhesion and have been
demonstrated to adsorb to cationic surfaces [354, 355]. The adhesion, spreading
and proliferation of fibroblasts and osteoblasts was enhanced on cationic surfaces
in comparison to neutral and negatively charged surfaces[338, 356, 357]. In
addition, the incorporation of PEI into polyester microspheres can increase
porosity [358].
6.1.4 Growth Factor Delivery
Humans differ significantly from one another with respect to the cellularity of
bone marrow and the prevalence of osteoblastic progenitor cells. Bone marrow
cells from the ilium exhibiting osteoblastic phenotype decrease sharply with age
after 20 years [359] with the number of alkaline phosphatase positive cells
decreasing stronger in women than men [360]. In addition, the proliferation
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potential of osteogenic progenitors decreased with age [361]. Low bone density,
compromised repair potential and ageing conspire to reduce the rate at which
fractures heal [64]. Stem cells derived from bone, muscle, cartilage, fat and
vascular pericytes all require growth factor stimulation to direct differentiation into
bone forming tissue [318, 362]. Delivery of osteogenic and angiogenic factors are
key to the success of large diameter tissue engineered constructs [363]. Large
doses are cost prohibitive and dangerous with tissue exposure being broader than
necessary and in acute wounds BMP turnover is rapid, requiring protection [56,
76]. Microsphere based scaffolds act as growth factor depot delivery systems that
can mimic natural signal events in a spatiotemporal manner, to regulate timing and
the extent of tissue regeneration [257, 258]. Polymer immobilised sequential
growth factor release is metered through the carrier degradation rate that dictates
the concentration profile and has potential to dramatically improve effectiveness
[333, 364]. Physiological levels of BMP-2 delivery were determined to have
greater efficacy than pharmacological doses [365]. Sustained delivery of BMP-2
was demonstrated to enhance differentiation and bone formation [366]. Therefore,
microspheres as an example of a solid delivery system can reduce administered
dose with defined gradients and minimise unwanted collateral damage through low
systemic exposure [318]. Reduced burst phase protein release from PLGA
microspheres was achieved by incorporation of the growth factor onto a BSA
carrier [258, 364]. There was no significant difference in the total BSA release
from loose microspheres and 3D constructs; hence, the spatial release of growth
factors from microspheres could be predicted. BSA has been shown to protect
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growth factor integrity when used as an adjuvant during the loading process and
slow PLGA polymer degradation[367].
The aims of the work in this chapter are to determine the habitability of the
scaffold for cell attachment and proliferation in the presence of PEG; evaluate the
interconnectivity of the particulate architecture through cell migration study;
determine the compatibility of cells in situ with the hardening process;
demonstrate sustained release of pharmacologically relevant dose of an active
growth factor to control cell differentiation.
6.2 Methods
6.2.1 Viability and Proliferation Assay
Cells were cultured in supplemented Dulbecco’s Modified Eagle’s Medium
(42430-025) as described in section 2.4. Briefly cells on tissue culture plates and
scaffolds were washed in PBS prior to incubation with Alamar Blue solution
(Serotec) diluted to 10% in HBSS, for a maximum period of 90 minutes as
described in section 2.4.1. Cell number was correlated to metabolic activity for
each cell type. Plates were read on a MFX Microplate reader with Dynex
Revelation 4.21 software (Dynex Technologies Ltd., UK) at excitation 530 nm and
emission 590 nm.
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6.2.2 Toluidine Blue Staining
A 1% filtered (0.45 µm) toluidine blue solution in 25% IMS was added to
cells/scaffolds rinsed in PBS, for 5-10 minutes then washed in distilled water to
remove the excess before visualization.
6.2.3 Calcium Deposition
Scaffold samples were prepared as detailed in section 2.4.5 and stained with
alizarin red to detect calcium deposition.
6.2.4 Alkaline Phosphatase Detection
Alkaline phosphatase enzyme activity was used as a marker of osteoblastic
differentiation and conducted as detailed in section 2.4.6.
6.2.5 Comparison of Cell Growth on Scaffold Materials
Microspheres and particles used to make the two component scaffold were
evaluated in culture using mouse 3T3 cells. The components examined were 95%
PLGA 85:15 with 5% PEG 400 particles, PLGA 85:15 spheres and PEI/PLGA
85:15 spheres (200 mg). The components were UV irradiated on a plate shaker for
2 hrs then soaked in antibiotic/ antimycotic (5x) solution overnight at 4 °C.
Spheres were washed three times in distilled water then soaked in media for 45
minutes in the incubator. Cells were seeded at 4x10
5
in standard supplemented
media with ascorbic acid (50 µg/mL) and cultured for eight days.
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6.2.6 Impact of Cell Surface Area on Metabolic Activity
To determine which growing condition would best approximate those on the
scaffold, cell metabolic activity was determined on tissue culture plastic of
different surface areas. Human dermal fibroblasts were seeded in duplicates into
six and 24 well plates over 24 hours and compared by Alamar Blue reduction.
6.2.7 Carrier Fluid Impact on Primary Cells
Human dermal neonatal fibroblast passage 4 cells (5x10
5
) were suspended in both
HBSS and 0.9% sodium chloride solutions and seeded onto 6 well tissue culture
plates to determine the impact of carrier fluid on cells seeded onto tissue culture
plastic. In addition, cells suspended in 1 mL volumes of HBSS and sodium
chloride (5x10
5
) was seeded into six well plates containing 1 mL of media. All
samples were placed in the incubator for thirty minutes before an additional
volume of media (3 mL) was added to each well. After 24 hours incubation,
metabolic activity was assessed. The control consisted of cells seeded in standard
supplemented media.
6.2.8 Growth of Cells on Preformed Scaffolds
Sieved scaffold components were separated into 100 µm bands, UV irradiated for
2 hours; and combined in a 4:3 ratio of 95% PLGA 85:15 with PEG 400 adhesive
particles to PLGA 85:15/PEI spheres, loaded into a mould and sintered for 2.5
hours in distilled water at 37 °C in the incubator. The cylindrical (9x5 mm)
scaffolds, four replicates for each particle size were treated with 5 x antibiotics
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solution overnight as previously described then rinsed 3x in PBS and placed in the
incubator for 45minutes in universal tubes in standard media. Human dermal
neonatal fibroblasts (TCS cell works, UK), passage 4, were seeded at 4x105onto
preformed scaffolds in universal tubes with supplemented media containing
ascorbic acid (50 µg/mL). The scaffolds were cultured for a month with regular
changes of media every 2-3 days on an orbital shaker (88 rpm).
6.2.9 In Situ Cell Seeding of Scaffold
Sieved scaffold components were separated into 100 µm bands, UV irradiated for
2 hours and combined in a 3:1 ratio of 95% PLGA 85:15 with PEG 400 adhesive
particles to PLGA 85:15/PEI spheres. The scaffold sizes examined were > 200
µm, > 300 µm, and > 400 µm. The scaffold loading procedure described in section
2.4.3. was used with human dermal neonatal fibroblasts (5x105) suspended in 200
µL of either HBSS or 0.9% sodium chloride solution to a 1:1
wt
/wt mix. The
syringes were placed in a humidified incubator (37 °C, 5% carbon dioxide in air)
for thirty minutes to sinter, then ejected into a non-tissue culture treated plastic 24
well plate with media. Alamar Blue assays were carried out at 24 and 72 hours
post seeding.
6.2.10 In Situ Growth of Primary Human Osteoblasts on Scaffolds
Sieved and sterilized scaffold components were prepared as in section 6.2.9. The
range of scaffolds examined were reduced to three with the following sizes > 200
µm, > 300 µm, and > 400 µm. The loading of scaffold components into syringes
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and seeding were as previously detailed. Passage 4 human osteoblasts (TCS cell
works, UK) were seeded at 5x105 per scaffold.
The effects of supplementation without L-glutamine (Diff. media) and with
various levels of ascorbic acid 2- phosphate (Diff Asc) were investigated. Cells
were seeded at 2x10
4
per well in duplicates and grown for eight days.
6.2.11 Effect of Supplementation on C2C12 Growth
C2C12 cells were maintained in a pre-confluent state in standard DMEM
supplemented media and passage 19 cells seeded at 5x10
4
per well in six well
plates overnight. Cells were treated with varying levels of dexamethasone in media
supplemented with and without L-glutamine for eight days.
6.2.12 Controlled Differentiation of C2C12 Cells
The effects of varying rhBMP-2 concentration 0-500 ng/mL were evaluated on
P19 C2C12 cells seeded at 2x10
5
per well (6 well plates) in media supplemented
with and without L-glutamine for eight days. The stock solution of rhBMP-2 was
1 mg/mL with 0.01% BSA carrier.
6.2.13 Evaluation of Dye Encapsulation in Spheres
An evaluation of dye encapsulation in spheres was conducted by comparing
aqueous and oil phase addition using a Eosin-y (Sigma E4382) 1% solution in
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PVA 0.3% added as the primary emulsion and oil red-O (Sigma O-0652) 1%
dissolved with the polymer in DCM as described in section 2.1.1.
6.2.14 Preparation of rhBMP-2 Loaded PLGA Spheres
Protein loaded spheres were manufactured using a method adapted from Morita et
al [368-370]. In this study, 300 µL rhBMP-2 (1mg/mL) in 0.01% BSA was
lyophilized with 1mL PEG 6000 (60 mg/mL). Microspheres were made as
previously described in section 2.1.1 in a hardening bath of 800 mL 0.3% PVA.
The lyophilized PEG 6000/rhBMP-2 blend was dispersed in DCM (500 µL) and
transferred to the dissolved polymer PLGA 50:50 (Low IV 0.5-0.65 dL/g) 1 g in
DCM 3 mL. The scintillation vial that contained the lyophilized protein was
rinsed with a further 500 µL of DCM and added to the dissolved polymer. The
polymer-protein mixture was vortex mixed for a minimum 60 seconds at
maximum speed. To this was added 4 mL of PVA 0.3% solution and vortex mixed
at 2000 rpm for 30 seconds. The primary emulsion was pipette transferred under
the surface of the hardening bath and stirred for 8 hours to allow evaporation of
DCM. The protocol was repeated to produce blank and FITC-BSA loaded spheres.
The spheres were recovered by filtration, washed and vacuum dried for a
minimum 48 hours. The spheres were sieved for 10 minutes on a Retsch 200
(Retsch., Germany), at amplitude 1.4 interval 40 seconds into 100 µm size bands
protected from light and stored cold in vacuum sealed packs.
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6.2.15 Evaluation of rhBMP-2 Loaded Spheres
A 3:1 scaffold blend was prepared using 95% PLGA85:15 with PEG 400 and the
rhBMP-2 loaded PLGA 50:50 spheres from the > 300 µm fraction. The control
contained blank > 300 µm PLGA 50:50 spheres. The scaffolds were prepared as
previous by UV irradiation and dry loading into a 1 mL syringe barrel. Passage 18
C2C12 cells were seeded at 5x10
5
per scaffold in HBSS (200 µL) and mixed using
a plunger as previously described. The syringes were placed in a 37 °C incubator
for 30 minutes then ejected into media contained within centrifuge tubes. There
were three experimental conditions of scaffolds and cells (a) placed in media alone
with PLGA 50:50 spheres without protein, (b) media supplemented with rhBMP-2
(100 ng/mL) up to day 18 and (c) scaffold containing rhBMP-2 loaded spheres in
media. Scaffolds were examined at day 5, 18 and 28 time points for metabolic and
alkaline phosphatase activity.
6.3 Results and Discussion
6.3.1 Comparison of 3T3 Cell Growth on Scaffold Materials
Scaffold components were shown by SEM (Figure 6-1) to have variation in
surface morphology due to composition and the method of fabrication.
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Figure 6-1 SEM images of 85:15 PLGA scaffold components showing spheres
made by emulsion and solvent evaporation (a) by standard protocol, (b) with PEI
in the polymer phase and (c) the adhesive component made by brittle fracture.
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All particles supported cell attachment and proliferation (Figure 6-2). In media,
standard PLGA spheres with smooth surfaces (Figure 6-2a,b) were submerged,
with cells growing in sheaths. Spheres were not linked prior to seeding, but
became encapsulated by cells and matrix. Similar observations have been reported
for a variety of microspheres [257, 371]. PEI as a surfactant stabilized the air-
polymer interface, forming foamed spheres that scattered light to appear white,
with textured surfaces and tended to float [372]. Cells have spanned pores
becoming anchored onto the spheres instead of forming encapsulating sheaths.
Material was lost during media change making direct quantitative comparison of
metabolic activity difficult. PEI has been used previously to produce porous
particles [358].
Figures 6-2e,f show cell growth patterns on adhesive particles to align with
surface contours and have a spindle like appearance. It was thought that PEG
might reduce cell adhesion to the scaffold surface, but this was contrary to
observations. Surface entrapment of PEG is known prevents polymer-protein
interaction and hinder subsequent cell attachment [373, 374]. Low molecular
weight PEG 600 and below were demonstrated to have poor surface entrapment
and adsorption [305, 375]. Brittle fracture of the adhesive component produced a
surface containing crevices and tracks. The subsequent alignment and growth
pattern of cells (Figure 6-2e) show topography to influence cell morphology as
reported in previous studies at nano and micron scale [112, 376, 377].
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Figure 6-2 Light microscopy and SEM images of 3T3 cell growth on scaffold
components. Cells grown on standard PLGA spheres (a, b), PEI in PLGA spheres
(c,d) and 95% PLGA/PEG400 adhesive particles (e,f). Cells were seeded at 4x10
5
in standard supplemented media with 50 µg/mL ascorbic acid and cultured for
eight days. The cells were stained with toluidine blue for light microscopy.
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The components examined were significantly different in surface chemistry and
produced different patterns of growth, but indicate that cells can attach and spread
across both components of the scaffold system. PEI has been utilized to enhance
cell adhesion to spheres [356]. Toluidine Blue stains sulfated glycosaminoglycans
and ȕ pleated proteins [378]. Adhesive particles were also noted to undergo
significant swelling in comparison to spheres.
6.3.2 Growth of Cells on Preformed Scaffolds
Human dermal fibroblast cells were seeded onto preformed scaffolds varying in
particle size and grown for a month. In Figure 6-3a, b cell sheaths were observed
on the surface of scaffolds with particles < 100 µm and >100 µm in size.
Progressively less surface growth was present on scaffolds with increased particle
size. Comparison of the initial sintered structure with the final cell colonized
scaffolds show swelling to have occurred. The swelling appeared to increase with
particle size; being most pronounced in the > 400 and > 500 µm scaffolds that
have nearly doubled in size. Swelling was shown to be time dependent and
progressive with degradation on diffusion [373, 375]. The loss of peripheral
particles during growth and subsequent handling of scaffolds with >500 µm and to
a lesser extent > 400 µm was probably due to the reduced number of sintering
points with increased particle size. The >400 and >500 µm scaffolds therefore
appear to be covered in cell growth due to the loss of peripheral particles.
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Figure 6-3 Preformed scaffolds (A) before and (B) after 3T3 growth for one
month. The control (ctrl) shown was a >200 µm particle sized scaffold cell free as
a comparison. The scaffolds seeded with 4x105cells were (a) < 100 µm, (b) > 100
µm, (c) > 200 µm, (d) > 300 µm, (e) > 400 µm, and (f) > 500 µm. Sieved scaffold
components were separated into 100µm bands, UV irradiated for 2 hours and
combined in a 4:3 ratio of 95% PLGA 85:15 with PEG 400 adhesive particles to
PLGA 85:15/PEI spheres. The blended particles were packed into a mould and
heat sintered for 2.5 hours at 37 °C then soaked in a 5X antimicrobial solution
overnight before use.
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Metabolic activity was determined by Alamar Blue conversion assay in Figure 6-4
and shows a positive trend with increased particle size. There was a significant (p
< 0.05) increase in detected activity with each step change in particle size with the
comparison between <100 and > 300 µm being extremely significant (p < 0.001).
The results from the > 500 µm scaffolds were not included as fragments with cells
were lost during handling. Previous micro Ct measurements (Section 5.4.4)
showed increased pore size and broadening distribution with incremental particle
size blends of scaffold components. This may have facilitated an increase in the
available surface area for cell growth and access to the Alamar Blue solution
resulting in the observed trend. Similar trends for increased viability with pore size
have been reported [379].
Cell distribution was shown through sulfated glycosaminoglycans and ȕ-pleated
protein staining with toluidine blue in Figure 6-5). This shows the surface
aggregation of cells on the < 100 and >100 µm scaffolds. There was diminished
surface cell aggregation with increased particle size in Figures 6-5 and 6-6 to >
200 and > 300 µm particle sized scaffolds. Cell growth on scaffolds with > 400
and > 500 µm particle size was different with concentrated clumps of cells
growing around particles and through the large pores in Figure 6-6. The increased
access to nutrients provided by the larger pores appeared to have facilitated growth
on the inside of these scaffolds.
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Figure 6-4 Alamar Blue reduction by 3T3 cells grown on preformed PLGA 85:15
scaffolds for one month. Scaffolds (n = 4) were seeded with cells on the outer
surface. Statistical significance denoted as * (p < 0.05) and *** (p < 0.001).
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Figure 6-5 Representative photomicrographs showing toluidine blue stained 3T3
cell growth on PLGA 85:15 scaffolds. 3T3s were cultured for a month on the
scaffolds and show the encapsulation of the outer surface of < 100 and > 100 µm
component particle sized scaffolds in cells. The samples of component particle
size > 400 and >500 µm were fragile and the peripheral scaffold components were
lost showing the cell mass to have grown through the structure filling the pores.
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Figure 6-6 Representative photomicrograph at x5 magnification of toluidine blue
staining, showing aggregated 3T3 cell growth after 1 month on scaffold surfaces.
These images show the pattern of cell growth on restricted particle sized scaffold
components.
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The secondary staining with Sirius red to detect collagen in Figure 6-7 shows it to
be pervasive across the scaffold structure, being produced on both particles present
in the scaffold. The cells have spread across the scaffold components to colonize
it. The pattern of cell growth across the adhesive component was similar to that
seen earlier with 3T3 cells in Figure 6-2.
Micro Ct 3D reconstructed evaluation of these 3T3 colonized scaffolds with
osmium tetroxide densification shows the pattern of cell ingrowth to vary with
particle size (Figure 6-8). Scaffolds with particle < 100 µm in size and > 100 µm
were similar in appearance and show high cell densities to occupy the periphery of
the scaffold. Cells have penetrated into the centre of the structure by migration and
indicate the interconnectivity of pores. There was reduced cell aggregation at the
periphery of scaffolds with particles > 200 µm. Scaffolds with particles > 300 µm
had cell growth throughout the structure. The size of cell aggregate clusters in the
centre of the constructs (Figure 6-8) increased with particle size. Previous micro
Ct results for scaffolds of varying pore size have reported tissue growth to be
concentrated at the periphery [244]. Improved ingrowth was observed in pores >
100 µm [236]. Pores < 80 µm in diameter were shown to induce hypoxia and
reduced bone growth [235, 244, 245]. Pore size and interconnectivity determine
cellularity, cell migration and infiltration into the scaffold [132, 258, 380].
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Figure 6-7 Representative photomicrograph at x5 magnification of scaffolds with
sirius red stain for collagen on scaffolds with 3T3 cell growth after one month.
Preformed scaffolds were seeded with cells on the surface and show wide
coverage of all scaffolds with collagen based matrix. The scale bar represents 1
mm.
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Figure 6-8 Representative micro Ct 3D reconstructed segments of 200 slices at a
scan resolution of 14 µm with the PLGA 85:15 polymer in grey and osmium
tetroxide stained 3T3 cells in red. These slices show the distribution pattern of cell
growth to vary with particle size.
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6.3.3 Comparison of Cell Seeding on Different Surface Areas
The effect of tissue culture plastic surface area on metabolic activity was assessed
to determine the condition to best approximate the scaffold seeding condition. An
Alamar Blue comparison of equivalent cell activity incubated for 12 hours post
seeding on 6 and 24 well plates with surface areas of 9.6 cm
2
and 2 cm
2
respectively produced very significantly different (p < 0.001) values in Figure 6-9.
The larger surface area of the 6 well plates produced a greater reduction of Alamar
Blue throughout the cell seeding range. Six well plates provided better correlation
with fibroblasts seeded onto scaffolds at 80 ± 10%. Alamar Blue penetrates the
cell membrane and is reduced to resorufin that is released from within the cell and
detected [265, 266].
6.3.4 Carrier Fluid Impact on Primary Fibroblasts
The effect of carrier fluids on primary human dermal fibroblasts were assessed 24
hours post seeding by Alamar Blue reduction. Cells were seeded on tissue culture
plastic in a 1ml volume of carrier fluid for thirty minutes before the addition of
serum supplemented media to simulate scaffold implantation in vivo.
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Figure 6-9 Primary human fibroblast cell activity following cell number seeding onto
tissue culture plastic (n = 3) in 6 and 24 well plates. The cells were evaluated 12 hours
after seeding with a 90 minute alamar blue assay.
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The results in Figure 6-10 were conducted over three time points and show a
significant difference (p< 0.001) between cells seeded in HBSS and 0.9% sodium
chloride solutions at each time point recorded. The metabolic activity of fibroblast
cells in 0.9% sodium chloride solution was higher than cells in HBSS buffer. The
metabolic activity of cells in sodium chloride solution was not significantly
different from the positive control at the 90 minutes end point. There was no
significant difference between cells grown in mixed supplemented media
conditions with HBSS or 0.9% sodium chloride solution. HBSS and mixed media
with 0.9% sodium chloride solution were not significantly different in metabolic
activity after 90 minutes.
The metabolic activity of fibroblast cells in 0.9% sodium chloride solution alone
was significantly (p < 0.001) different to the mixed media with sodium chloride
solution. This may be explained by metabolic stress induced by sodium chloride
solution causing an up regulation of cell reduction / oxidation activity. The effect
of HBSS on fibroblasts alone and in combination with media was similar, but less
than that of the standard media. This induced metabolic stress may be due to
sodium chloride solution containing no energy source to support cells actively
trying to reattach to the substrate. The period of exposure was relatively short
however its effect was significant. HBSS contains glucose as an energy source
and has been found to sustain cells through the Alamar Blue evaluation for 90
minutes with minimal impact on cell activity.
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Figure 6-10 Primary human fibroblasts cell activity 24 hours after seeding 5x10
5
cells in different fluids using 6 well tissue culture plastic and the Alamar Blue
assay (n = 3). It shows the impact of an initial 30 minutes cell seeding period in
test fluids on the ability of cells to convert alamar blue. Media was added to all
cells prior to the 24 hours incubation. Statistical significance denoted as ** (p <
0.01) and *** (p < 0.001).
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The results of DNA titration of human dermal fibroblast cells seeded on tissue
culture plastic 6 well plates in Figure 6-11 shows that there was no significant
difference in cell number between HBSS buffer and 0.9% sodium chloride
solution. There was a significant (p < 0.01) reduction in cell number between
0.9% sodium chloride solution alone and the mixed media with HBSS or NaCl
carrier. In mixed media, cell number was very significantly (p < 0.001) lower than
the media treated control.
The lack of a statistically significant difference in cell number by DNA titration
between HBSS and 0.9% sodium chloride as carrier fluids in Figure 6-11 was
contrary to the metabolic activity measured in the Alamar Blue assay of Figure 6-
10. This may indicate that difference in metabolic activity between cells exposed
to HBSS and 0.9% sodium chloride measured in the Alamar Blue assay of Figure
6-10 was due to induced metabolic stress [381]. This explanation was consistent
with the observation of no significant difference in cell number between media
with HBSS and media with 0.9% sodium chloride solution. The differences in cell
number for this experiment may have been caused by cell detachment during the
addition of media 30 minutes post incubation to the restricted cell seeding volume.
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Figure 6-11 Effect of carrier fluid on human dermal fibroblasts cell number (n= 3),
determined by DNA assay with Hoechst 33258 at excitation/ emission wavelength of
355/ 460nm. Well plates were seeded with 1mL of carrier fluid for 30 minutes in an
incubator then topped up with 3mLs media and left for 24 hours. Statistical significance
denoted as ns (not significant), ** (p < 0.01) and *** (p < 0.001).
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6.3.5 Viability of Osteoblasts in Carrier Fluids After in situ Seeding
For HBSS seeded scaffolds of increasing particle size (> 200 µm, > 300 µm and >
400 µm), there was no statistically significant increase in cell metabolic activity
detected at 24 and 72 hours (Figure 6-12). The level of cell activity detected after
24 hours with the 0.9% sodium chloride carrier was more variable and reduced in
comparison to HBSS. Exposure to sodium chloride solution reduced the measured
cell activity on scaffolds > 200 µm and >300 µm, in comparison to the > 400 µm
construct which was comparable to HBSS seeded scaffolds at 24 hours. Cell
activity was reduced further at 72 hours on all 0.9% sodium chloride treated
constructs. There was no significant difference between 0.9% sodium chloride
solution and HBSS buffer in the > 400 µM scaffold. This may indicate that
increased pore size may positively influence cell survival in sodium chloride
solution. The differences in cell activity detected with the > 200 µm and > 300
µm particle sized scaffolds may have been due to higher cell density in these
scaffold pores.
The relatively large pores formed by the restricted particle size of the scaffolds’
have enabled the Alamar Blue method to detect 80 ± 10% of the cell activity seen
on tissue culture plastic with HBSS treatment after 24 hours. This indicates good
cell survival through the handling processes of mixing with particulates,
compression through delivery and wet scaffold sintering.
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Figure 6-12 Human primary osteoblast cell survival and metabolic activity at
24 and 72 hr time points following in situ seeding and wet sintering with
scaffolds of differing component particle size ranges. Cells (5x10
5
) in 200 µL
of carrier fluid were mixed at a 1:1 weight ratio with dry scaffold components,
compressed by injection and extruded into a well plate. Scaffolds were
incubated at 37 °C for 30 minutes before the addition of media. The Alamar
Blue assay was conducted for 90 minutes in HBSS. Statistical significance
denoted as * (p < 0.05), ** (p < 0.01) and ns (not significant).
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HBSS was used as the material of choice for in situ seeding of further scaffolds in
this work. It is envisaged that an intraoperatively conducted procedure to recover
and seed bone stem cells might utilize this combination of materials.
6.3.6 Human Osteoblasts Response to Supplements
This investigation was conducted on tissue culture plastic and scaffolds to
determine the effects of supplementation on the proliferation of primary osteoblast
cells and measure the effect on alkaline phosphatase activity. Human primary
osteoblasts were cultured for eight days in six well plates at 2x10
4
cells per well in
standard supplemented media; media without supplementary L-glutamine (Diff.
media) and media without L-glutamine but added ascorbyl phosphate (Diff Asc).
The photomicrographs in Figure 6-13a, b, and c were representative of cell
coverage after 8 days. Cells grown in standard media experienced the slowest rates
of proliferation over 8 days. Cell numbers in standard media (1x10
5
± 9500) were
significantly (p < 0.001) lower than cells grown without L-glutamine
supplementation (1.5x10
5
± 8800). The addition of ascorbyl-2 phosphate further
enhanced osteoblast proliferation in a dose dependant manner with 3x105 ± 10500
cells at 200 µg/mL.
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Figure 6-13 Osteoblasts after 8 days cell growth on tissue culture plastic in (a)
standard supplemented media, (b) without added L-glutamine (c) with 200 µg/mL
ascorbic acid 2- phosphate and without added L-glutamine. (d) Alamar Blue
calibration 12 hours after seeding (R
2
= 0.9807); (e) cell proliferation on tissue
culture plastic after eight days (n = 3). Statistical significance denoted as ** (p <
0.01) and *** (p < 0.001).
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As an essential amino acid, L-glutamine is added to media as an alternative energy
source for cells with high metabolic activity. In addition, L-glutamine has been
shown to be an antagonist of dexamethasone [382]. Here, addition of L-glutamine
to serum supplemented media was shown to retard proliferation of primary
osteoblasts. Serum alone can stimulate collagen synthesis and alkaline phosphatase
activity; however, batch to batch variation necessitates the addition of ascorbate.
The addition of long acting ascorbic acid 2-phosphate was shown to stimulate
osteoblast proliferation and was similar to reported results [383].
Dimethyl sulfoxide is used as a carrier for dexamethasone and the compatibility of
the material was evaluated on primary osteoblast cell activity after 8 days in
differentiated media without L-glutamine (Figure 6-14). Dimethyl sulfoxide at 10
µL/mL did not significantly reduce cell proliferation in media without
supplementary L-glutamine and was not significantly different to the control
differentiated media. At levels > 10 µL/mL dimethyl sulfoxide was inhibitory to
cell proliferation. Alkaline phosphatase activity in the presence of dimethyl
sulfoxide at and above 100 µL/mL (Figure 6-15) was significantly (p< 0.01)
reduced. The level of alkaline phosphatase produced without additional L-
glutamine supplement was very significantly higher than that produced in media
with supplementary L-glutamine. The results for alkaline phosphatase activity
were of similar profile to that obtained for cell activity in Figure 6-14, 15.
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Figure 6-14 Effect of dimethyl sulfoxide on the reduction of Alamar Blue by
primary osteoblasts after eight days growth on tissue culture plastic (n = 3).
Statistical significance denoted as ns (not significant) and ** (p < 0.01).
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Figure 6-15 Effect of dimethyl sulfoxide (0-400 µL/ mL) on alkaline phosphatase
activity in human osteoblasts after eight days growth in media. Statistical
significance denoted as ** (p < 0.01) and *** (p < 0.001).
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6.3.7 Impact of Dexamethasone on Human Primary Osteoblasts
In Figure 6-16, comparison of dexamethasone impact on cell activity shows that it
is inhibitory at all concentrations above 0.01µM when compared to cell activity in
full media. Supplementary addition of ascorbic acid 2-phosphate (50 µg/mL)
significantly diminished the negative impact of dexamethasone on osteoblast cells
throughout the range of concentrations used. The degree of protection and
enhanced proliferation was significant (p < 0.01) with 100 µM dexamethasone
having higher metabolic activity than cells in full media.
Alkaline phosphatase production (Figure 6-17) mirrored the results for cell activity
determined with Alamar Blue in Figure 6-16. The inhibitory effect of
dexamethasone was concentration dependant and effective throughout the range
evaluated. The impact of ascorbic acid 2- phosphate supplementation (50 µg/mL)
became significant at 300 µM dexamethasone addition when compared to the 400
µM dose on cells. The increase in alkaline phosphatase activity in osteoblasts was
inversely related to the concentration of dexamethasone added. Ascorbic acid 2-
phosphate increased cell proliferation and detected alkaline phosphatase activity in
a dose dependent manner (Figure 6-16 and 6-17). The positive impact of ascorbic
acid 2-phosphate addition was observed in the extremely significant (p < 0.001)
difference between dexamethasone concentrations at 400 and 100 µM Figure 6-16.
Alkaline phosphatase activity in Figure 6-17, showed a similar trend and was
therefore linked to cell number.
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Figure 6-16 Effect of ascorbic acid 2-phosphate supplementation at 50 µg/mL on
osteoblasts cell growth in media with dexamethasone after 8 days. Osteoblasts
metabolic activity was determined by an end point Alamar Blue conversion after
90 minutes. Statistical significance denoted as ns (not significant), ** (p < 0.01)
and *** (p < 0.001).
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Figure 6-17 Comparison of dexamethasone and 50 µg/mL ascorbic acid 2-
phosphate supplementation on alkaline phosphatase activity of primary human
osteoblasts. Statistical significance denoted as ** (p < 0.01).
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Ascorbic acid 2-phosphate addition was extremely significant (p < 0.001) to
increasing osteoblast alkaline phosphatase activity in the comparison made in
Figure 6-18 between media with and without it. Differences observed in alkaline
phosphatase activity with cell number indicated that dexamethasone inhibited
primary cell proliferation.
At the highest levels dexamethasone inhibited cell proliferation. Time dependent
effects of dexamethasone have been recorded after 4 hours with depression of
protein synthesis and reduced proliferation of cells [384]. In addition,
dexamethasone can disturb the homeostatic balance within cells through
suppression of the genes encoding antioxidant enzymes leading to impaired
viability and reduced proliferation attributable to increased hydrogen peroxide
within cells [385]. The antioxidant effect of ascorbic acid 2-phosphate abrogated
dexamethasone induced cell death [385]. Dexamethasone is a differentiation factor
for osteoprogenitor cells that can induce bone nodule formation in culture and
increase the size of bone nodules formed [386].
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Figure 6-18 Alkaline phosphatase activity in primary human osteoblasts after
eight days growth in media supplemented by ascorbic acid 2-phosphate (n=3).
Statistical significance denoted as ** (p < 0.01) and *** (p < 0.001).
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6.3.8 In Situ Osteoblast Seeding in Scaffolds
Osteoblasts were in situ seeded with a 3:1 wt/wt adhesive particle to PEI sphere at
three particle size ranges of; > 200 µm, > 300 µm and > 400 µm, for eight days in
triplicate. Standard supplemented media was used with 50 µg/mL ascorbic acid 2-
phosphate. Cell attachment was observed on both scaffold components and varied
in distribution with pore size in Figure 6-19. Cells on the > 200 µm scaffold were
visually, more densely distributed on the surface and ends of the scaffold.
Progressively fewer cells were apparent on the outside of structures as pore size
increased in accordance with earlier observations (section 6.3.2). Transversely
fractured dried scaffold specimens examined by SEM show cells were distributed
across the scaffold components and in addition crystalline deposits were present
on the scaffold Figure 6-20. The crystals were most prominent on adhesive
components, but were also observed on the carrier component of the scaffold.
These scaffolds were positively stained for calcium deposition with alizarin red
indicating that the primary osteoblasts were attached and producing calcified
deposits after eight days. Mineralization in vitro has typically been reported to be
initiated from day 14-21 on both tissue culture plastic and polyester scaffold in the
presence of ȕ-glycerophosphate [148, 182, 387-390]. There is no in vivo
equivalent of ȕ-glycerophosphate [391].
Chapter 6
226
Figure 6-19 Scaffolds varying in particle size were stained with alizarin red to
detect calcium deposition following in situ osteoblasts seeding and growth in wet
sintered scaffold for eight days in standard media supplemented with 50 µg/mL
ascorbic acid 2- phosphate (n = 3).
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Figure 6-20 SEM images of freeze fractured two component wet sintered
scaffolds, following 8 days of osteoblasts growth in standard media supplemented
with 50 µg/mL ascorbic acid 2- phosphate. Scaffolds were fractured transversely
to show cell distribution.
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Analysis of the crystals by energy dispersive x-ray, Figure 6-21 confirmed calcium
to be present. Areas of the scaffold without the crystals produced a carbon and
oxygen rich component indicative of the polymer itself. Mineralization has been
reported to be dependent on the presence of ascorbic acid, dexamethasone and ȕ-
glycerophosphate [388]. However, previous work has demonstrated that in the
presence of long acting ascorbyl-2-phosphate mineralization can occur in the
absence of beta-glycerophosphate [387]. The crystalline materials were not present
after 3T3 growth in the same media Figure 6-2 and therefore specific to
osteoblasts.
The type of polymorph crystal formed is dependent on calcium concentration in
the media and mechanism of crystallization. Aragonite (sheaf-bundle) crystals
were demonstrated to be formed from anionic polymer induced heterogenous
nucleation and growth by an ion-by-ion addition at low calcium concentration (1-
25 mM) over six days [392]. The crystals formed on these scaffold surfaces were
of high uniformity and narrow size distribution that indicate controlled growth.
Mineralization was not observed with fibroblast or 3T3 growth over 28 days in
DMEM. Colonization by osteogenic cells is an essential prerequisite of de novo
bone formation on scaffold surfaces. Osteogenic cells stimulate matrix initiation
by producing non-collagenous proteins that adsorb to solid surfaces [27]. Mature
osteoblasts are not expected to achieve end points representative of relatively
young precursor cells in vitro [386].
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Figure 6-21 Elemental abundance distribution X-ray analysis plots obtained
during SEM examination of wet sintered scaffolds following eight days of
osteoblasts cell growth with (a) representative of clear polymer surface without
crystals and (b) of crystals with high levels of calcium detected.
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In new bone growth, mineralization requires bone sialoprotein and osteocalcin
[393, 394]. Ascorbate is a cofactor in osteocalcin binding of calcium ions that
controls mineral maturation [16, 395]. In the absence of adhesion peptides, cells
interact with scaffolds via adsorbed proteins with hydrophilicity and topography
being critical features. Hydrophilic polymers adsorb proteins in a hydrated
interfacial phase where the proteins are likely to retain functionality [396, 397]. In
addition, hydrophilic surfaces induce more homogeneous cell growth and mineral
deposition in comparison to hydrophobic surfaces [398].
The surface charge of functional groups can alter the conformation of bound
fibronectin to up regulate alkaline phosphatase activity and mineralization to
produce a carbonate-containing hydroxyapatite similar to the mineral phase of
bone. The influence of surface chemistry on osteoblastic matrix mineralization
was demonstrated to be independent of cell proliferation [399]. Hydrophilic
surface chemistry of hydroxyl and amino groups were shown to modify adsorbed
fibronectin structure and positively influence the binding of Į5ȕ1 integrin. Surfaces
enriched with hydroxyl and amino groups up regulate osteoblast- specific gene
expression for alkaline phosphatase activity and mineralization in comparison to
carboxylic acid and hydrophobic methyl groups. PEI modified PLGA surface with
amino presenting groups, increase hydrophilicity and control the conformational
presentation of adsorbed bioactive moieties to influence cell-biomaterial
interaction [356].
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The texture of biomaterial substrates at nano and micron scale have been known to
influence cell morphology, adhesion and gene expression [376, 400]. Cell
response to surface topography varies, with stem cells more responsive to concave
pits than fibroblasts [102, 401]. PLGA surfaces modified with concave pits had
improved cell coverage and osteoinductive properties [55, 102]. Textured
orthopaedic devices have been demonstrated to have the potential to initiate
osteoinduction and osteogenesis by topography [402, 403]. The dimensions of
surface features vary, but Biggs et al have shown grooves 330 nm deep to increase
osteoblast-specific function and skeletal development in primary human
osteoblasts [377]. Primary human osteoblasts, here in non optimized DMEM
media show up regulation of calcium deposition. In addition, the wet sintering
mechanism involving the migration of PEG produced a change in particle
appearance attributed to the formation of light scattering voids of the order 200-
400 nm [133, 293]. The effectiveness of a scaffold in bone repair is dependent on
its bone-bonding ability. Achieving a strong bond between native tissue and
synthetic material is a major challenge in regenerative medicine that can be
overcome by matrix accumulation that facilitates integration by transition.
Contact osteogenesis results in direct matrix deposition onto a solid surface to
establish anchorage and mechanical stability [404].
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6.3.9 Controlled Differentiation of C2C12 Cells
C2C12 cells were subjected to growth in media with a range of dexamethasone
concentrations without supplementary L-glutamine (Diff. media) for 8 days.
Dexamethasone levels up to 10 µM had the highest plateau cell activity observed
in Figure 6-22. Incremental dexamethasone levels greater than 10 µM were
inhibitory (p < 0.01), progressively retarding cell activity. The decrease in
metabolic activity detected in control wells without dexamethasone may have been
due to C2C12 cell confluence that can result in the formation of myotubes that
contract and are easily detached from plastic surfaces.
Many cells are alkaline phosphatase positive, but do not produce the abundant
quantities of osteoblast-like cells. At dexamethasone concentrations of 100 nM
myotube formation was evident. At  300 µM there appeared to be some evidence
of cell blebbing that was reflected in the metabolic activity determined by Alamar
Blue profile of. There was no evidence of enhanced alkaline phosphatase activity
present in any of the wells screened and indicates serum to have minimal impact.
Neither the presence nor absence of dexamethasone stimulated C2C12 cells to
produce alkaline phosphatase.
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Figure 6-22 (a) Alamar Blue calibration of C2C12 cell activity 12 hours post
seeding (R
2
= 0.9929) and (b) effect of dexamethasone supplementation on C2C12
cell activity after eight days in culture. Statistical significance denoted as ** (p <
0.01) and *** (p < 0.001).
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C2C12 cells (2x104) were incubated with rhBMP-2 (0-50 ng/mL) in standard
supplemented media with and without supplementary L-glutamine for five days.
From Figure 6-23, media without supplementary L-glutamine addition again
stimulated an increase in cell number. Alamar Blue determination of cell numbers
in standard media was 1x10
5
and 1.5x10
5
in media without supplementary L-
glutamine. Variation in rhBMP-2 concentration did not affect cell number and was
apparently non-toxic to cells throughout the administered range of concentrations
used.
There was positive correlation (R2= 0.949) of alkaline phosphatase stimulation,
with rhBMP-2 up to 200 ng/mL followed by saturation in Figure 6-24. Similar
results have been previously reported [257]. The lowest concentration of rhBMP-2
used increased alkaline phosphatase production to an extremely significant level (p
< 0.001), above the baseline detected. The step change from 50-100 ng/mL
rhBMP-2 was very significant (p < 0.01) doubling the level alkaline phosphatase
detected without an increase in cell number. The confluence of these factors of
stimulation without toxicity was considered ideal for selection of C2C12 cells to
demonstrate controlled growth factor delivery in a scaffold.
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Figure 6-23 Effect of varying rhBMP-2 levels (0-500 ng/mL) on C2C12 cells after 8
days of growth in standard and differentiated media without L-glutamine (Diff media).
Statistical significance denoted as ** (p < 0.01) for n = 3.
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Figure 6-24 Effect of varying rhBMP-2 levels (0-500 ng/mL) on the induction of
alkaline phosphatase activity in C2C12 cells in standard media. Statistical
significance denoted as ** (p < 0.01) and *** (p < 0.001) for n= 3.
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6.3.10 Dye Encapsulation in Spheres
On addition of the hydrophilic dye formulation to the hardening bath there was a
significant amount of colour leaching observed as polymer spheres were formed.
The light microscopy images in Figure 6-25 a, c show the distribution of the
remaining dye to be patchy with few particles retaining any colour. The extent of
colour leaching can be ascertained from bulk comparison of spheres in Figure 6-
25e. During production aqueous channels were believed to be formed within the
microsphere during polymer solidification and solvent removal [358, 405]. There
was no colour leaching observed from dye addition to the oil phase Figure 6-25
b,d.
6.3.11 Manufacture of Spheres for rhBMP-2 Delivery
FITC-BSA had a 75% yield by weight for spheres > 200 µm in size compared to
85% for BSA microspheres Figure 6-26c. FITC addition to BSA alters protein size
and charge; hence its use to estimate behaviour [406]. Lyophilized BSA
entrapment in microspheres without loss of function has been demonstrated. FITC-
BSA was used to model rhBMP-2-BSA distribution and release from PLGA
spheres [368, 407-409]. As a transport protein, BSA is negatively charged at
neutral pH and interacts with positively charged rhBMP-2 [53, 410]. BSA was
shown to protect BMP-2 when used as an adjuvant during the loading process [81,
411].
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Figure 6-25 Comparison of dye retention and distribution within spheres following
inclusion of 1% eosin-y into the primary emulsion water phase (a & c) with (b,d)
oil red-O addition to the polymer phase. Image (e) shows the bulk appearance of
the spheres.
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Figure 6-26 Photomicrograph of (a) blank PLGA 50:50 microsphere without
fluorescent protein (b) microsphere loaded with FITC-BSA and (c) graph showing
the distribution of sphere sizes obtained from the batches.
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6.3.12 Controlled rhBMP-2 Release in Scaffolds
Scaffolds > 300 µm size in a 3:1 ratio of adhesive particles to BSA/rhBMP-2
loaded spheres were produced in situ with C2C12 cells seeded in HBSS for 30
minutes prior to being ejected in standard media. The controls were both in situ
C2C12 seeded scaffolds with blank spheres ejected into standard media with and
without 100 ng/mL rhBMP-2 supplement. Cells on the particulate scaffolds at the
first time point of 5 days were demonstrated to be metabolically active (Figure 6-
27a), showing survival of the wet in situ sintering process. Variation in the levels
of cells detected on the scaffolds at day 5 was not significant. There was
significant proliferation (p < 0.001) demonstrated over the two successive time
points at 15 and 28 days.
Very significant alkaline phosphatase activity was detected at day 5 and was
demonstrated to increase significantly (p < 0.01) at the second time point of day 18
in the scaffolds where rhBMP-2 was present (Figure 6-26b). The images in Figure
6-28 at day 5 show cells to be present on all scaffolds, but alkaline phosphatase
activity was detected only in conditions where rhBMP-2 was present. Alkaline
phosphatase activity on scaffolds sintered with loaded rhBMP-2 spheres was 80%
of that detected in the 100 ng/mL supplemented media.
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Figure 6-27 Response of in situ seeded C2C12 cells on scaffold over 28 days with
control (Ctrl) without rhBMP-2, a 100 ng/mL Bmp-2 supplement in media and in
situ BMP-2 loaded microspheres (Bmp-2 scaf). Graph (a) shows cell activity
determined by Alamar Blue and (b) alkaline phosphatase production at 5,18 and
28 day time points. The rhBMP-2 was withdrawn from the media supplement after
day 18 (media+ BMP-2). Statistical significance denoted as ns (not significant), **
(p < 0.01) and *** (p < 0.001).
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Figure 6-28 Alkaline phosphatase activity of C2C12 cells at day 5 on scaffolds in
media supplemented with (a, b)100 ng/mL rhBMP-2, (c, d) BMP-2 scaff with
growth factor loaded microspheres and (e, f) blank microspheres without growth
factor (Ctrl).
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Increased alkaline phosphatase activity was detected at day 18 in Figure 6-29
indicating sustained release of rhBMP-2 from the loaded microspheres. The
images of alkaline phosphatase positive cells showed attachment and spreading on
both the spheres and the adhesive component. At day 18 the difference in alkaline
phosphatase activity between rhBMP-2 supplemented media and that released
from scaffold components was not significant (Figure 6-27b).
For the final stage of the incubation between days 18 to 28, rhBMP-2 was
withdrawn from the supplemented media. The effect seen in Figure 6-27b was a
reduction in the level of alkaline phosphatase detected in this treatment in
comparison to the day 18 result with a significant (p < 0.001) increase in cell
number in Figure 6-27a. The rhBMP-2 loaded microspheres continued to release
active protein resulting in further stimulation of the proliferating C2C12 cells and
detection of significantly (p< 0.01) higher levels of alkaline phosphatase activity at
day 28 Figure 6-27b. The detected increase in alkaline phosphatase levels may be
linked with cell proliferation throughout the experimental period.
Figure 6-30 shows the scaffolds at day 28 with alkaline phosphatase negative
control scaffolds. The media in which supplementation was withdrawn, shows
patchy alkaline phosphatase staining with areas of new cell growth that were
negative for alkaline phosphatase activity. BMP-2 loaded scaffolds, maintained
differentiation of C2C12 cells and were intensely stained.
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Figure 6-29 Alkaline phosphatase activity of C2C12 cells at day 18 on scaffolds in
(a, b) media supplemented with 100 ng/mL rhBMP-2, (c, d) BMP-2 scaff growth
factor loaded microspheres and (e, f) blank microspheres without growth factor
(Ctrl).
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Figure 6-30 Alkaline phosphatase activity of C2C12 cells at day 28 on scaffolds
(a, b) in standard media after rhBMP-2 supplement was withdrawn at day 18 (0
ng/mL), (c, d) BMP-2 loaded microspheres and (e, f) without growth factor (Ctrl).
The arrows indicate areas of cell and matrix production where there were no
alkaline phosphatase positive cells on the withdrawn supplemented scaffold and on
the control.
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Growth factors in vivo are bound to extracellular matrix and therefore function in a
localized manner as part of a membrane complex. Simple tethering of growth
factors to biomaterial surfaces can elicit a more potent response than the soluble
form of the protein. Incorporation of growth factors into polymeric matrices can
stabilize the protein and retain activity at the point of release [81, 155, 156].
Localized growth factor release and concentration have been previously
demonstrated and diffusion gradients in 3-d structures have been documented
[233, 257, 262].
6.4 Conclusion
This two component scaffold system has demonstrated both components to be
capable of supporting cell attachment, proliferation and migration. Pore size
controls nutrient diffusion and influences cell migration. In this system, control of
pore size was achieved by restriction of particulate size distribution. The
interconnectivity of this particulate system was demonstrated by cell migration
from the outside into the scaffold. Scaffolds with different porosities can be
tailored to fit different site requirements as bone is produced by intramembranous
and endochondral ossification. The duration of experiments and proliferation
results demonstrates the mildness of the in situ sintering process with cell
suspension to develop mechanically strong structures. The potential for
osteointegration was demonstrated by the cultivation of osteoblasts cells that
rapidly synthesized calcium based deposits throughout the scaffold following in
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situ seeding. Dexamethasone did not significantly up regulate alkaline
phosphatase activity in mature osteoblasts or C2C12 cells; however, rhBMP-2 did
significantly up regulate alkaline phosphatase activity in C2C12 cells in a dose
dependent manner. Prolonged release of rhBMP-2 was demonstrated to induce and
maintain differentiation of C2C12, for a sustained period of time from an in situ
sintered scaffold without affecting proliferation. The scaffold has been
demonstrated to have the potential to function as an injectable device with the
ability to support in situ cell survival and invasion.
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7 Final Conclusions
The strategy of tissue engineering utilises space filling scaffold materials that
can support cells and deliver therapeutic agents. The ideal material needs to
meet a range of requirements that include being biodegradable,
osteoconductive, integrative, mechanically compatible with native bone and
ideally osteoinductive. Injectable delivery systems are placed at the target site
and interaction with the surrounding tissue is determined by surface area,
diffusion, porosity and pore size. Injectable scaffolds have potential to deliver
therapy cheaper, faster and arguably safer given the developing methods of
minimally invasive surgery. The objective of this work was to develop an
injectable scaffold system capable of cell and growth factor delivery. The
strategy used a two component scaffold system that sintered at body
temperature. Component I was multifunctional as a porous cell carrier and
spacer that facilitated the hierarchical design of a macroporous system with
additional functionality for controlled release.
In Chapter 3 the adhesive component II was refined using a combination of
techniques to monitor thermal, physical and mechanical changes in polymer
behaviour that defined the sintering regime needed to make three- dimensional
structures. In Chapter 4 formulations were evaluated to determine the uniaxial
compressive strengths, temperatures and rates at which structures were
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formed. The prominent discovery here was the significant compressive
strength developed by the wet sintered scaffold with Young’s modulus within
the range desired for applications in cancellous bone. Investigation of the wet
sintering systems was fundamental in enabling the survival of suspended cells
in a formulation that was shown to be injectable in Chapter 5. The
solidification mechanism was demonstrated to occur over a clinically relevant
timescale comparable with currently used bone cement. The process of
bonding and densification is commonly used to make solid structures with
changes in physical properties after sintering that include porosity loss after
aggregation. The injectable scaffold proposed does not form a viscous gel, but
a particulate skeleton system surrounded by low viscosity media without
restricting diffusion. The proposed mechanism of wet sintering was by
desorption using surface mobilisation of non-toxic PEG. Wet scaffold strength
increased with sintering temperature.
In Chapter 5, the injectability through a simple syringe system showed the
material to remain cohesive at constant loading and low carrier content. When
the syringe was loaded to higher densities heterogeneous extrusion occurred.
The two component system with restricted particle size distribution
demonstrated that the control of porosity was positively correlated to particle
size of the system. It showed that pore size distribution increased with particle
size and a high content of pores > 100 µm was achieved in the scaffold with
sieved particles > 300 µm in diameter.
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The priority of preserving cell viability restricts the use of many materials to
those compatible with living tissue. In Chapter 6 the interaction of scaffolds 5
mm in diameter with cells were examined. Both scaffold components were
shown to support cell growth and migration. Cell additions to preformed
scaffold surfaces were observed to spread and migrate to the centre of the
structure with increased particle and pore size. In situ seeding and sintering
showed cells to survive processing proliferate and colonise the structure. The
survival of primary osteoblasts and their deposition of calcium based crystals
onto the scaffold after 8 days in culture showed the surface to be
osteoconductive. Cell growth and spreading on the solid PLGA adhesive
particles was probably due to a combination of factors including surface
topography created during particle size reduction by fracturing and PEG
migration.
Surgery utilizes compression and immobilization for alignment between
fracture surfaces to stimulate repair. Here swelling of the polymer may be
utilized to tightly fit the interface to avoid issues of implant shrinkage and
loosening. Press fitting also allows transmission of strain that directionally
stimulates metabolism and growth, reflecting the native mechanical
environment. The encapsulation and delivery of the differentiation factor
rhBMP-2 over 28 days confirmed the scaffold to have potential as a cell
carrier, template for tissue growth and therapeutic protein delivery.
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The overall conclusions from the work presented here suggest that the two
component scaffold design has significant potential to be developed into a
therapeutic tissue engineered control delivery system with and without cells.
Under the sintering conditions used, cell delivery and prolonged growth factor
release were demonstrated. The materials used were of low toxic potential in
the in vitro studies conducted. PEI was used as a modifier of the cell carrier
component and could be replaced by alternative treatments. The materials can
be manufactured on an industrial scale by well established procedures with
known controllable process parameters. All reactions can occur within the
normal range of body temperatures in the presence of cells without significant
viability loss in dimensions that approach critical sized defects. The sintering
process manipulates the response of the materials to temperature and time
producing strong porous open celled scaffolds.
The biodegradable injectable scaffold system as presented has potential to be
utilised as a therapeutic cell and protein delivery device to provide
environmental cues to direct differentiation, template tissue growth and
develop mechanical properties compatible with cancellous bone.
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7.1 Future Work
The work presented in this thesis has looked at aspects of design,
characterisation and simulation of use for this injectable scaffold system. This
two component system has potential for multi-component release at different
rates. The particulate scaffold system forms a predictably porous
interconnected structure that may deliver cells, growth factors and other
materials such as antibiotics and therapeutic actives. Substitution of
component I with hydroxyapatite or bisphosphonates should be investigated to
determine the localised impact on stem cell differentiation.
The ideal material needs to meet a range of requirements that change with time
and the swelling behaviour may increase porosity and pore size in a temporal
manner to satisfy the diffusion requirements of proliferating cells. In addition
the influence of polymer swelling on attached cells should be investigated as it
is a source of further mechanical stimulation. Evaluation of sintering
conditions showed the strength of the scaffold to increase with temperature.
The localised wound temperature due to inflammation can exceed 40°C and
cell viability in these environments should be studied in mono and co-culture.
The evaluation of endothelial with osteoblast cells may prove beneficial in
aiding repair.
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